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Abstract 
Thanks to their high sensitivity and specificity, short-processing times, low 
cost of production, small size, and no requirement for professional users, biosensors 
have increasingly gained popularity. Electrochemical impedance biosensors have 
successfully been applied to detect a wide range of target analytes including whole 
cells, proteins, and small molecules. However, there are some limitations, for 
example reproducibility and non-specific binding, which still require further 
development. The main objective of this thesis is to develop impedimetric biosensors 
using Affimers, novel non-antibody binding proteins, as bioreceptors to detect a small 
molecule target, dichlorodiphenyltrichloroethane (DDT), and a protein biomarker, 
fibroblast growth factor receptor 3 (FGFR3).  
 Initial work in this thesis was the selection of Affimers using phage display 
technology. Affimers were selected from a phage library provided by the 
BioScreening Technology Group (BSTG) at the University of Leeds. The selected 
Affimer-encoding sequences were then subcloned into the pET expression vector 
and expressed in E.coli cells. Prior to using the selected Affimers for biosensor 
fabrication, specific interaction of the Affimers with their analytes was investigated 
using ELISA, surface plasmon resonance (SPR) and immunoprecipitation (pull-
down) assay. Even though none of the Affimers against DDT succeeded in binding 
specifically to DDT, some of the Affimers against FGFR3 showed binding to it and 
were then utilised for biosensor fabrication.  
 Two sensor fabrication methods, the ELISHA “gluing” protocol and 
NeutrAvidin-biotin linkage, were tested and the latter one was selected for further 
study. By using the NeutrAvidin-biotin interaction method to functionalise the sensor 
surfaces, several parameters such as Affimer concentration, NeutrAvidin 
concentration and blocking agents to minimise non-specific binding were optimised. 
The fully fabricated Affimer-based biosensors were incubated with the analyte 
iv 
 
  
(FGFR3) and electrochemical impedance spectroscopy (EIS) was employed to 
interrogate FGFR3 binding. The data showed that the Affimer-based sensors could 
detect FGFR3 protein to very low levels. However, further optimisation is still needed 
in order to minimise non-specific binding effects and make the sensors work 
consistently. 
 The work presented in this thesis is the first Affimer-based impedimetric 
biosensor for the detection of FGFR3, a promising biomarker for early diagnosis of 
bladder cancer. This sensor platform may not only provide an effective tool for 
bladder cancer surveillance, but also pave the way of designing a new analytical 
method for monitoring other protein biomarkers of disease.  
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Chapter 1 
Introduction 
 
1.1 Overview 
Recently, point-of-care (POC) diagnostics and environmental (“point of use”, 
POU) monitoring have gained popularity among scientific communities because they 
offer very rapid analyses without loss of process or use of expensive equipment. 
Biosensors are small devices developed to detect a variety of targets of interest, 
which can be small molecules, oligonucleotides, proteins, viruses and bacteria. Due 
to their capabilities of detecting a vast range of targets, biosensors are invaluable 
tools to track emergence of life-threatening diseases for POC diagnosis and for 
monitoring contamination by pollutants in the environments. Based on the methods 
of transduction, biosensors are in general categorised into three major types, namely 
optical, mechanical and electrochemical sensors. 
 Since the first glucose biosensor was launched in 1962 (Clark and Lyons, 
1962), electrochemical biosensors have gained substantial attention from 
researchers because of their high sensitivity, ease of operation and possibility for 
miniaturisation. Impedimetric biosensors are a type of label-free electrochemical 
sensor, depending on the measurement of changes in capacitance and charge-
transfer resistance. The benefit of using impedance rather than amperometry or 
potentiometry is that biorecognition elements are not limited to biomolecules 
involving enzymatic reactions, and for amperometric biosensors, oxidases and 
reductases. Mostly, antibodies have been used as bioreceptors for impedance 
biosensor fabrication during the past decade.  
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 Although antibodies offer many advantages as bioreceptors, especially their 
antigen recognition specificity, they have disadvantages that can make them 
troublesome. It is not possible to produce antibodies such as IgG in microbial systems 
because post-translational modifications, e.g. glycosylation are required. Production 
of antibodies needs animal hosts, which leads to batch-to-batch variation. This can 
produce problems with repeatability of biosensor performance. Synthetic binding 
proteins have been developed in order to overcome the downside of antibodies and 
the Affimer is a recently developed non-antibody binding scaffold. In addition to 
properties such as specific recognition of the targets at high affinity, the ease of 
production and thermal stability are additional bonuses, making them an alternative 
to antibodies in biosensing applications. 
 In this thesis, the major focus is to develop a biosensor platform using the 
principle of electrochemical impedance spectroscopy (EIS), together with Affimers to 
detect specific targets, which can be a small molecule or a protein biomarker. This 
work includes Affimer screening, characterisation and the use of Affimers in 
impedance biosensor application.   
 
1.2 What is biosensor and how is it important? 
Recently, biosensors have gained increasing attention from the scientific 
communities since they offer a rapid and cost-effective measurement that can be 
applied to a wide range of research areas. Typically, for conventional laboratory-
based methods, long-processing times, low sensitivity and specificity, cost, and 
specialised requirement for technicians and trained users are the disadvantages that 
prevent them from use in point-of-care (POC) diagnostics and for environmental 
monitoring. However, the advent of biosensors and miniaturisation technology, 
including microfluidics, make small lab-on-a-chip devices possible for self-monitoring 
and POC diagnosis (Rushworth et al., 2013, Ahmed et al., 2014). 
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A biosensor is an analytical device which detects the change in analyte 
concentration, which it then converts into a measurable signal that can be displayed 
by a detector (Rushworth et al., 2013, Conroy et al., 2009, Ronkainen et al., 2010). 
Basically, a biosensor is comprised of three components (Figure 1.1). The first part 
is a biorecognition element which binds to the target analytes such as small 
molecules, proteins, DNA, RNA, bacteria and viruses. The second component is a 
transducer e.g. electrochemical, optical and piezoelectric transducers that changes 
a biological event to a detectable signal. Finally, a measurable readout or signal 
processing display amplifies and interprets the signal and displays it (Rushworth et 
al., 2013).  
In comparison with other conventional laboratory-based techniques, 
biosensors offer considerable advantages. Biosensors usually offer higher sensitivity 
and specificity. The processing time of target monitoring is short. As biosensors are 
created as smaller devices, they can be portable for field use. There is also minimal 
need for any specialist training before operation (Ahmed et al., 2014). Since the 
launch of the first glucose biosensor invented by (Clark and Lyons, 1962), there have 
been applications of biosensors to measure a wide range of analytes including 
bacteria, viruses, nucleic acids, small molecules and protein biomarkers of disease 
(Rushworth et al., 2013, Barton et al., 2009, Mejri et al., 2010, Ravalli et al., 2013). 
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Figure 1.1 A schematic showing basic components of a biosensor system. A basic biosensor is comprised of three components, a biorecognition 
element, a transducer and a measurable readout.
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1.3 Types of biosensors 
 
1.3.1 Optical biosensors 
Optical biosensors are sensors that work on the principle of measuring the 
changes in optical properties resulting from analyte-bioreceptor binding at the sensor 
surface (Ahmed et al., 2014).  In general, based on different detection methods, 
optical biosensors are categorised into two types, label-based and label-free 
detections. In label-based platforms, either the target molecule or the biorecognition 
element is tagged with a chromophore or a fluorophore. In fluorescence-based 
biosensor platform, the fluorescent intensity detected indicates the concentration of 
the target molecules in the sample (Fan et al., 2008).  Despite the fact that the 
fluorescence-based methods offer extreme sensitivity, possibly down to single 
molecule detection, the requirements for sample labelling and processing are the 
main disadvantages of this techniques (Ahmed et al., 2014, Fan et al., 2008). An 
example of fluorescence-based optical biosensors is fluorescence resonance energy 
transfer (FRET) biosensors. The FRET biosensor is non-radiative and works 
principally on the energy transfer from an excited donor fluorophore to an acceptor 
fluorophore via dipole-dipole interaction (Shi et al., 2015a, Shi et al., 2015b).  The 
acceptor molecule is required to absorb energy at the emission wavelength of the 
donor (Chen et al., 2013). Despite its high sensitivity, the efficiency of a FRET sensor 
is limited by the nature of the dipole-dipole interaction with the distance ≤ 10 nm. In 
one study, the researchers applied a FRET biosensor to detect mecA gene of 
Staphylococcus aureus (Shi et al., 2015a). The oligonucleotide probes were 
immobilised onto graphene quantum dots (GQDs) whilst the reporter probes were 
captured on gold nanoparticles (AuNPs). In the presence of target oligonucleotides, 
the co-hybridisation of the target oligonucleotides, the capture probes and the 
reporter probes takes place, bringing GQDs and AuNPs into close proximity. This 
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leads to the decrease in fluorescene intensity or fluorescence quenching, which is 
measurable. The detection limit of the S. aureus gene was down to 1 nM.  To date, 
label-free optical methods overcome these weak points of fluorescence-based 
techniques. Surface plasmon resonance (SPR) is one of the most widely-used label-
free biosensors employed to detect a multitude of analytes (Owen, 1997). SPR 
system basically consists of plane-polarised light that passes through a glass prism. 
When the light propagates in the prism (higher refractive index medium) and hits the 
interface of a thin gold film and the solution (lower refractive index medium), total 
internal reflection (TIR) occurs. At the incident angles larger than the critical angle, 
evanescent waves, which decay exponentially with the distance away from the 
interface, are generated at the side of lower refractive index medium (solution). At a 
specific angle, the evanescent wave is able to excite delocalised electrons or 
plasmons of the gold film, leading to surface plasmon resonance phenomenon. This 
causes the immediate decrease of the intensity of reflected light. The incident angle 
with minimum reflectivity is called ‘SPR angle’. The SPR angle can be shifted upon 
the change in refractive index of the solution of interest, which is subject to mass 
and/or density of materials deposited on the gold surface.  In general, at the base of 
the prism, bioreceptors are functionalised onto gold surface. When the target 
analytes bind to the receptors, the refractive index in the transducer surface is 
altered, leading to a shift in the SPR angle. Optical biosensors based on SPR have 
been employed with various types of bioreceptors, for example, antibodies (Baccar 
et al., 2010, Wang et al., 2012), bacteriophage (Tawil et al., 2012, Tripathi et al., 
2012), lectins (Gasparyan and Bazukyan, 2013, Wang et al., 2013), synthetic binding 
peptides (Michel et al., 2017, Hanenberg et al., 2014, Cheung et al., 2012) and 
oligonucleotides (Kambhampati et al., 2001, Teh et al., 2007). 
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1.3.2 Piezoelectric biosensors 
A piezoelectric biosensor is an analytical device that measures the change in 
resonant frequency caused by the binding of an analyte to its bioreceptor (Rushworth 
et al., 2013, Borman, 1987, Janshoff et al., 2000). There are several examples of 
piezoelectric biosensors including the quartz crystal microbalance (QCM), atomic 
force microscopy (AFM), cantilever biosensors, surface acoustic wave (SAW) and 
others. QCM sensors measures the alteration in resonant frequency due to an 
increase of mass on the sensor surface. This technique has been applied in many 
fields (Xi et al., 2013). AFM is a very high-resolution scanning probe microscopy 
developed by (Binnig et al., 1986). For the basic principle, a cantilever with a sharp 
tip is employed to scan cross the surface of the target to measure its surface 
morphology and show up a 3D image of the surface. In biosensor technology, the 
cantilever surface is modified with a layer of bioreceptors to increase detection of the 
analyte more selectively and specifically (Rushworth et al., 2013). Because of its 
highly sensitivity, AFM is a promising analytical method that has been used for 
pathogen detection, DNA analysis, and biomarker detection (Lavrik et al., 2004), 
although the equipment is complex and costly. Cantilever sensors work on the same 
principle of AFM. However, instead of using a sharp tip as in AFM, free-standing 
beams are used for bioreceptor immobilisation. The bottom of the beam is 
functionalised with bioreceptors whilst the top is coated with a protein resistive 
monolayer film in order to prevent the surface from non-specific binding of analyte 
and unwanted components (Fritz, 2008). In the presence of analyte, the binding of a 
bioreceptor and an analyte causes a compressive surface stress, leading to bending 
of the cantilever. This response changed can be detected by optical beam deflection, 
which is translated into a change of the reflected laser spot position on a detector. 
Cantilever biosensors have been applied for detection of a number of targets such 
as bacteria (Campbell and Mutharasan, 2006, Tzen et al., 2011), parasite (Xu and 
Mutharasan, 2010), biomarker proteins (Arntz et al., 2003, Wu et al., 2001) and 
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oligonucleotides (Calleja et al., 2005, Johnson and Mutharasan, 2012). A SAW 
biosensor is a piezoelectric biosensor which relies on the use of surface acoustic 
waves to monitor biological phenomena such as binding of biomolecules. A basic 
SAW device contains a piezoelectric substrate such as quartz, GaAs, or LiNbO3, an 
input interdigitated transducer, an output interdigitated transducer, and a space 
between two interdigitated transducers known as “the delay line”. The input 
interdigitated transducer converts an electrical signal into an acoustic wave, which 
travels across the surface of the delay line. At the output interdigitated transducer, 
this acoustic wave is converted back into an electrical signal by piezoelectric effect. 
For analyte detection, the delay line is functionalised with bioreceptors. When the 
bioreceptors bind their specific targets, changes in the mass or viscosity occurs 
(Durmuş et al., 2014). This leads to the change of acoustic wave velocity, which can 
be measured by the electrical signal. This type of biosensor has been used for 
monitoring many targets including pathogens (Rocha-Gaso et al., 2009, Howe and 
Harding, 2000, Bisoffi et al., 2008, Berkenpas et al., 2006), proteins (Krishnamoorthy 
et al., 2008, Lee et al., 2011) and odorant molecules (Di Pietrantonio et al., 2013). 
 
1.3.3 Electrochemical biosensors 
Electrochemical biosensors are one of the largest groups of biosensors and 
are widely used in many areas (Zelada-Guillen et al., 2013). Generally, 
electrochemical biosensors are divided into three different subtypes, amperometric, 
potentiometric, and impedimetric biosensors. 
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1.3.3.1 Amperometric biosensors 
Amperometric biosensors are based on the direct monitoring of current 
produced by an electrochemical redox reaction in response to the interaction of 
analyte and bioreceptor while the potential applied between two electrodes remains 
at a constant value (Rushworth et al., 2013, Ahmed et al., 2014, Ronkainen et al., 
2010). The relationship between current and time can be described using the Cottrell 
equation (equation 1.1) as follow. 
𝐼 =  𝑛𝐹𝐴𝐶0√
𝐷
𝜋𝑡
 …………………….(1.1) 
Where :  
I is current in amperes (A), 
n is number of electrons, 
F is Faraday constant (96,485 C mol-1), 
A is area of the electrode in cm2, 
C0 is initial concentration of analyte in bulk solution, 
D is diffusion coefficient of species, 
t is time in second (s). 
In a flow or stirring system where mass-transfer limitation is eliminated, the 
current generated is directly proportional to the concentration of the target analytes 
in the samples (Hirst, 2014). In order for the sensors to measure the analyte-
bioreceptor interaction, oxidoreductases and dehydrogenases are commonly used 
as biorecognition elements for constructing the sensors. A major example is glucose 
oxidase present in many medical glucose sensors (Wang, 2001).  There are several 
advantages that amperometric biosensors can offer including a short response time 
when being used in point-of-care diagnostics. They are also sufficiently sensitive for 
detection, and can be miniaturised. However, because of the electrochemical 
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potential applied to the system, the specificity of the detection process can be low 
and other oxidisable species such as ascorbate and urate can interfere with the 
signal, leading to an error in the results (Higson, 2012). In modern amperometric 
biosensors, electron mediators such as Prussian Blue (PB) and ferrocene (Fc) or 
conducting polymers such as polypyrrole, polythiophene and polyaniline are 
introduced to sensor surface in order to facilitate electron transfer from substrate to 
transducer (Goode, 2015, Hirst et al., 2013, Dong et al., 1992, Qiu et al., 2009, Vidal 
et al., 2003). This enables amperometric biosensors to be operated at much lower 
applied potential and makes the sensors more specific to the analytes. More 
importantly, amperometric biosensors are limited to use for the detection of analytes 
in which an oxidoreductase is available (Rushworth et al., 2013, Ahmed et al., 2014) 
such as the pyrocatechol oxidation catalysed by the laccase enzyme (Kulys and 
Vidziunaite, 2003). 
 
1.3.3.2 Potentiometric biosensors 
In contrast to amperometric biosensors, potentiometric biosensors employ 
ion-selective electrodes to detect the change in potential that occurs in response to 
analyte-bioreceptor interaction while the current used in the system is kept constant 
at zero (Ahmed et al., 2014, Ronkainen et al., 2010, Hirst, 2014). In the sensor 
fabrication step, the chemical sensors are coated with a biorecognition element such 
as a hydrolase which catalyses and generates measurable ions such as H+ or NH4+ 
(Ronkainen et al., 2010). The use of an ion-selective membrane defines the target 
ion measured (Korotcenkov, 2010). In potentiometry, the relationship between free 
ion concentration and potential is governed by the Nernst equation (equation 1.2). 
 
𝐸𝑐𝑒𝑙𝑙 = 𝐸𝑐𝑒𝑙𝑙
0 −
𝑅𝑇
𝑛𝐹
𝑙𝑛𝑄 …………………………..(1.2) 
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Where : 
Ecell is the observed cell potential at zero current and sometimes known as 
electromotive force (EMF), 
E0cell is the constant potential contribution to the cell, 
R is the universal gas constant (8.314 J K-1 mol-1), 
T is the absolute temperature in degree Kelvin, 
n is the charge number of electrode reaction,  
F is the Faraday constant, 
Q is the ratio of ion concentration at the anode to cathode. 
An example of these sensors is the penicillin sensor that uses a pH electrode 
coated with the enzyme penicillinase. This enzyme catalyses penicillin cleavage and 
production of H+ which contributes to the change in pH that can be measured by the 
electrode (Papariel et al., 1973). The construction of potentiometric biosensors is 
inexpensive and the sensors are also easily portable. However, potentiometric 
biosensors are sensitive to pH-active components and interfering species such as 
urea, ammonia and creatine in the samples (Keusgen, 2002, Koncki, 2007). 
Therefore, the measurements of the sensors have to be performed in low buffer 
concentrations to avoid any interferences. However, in diluted buffer, the sensors are 
more sensitive to non-specific effects from pH and buffer capacity of samples 
(Koncki, 2007). In addition, they show a log response to the analyte concentration. 
Potentiometric biosensors are often used in food processing e.g. measurement of 
alcohol concentration in brewing (Rotariu et al., 2004), determination of urea in milk 
(Trivedi et al., 2009) and detection of bacteria in vegetables (Ercole et al., 2003). 
 
1.3.3.3 Impedimetric biosensors 
Impedimetric biosensing is based on the alteration in impedance, namely 
double-layer capacitance and charge transfer resistance, across the surface of 
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working electrodes resulting from the binding of an analyte to its bioreceptor (Ahmed 
et al., 2014, Rushworth et al., 2013). Typically, the change in impedance signal 
detected is proportional to the logarithmic scale of the concentration of analyte 
binding to the biorecognition element. However, as the concentration of analytes 
increases, the impedance might rise or fall down depending on the nature of the 
analyte (Rushworth et al., 2013). Impedimetric biosensors offer some advantages 
over other biosensors because they can be applied to a very wide range of target 
molecules since binding of the analyte and bioreceptor, rather than a specific 
substrate and enzyme, is required. However, there are currently limitations of using 
impedimetric biosensors owing to problems with reproducibility and nonspecific 
binding (Daniels and Pourmand, 2007, Berggren et al., 2001). Furthermore, no 
impedimetric biosensing device is commercially available in the market. In the work 
presented in this thesis, we focus on the use of impedimetric biosensors. 
 
1.4  Electrochemical impedance spectroscopy (EIS) 
Electrochemical impedance spectroscopy (EIS) has become one of the most 
promising and powerful tools employed in biosensor research, particularly for medical 
applications (Millner et al., 2012). The following are the general principle of EIS, and 
the fabrication and applications of impedimetric biosensors. 
 
1.4.1  The brief principle of electrochemical impedance 
spectroscopy 
As mentioned in Section 1.3.3.3, an impedimetric biosensor measures the 
change in capacitance and electron transfer resistance across the sensor surface of 
a working electrode when the biorecognition element captures the target molecule. 
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For faradaic impedance, an electron mediator solution which contains a redox pair 
such as Ru(NH3)63+/2+ (hexaammineruthenium III/II ions) or Fe(CN)63-/4- 
(ferricyanide/ferrocyanide) is present (Chang and Park, 2010). The use of electron 
mediators is to ensure that the charge transfer within impedance is not limited by the 
supply of electrons. Without electron mediators, the monitoring of impedance can be 
achieved and it is known as non-faradaic impedance. 
 In EIS, a small amplitude sinusoidal voltage is applied to the system over a 
broad range of frequencies, typically 100 kHz to 1 mHz (Sekar and Ramasamy, 
2013). The impedance value is calculated as the ratio between the voltage (V) 
applied to the system and the alteration of current (I) detected when V and I are 
plotted as an amplitude sine wave against time (t), or phase angle (𝜃). Both phase 
shift (𝜃) and the change in magnitude (|Z|) of the sine wave lead to the change in the 
impedance, that can be shown by the following equation (equation 1.3). 
 
|𝑍| =
𝑉𝑠𝑖𝑛𝜔𝑡
𝐼𝑠𝑖𝑛(𝜔𝑡+𝜃)
     ………………………………(1.3) 
 Where :  
|Z| is impedance,  
V is maximum voltage,  
I is maximum current,  
t is time (s),  
𝜔 is frequency of oscillating voltage (rad s-1), 
𝜃 is phase angle (rad). 
The data resulting from the EIS is often presented as a Nyquist plot (Figure 1.2A) 
and is modeled according to a Randles’ equivalent circuit (Figure 1.2B). In general, 
a Nyquist plot is comprised of two components; the first is the real or resistive (Z’) 
component of impedance whilst the other is the imaginary or capacitive (-Z’’) 
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component. The shape of the Nyquist plot is semi-circular with a 45-degree rise of 
the Warburg impedance (W) line found at low frequencies due to mass  transfer  
diffusion  effects  (Figure 1.2A).  The semi-circle of the Nyquist plot indicates the 
different electrochemical phenomena on the sensor surface at a range of frequencies 
after the application of voltage. At high frequencies, Z’/-Z’’ does not result from the 
binding between the analytes and receptors, but from the resistance in the solution 
itself. Under this condition, transfer of electrons can reach only the top of an electrode 
surface, but cannot go through it, since the oscillation in current happens too fast for 
electron transfer to take place between electron mediators in the solution and the 
sensor surface. This parameter is represented by the solution resistance (Rs), the x-
axis intercept, which is actually constant. On the other hand, at low frequencies, there 
is adequate time for electrons to move from the mediators in the solution into 
electrode surface. Therefore the ratio of measured impedance is from both dielectric-
layer capacitance (Cdl) and charge transfer resistance (Rct). The Nyquist plot can also 
be translated into the Randles’ equivalent circuit model which was first presented by 
(Randles, 1947).  
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Figure 1.2 Schematic of a Nyquist plot alongside a Randles’ equivalent circuit. (A) a 
Nyquist plot and (B) a Randles’ equivalent circuit model. The values of Rct and Cdl 
can be calculated from the Nyquist plot. (Rs = solution resistance; Rct = charge 
transfer resistance; Cdl = dielectric-layer capacitance; W = Warburg impedance). 
 
 
 The signal intensity from impedimetric biosensors depends on the deposition 
of bulk materials on the sensor surface. In general, when the amount of material 
deposited on the electrode surface increases, a rise in impedance signal is seen 
(Figure 1.3A and 1.3B). There are two main reasons for this event. The first is that 
A 
B 
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the electrons from the mediator in the solution need to get through the multiple layers 
of bulk materials to reach the sensor surface, leading to an increase in charge 
transfer resistance. The other reason is that as the material over the electrode 
surface increases, there is an increase in charge storage capacity. An example of 
this is presented by the experimental data from myoglobin impedimetric sensors 
(Billah et al., 2010). It was observed that as the concentration of myoglobin increased, 
there was a rise in the Rct values. However, this is not for all cases. In the presence 
of analytes that changes the nanostructure or chemical nature of the sensor surface 
(Rushworth et al., 2013), a fall in Rct can be seen (Figure 1.3A and 1.3C). For 
example, in a previous study of a label-free electrical impedimetric biosensor for 
Alzheimer’s amyloid-beta oligomers, it was found that the measured Rct decreased 
with an increase of AβO concentration, corresponding to increased capacitance and  
decreased resistance on the sensor surface (Rushworth et al., 2014). This is most 
likely due to the binding of AβO to the biorecognition element, PrP95-110, that can 
increase the conductivity of the electrode surface, leading to a decrease in 
impedance. 
 According to the Randles’ equivalent circuit model (Figure 1.2), Rct is the 
most frequently used parameter to evaluate the performance of impedimetric 
biosensors as the change of Rct is proportional or inversely proportional to the 
amount or concentration of target analyte (Billah et al., 2010, Rushworth et al., 2014, 
Ahmed et al., 2013, Goode et al., 2016, Barton et al., 2008, Caygill et al., 2012). 
However, the change in capacitance has occasionally been employed for the same 
purpose. Double-layer capacitance (Cdl) is a parameter representing the storage of 
electrical energy occurred by the formation of electrical double layer at the interface 
between the electrode and the solution of electrolyte. This parameter is equivalent to 
a capacitor in the electrical circuit (Sekar and Ramasamy, 2013). The Cdl can be 
changed depending on a number of factors such as electrode polarisation, ionic 
concentration in bulk solution, temperature, type of ions and roughness of electrodes.   
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Figure 1.3 Schematic showing possible impedance shifts resulting from binding of 
analytes and receptors on the sensor surface.The Fe(CN)63-/4- redox pair is widely 
used as electron mediator. In general, the impedance increases from (A), an 
electrode surface with attached bioreceptors to (B), an electrode surface with 
bioreceptors binding to target molecules. In some circumstances (C), a decrease in 
impedance can be found after bioreceptors bind to analytes. 
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In the case of a pure capacitor, the metal surface is perfectly smooth and 
undamaged, providing very high impedance with the phase shift at 90o. However, in 
impedimetric biosensors, the purely capacitive surface does not truly exist as there 
is contamination and roughness of the electrodes and the phase angles normally fall 
between 0o and 90o (Sekar and Ramasamy, 2013). As a result, the Cdl is replaced by 
constant phase element (CPE). As well as the Rct, the CPE can be obtained from 
fitting with the Randles’ equivalent circuit model. In impedimetric biosensors, the 
change in capacitance values has been used for a vast range of analytes of interest. 
In 2015, Jolly and co-workers developed an aptamer-based impedimetric biosensor 
to detect prostate specific antigen (PSA), a biomarker for prostate cancer (Jolly et al., 
2015). The researchers used faradaic impedance measurement to investigate the 
binding of the aptamer and PSA. The impedance data were converted into complex 
capacitance and the changes in capacitance were then obtained. They found that the 
increase of capacitance was observed with increasing concentrations of PSA. 
Fernandes and his team reported the fabrication of impedimetric biosensors using 
antibodies to detect C-reactive protein (CRP) (Fernandes et al., 2014). The antigen-
antibody interaction was detected via the change in capacitance. The decrease in 
capacitance was observed as the concentration of CRP increased. Kim and her 
colleagues also employed EIS to monitor bacterial adhesion and biofilm maturation 
using the change in capacitance values (Kim et al., 2011). The researchers observed 
that the decrease in capacitance was seen as the predetermined times indicating the 
growth of bacteria increased. Taken these examples together, the change in 
capacitance (increase or decrease) depends on the nature of target analytes and 
bioreceptors. 
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1.4.2  Fabrication of impedimetric biosensors 
 
1.4.2.1 Electrodes 
Screen-printed transducers are usually composed of three different types of 
electrodes, namely a working electrode, a reference electrode and a counter 
electrode. In some cases there can be more than one working electrode. The working 
electrodes are functionalised by attachment of biorecognition elements such as 
antibodies, enzymes, peptides and nucleic acid oligomers on their surface. The 
reference electrode has a role in measuring and controlling the working electrodes’ 
potential when the current is applied to the surface of the working electrodes. 
Ultimately, the counter electrode supplies current to the system so that the balance 
of potential between the electrode and solution is still maintained.  
To select suitable electrode materials, there are several key properties that 
are needed including high conductivity and biocompatibility (Rushworth et al., 2013). 
Regarding the limitations of each material, materials generally used for construction 
of biosensors are gold (Au), platinum (Pt) and various forms of carbon (Barton et al., 
2009, Alizadeh and Akbari, 2013, Lee et al., 2008). However, in this review only gold 
is further mentioned in more detail. Gold is one of the most popular materials for the 
use as a working electrode material. This is because it can offer several advantages 
over other materials. For example, its high conductivity and potential surface flatness, 
which sometimes need to be modified for the reduction of roughness, can benefit 
functionalisation of the transducer surface. Moreover, for bioreceptors which possess 
external thiols, this makes it easy to attach the bioreceptors to the gold electrode 
surface via crosslinking between primary amine groups from the polymer and 
sulfhydryl groups from the bioreceptors (Millner et al., 2009). In principle, 
bioreceptors can be attached directly to gold via thiol-chemisorption, but this is 
usually inadvisable as it often causes inactivation of the bioreceptor.  Gold has been 
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applied for use in a wide range of bioanalytical systems such as disease biomarker 
detection (Hu et al., 2013, Rushworth et al., 2014, Johari-Ahar et al., 2015) and small 
molecule measurement such as lysine, chloramphenicol and lead (Chauhan et al., 
2013, Pilehvar et al., 2012, Cui et al., 2016). 
 
1.4.2.2 Functionalisation of transducer surface 
There are several techniques that are useful for functionalising transducer 
surfaces and the three most widely-used ones are self-assembled monolayers 
(SAMs), conducting polymers and non-conducting polymers. 
 
1.4.2.2.1 Self-assembled monolayers (SAM) 
SAM-based biosensors can be formed by chemisorption of organic molecules 
with functional groups such as thiols, disulphides, amines, acids and silanes, onto 
the surface of sensor electrodes (Arya et al., 2009). Typically, SAMs can be formed 
using long chain molecules consisting of a head group that can capture a target 
molecule, an alkyl chain that can make the assembly stable using van der Waals 
interactions and 𝜔-functionality that is essential for the formation of a monolayer. 
Examples of long chain molecules are mercaptohexadecanoic acid (MHDA) (Billah 
et al., 2010, Rodgers et al., 2010) and other fatty acids (Lim et al., 2007, Litjeblad et 
al., 2014). In addition, small aromatic molecules including 4-aminothiophenol (4-ATP) 
(Conroy et al., 2010, Billah et al., 2010, Valerio et al., 2008) and many types of silane 
(Lessel et al., 2015, Herzer et al., 2010) can also be used for SAM formation. 
Because of its high stability, homogeneity of the surface structure and ease of 
generating different layers, SAMs can be a suitable choice for biosensor 
development. To employ SAMs for biosensing applications, modification of the SAM 
is needed. There are several methods that have been used to modify SAMs, for 
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example, physical adsorption (Nam et al., 2004, de Groot et al., 2007), chemical 
activators (Dannenberger et al., 2000), chemical cross-linkers (Billah et al., 2010, 
Arya et al., 2007, Arya et al., 2006) and exchange processes (Satjapipat et al., 2001). 
 
1.4.2.2.2 Conducting polymers 
Recently, conducting polymers (CPs) have gain popularity for biosensor 
research thanks to their unique properties. Although some of their characteristics are 
similar to those of metals and semiconductors, many physical properties linked to 
their conventional counterpart such as flexibility and ease of synthesis, are still 
retained. It has been demonstrated that while interacting with biomolecules, CPs can 
still show good biocompatibility (Nambiar and Yeow, 2011). Therefore, CPs are 
promising candidates for biosensor development. 
CPs can be categorised into three groups: intrinsically conducting polymers, 
redox polymers and ionically conducting polymers. Intrinsically conducting polymers 
including polyacetylene (PA), polypyrrole (PPy), polythiophene (PT) and polyaniline 
(PANI) (Figure 1.4) have been widely used as sensor base layers for biosensor 
construction. This is because intrinsically conducting polymers are more conductive 
than two other classes of CPs. The chemical structure of intrinsically conducting 
polymers is highly flexible due to their delocalised 𝜋-electrons, which makes them 
possess the desired electronic and mechanical properties after modification. In 
addition, because of their ability to transfer electrons generated by biochemical 
reactions, intrinsically conducting polymers have been widely used as a supporting 
layer between the bioreceptor and transducer surface in biosensors (Nambiar and 
Yeow, 2011). There are previous studies on a diverse range of conducting polymer 
based biosensors for measurement of viruses (Borole et al., 2006, Janata and 
Josowicz, 2003, Gerard et al., 2002). For impedimetric biosensors, CPs have 
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successfully been employed as a part of the sensor for detection of many different 
targets, for example, whole viruses (Caygill et al., 2012), foodborne pathogens 
(Arshak et al., 2009), small molecules such as Ochratoxin A (Khan and Dhayal, 
2009), cardiac drugs e.g. digoxin (Barton et al., 2009) and oligonucleotides 
(Sosnowska et al., 2013, Peng et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Chemical structures of widely-used conducting polymers for construction 
of biosensors.The polymers are typically deposited onto sensor surfaces using 
electropolymerisation, which can be done by cyclic voltammetry. 
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1.4.2.2.3 Non-conducting polymers 
 In the recent years, non-conducting polymers have gained more attention for 
their applications into biosensor fabrication. Apart from their similar properties to 
conducting polymers, non-conducting polymers offer resistivity and perm-selectivity, 
avoiding interference from oxidisable species such as ascorbate, urea, and 
acetaminophen (Miao et al., 2004). In addition, when electropolymerising this type of 
polymers on a solid surface, the formation of the film is often self-limiting. The 
thickness of non-conducting polymer layer is significantly thin and usually between 
10-1000 nm. Often, charged species from aqueous solutions can easily travel 
through the polymer layer, making this type of polymer a suitable coating material for 
modifying transducer surface (Miao et al., 2004). Several non-conducting polymers 
have recently been applied for electropolymerisation in biosensors such as 
polytyramine, poly(1,3-diaminobenzene), poly(2-aminophenol), polyphenylene-
diamine and so on (Miao et al., 2004, Ahmed et al., 2013, Pournaras et al., 2008, 
Rushworth et al., 2014, Ekinci et al., 1996, Ekinci et al., 1998).  
 Polytyramine is one of the most non-conducting polymers extensively used 
for biosensor construction (Figure 1.5). A chain of polytyramine can be 
electrochemically formed from monomers known as tyramine or 4-(2-
aminoethyl)phenol which is a derivative of tyrosine. As well as other non-conducting 
polymers, polytyramine has excellent properties that are effective when incorporated 
into biosensor fabrication. This polymer has one primary amine group per tyramine 
which is of benefit for immobilisation of biomolecules. With self-limiting growth when 
being electropolymerised on the surface of electrodes, a polytyramine film is very thin 
(1-100 nm) and fairly smooth, which enables charged molecules to diffuse rapidly. 
Therefore, the response of polytyramine-coated sensors can be highly sensitive 
(Miao et al., 2004, Ismail and Adeloju, 2010). 
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Figure 1.5 Chemical structures of two non-conducting polymers used in biosensor 
applications. The polymers are typically deposited onto sensor surfaces using 
electropolymerisation, which can be conducted by cyclic voltammetry. 
 
1.4.2.3 Conjugation of bioreceptors to transducer surface 
There are several techniques that can be used for tethering bioreceptors to 
electrode surfaces. Several of the most common methods are now described in more 
detail.  
 
1.4.2.3.1 Adsorption 
Adsorption is the simplest technique used for immobilising biomolecules onto 
sensor surfaces (Figure 1.6A). There are two types of adsorption, namely physical 
adsorption and ionic binding (Liebana and Drago, 2016). Physical adsorption 
requires the formations of hydrogen bonds, Van der Waals forces and hydrophobic 
interactions between amino acid side chains and the solid support surfaces, whereas 
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Figure 1.6 General methods to immobilise bioreceptors to transducer surface. (A) 
Adsorption, (B) Matrix entrapment, (C) Covalent bonding via crosslinkers and (D) 
Bioaffinity. 
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for ionic binding, positively charged and negatively charged components are needed 
when forming salt linkages (Mohamad et al., 2015). This method is simple, rapid and 
cost effective. However, because of weak interactions in the adsorption process, 
there are drawbacks such as reduced reproducibility and desorption of biomolecules 
following changes in the solvent including ionic strength and pH (Sassolas et al., 
2012, Scouten et al., 1995, Liebana and Drago, 2016). Another downside is the 
random orientation of biomolecules attached to the surface that makes sensors less 
sensitive for detecting the analyte of interest.  
 
1.4.2.3.2 Entrapment 
Entrapment is a generally irreversible immobilisation technique (Figure 1.6B). 
Biomolecules, mostly enzymes, are entrapped in a polymeric support or fibre matrix, 
but do not bind or interact with the support (Liebana and Drago, 2016, Sassolas et 
al., 2012, Mohamad et al., 2015). The polymer layer allows substrates and products 
to pass through, whereas the enzymes are still trapped inside the matrix.  Using this 
technique is advantageous since no enzyme modification is required and the 
enzymes still retain their function. As the enzymes are entrapped inside the polymer 
matrices, it can help improve mechanical stability and minimise the effects of 
environmental changes. However, entrapping the enzymes in thick layers of polymer 
can lead to mass transport limitations. In some cases, if the pore size of the matrix is 
too large, enzyme leakage can occur, leading to the loss of sensor sensitivity 
(Liebana and Drago, 2016, Sassolas et al., 2012, Scouten et al., 1995).  
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1.4.2.3.3  Covalent bonding via cross-linking of bioreceptors  
Covalent bonding is another irreversible immobilisation method which is 
widely used for electrode surface modification in biosensor construction (Figure 
1.6C). To immobilise biomolecules to sensor surfaces, the crosslinkers are used to 
facilitate the reactions (Liebana and Drago, 2016, Sassolas et al., 2012). Crosslinkers 
are molecules which often contain reactive groups at both ends of their structure and 
can interact with specific functional groups in amino acid side chains although some 
crosslinkers such as the EDC/NHS couple described in detail below catalyse the 
reaction of two side chains e.g. –NH2 and –COOH to form a peptide bond. Covalent 
cross-linking offers several advantages such as high stability and high binding 
strength. However, disadvantages can be found when using this type of 
immobilisation. For example, the reagents can be costly and diffusion limitation might 
occur, causing inactivation of the bioreceptor (Sassolas et al., 2012, Scouten et al., 
1995, Liebana and Drago, 2016). The most common reactions used for covalent 
cross-linking are described as follows: 
N-hydroxysuccinimide (NHS) ester reaction (Figure 1.7A): this reaction 
requires a crosslinker containing a NHS-carboxy ester and a primary amine  
(-NH2) group typically found at the side chain of lysine (Hermanson, 2008). The 
reaction can be driven forward in pH 7-9 buffer and it should be noted that buffers 
containing primary amines cannot be used as they compete with the primary amine 
on biomolecules of interest. The examples of NHS ester crosslinkers are biotin N-
hydroxysuccinimide ester (biotin-NHS) and sulfosuccinimidyl 4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (sulfo-SMCC). 
EDC (carbodiimide) coupling reaction (Figure 1.7B): this reaction facilitate the 
conjugation of carboxylates (-COOH) to primary amine (-NH2) (Hermanson, 2008). 
Carboxylic acid reactive groups can be found at C-terminus of proteins and side 
chains of aspartic acid and glutamic acid. In the reaction, EDC first reacts with a 
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carboxylic group on the protein and forms an active O-acylisourea intermediate. By 
nucleophilic attack, the primary amine present at the polymer surface reacts with the 
carboxylic group to form an amide bond, causing the release of EDC by-product as 
a urea derivative.The EDC cross-linking reaction can effectively be performed in 
acidic (pH 4.5) condition. However the reaction can still occur at neutral pH with 
excess amount of EDC.  Frequently, NHS or sulfo-NHS (a more water-soluble 
analogue) is added to the reaction to improve the efficiency of the reaction and 
generate a dry-stable intermediate before the conjugation. 
Maleimide reaction (Figure 1.7C): a thiol group from the side chain of cysteine 
can form a covalent bond with a maleimide reactive group via the maleimide reaction 
(Hermanson, 2008). Prior to bioconjugation, any disulfide bonds are usually broken 
using reducing agents such as dithiothreitol (DTT), 2-mercaptoethylamine (2MEA) 
and tris-(2-carboxyethyl)phosphine (TCEP), allowing free thiol groups to interact with 
maleimide reagents. In recent times, TCEP is favoured as DTT or 2MEA must be 
removed before conjugation or they would also react with the maleimide group. To 
form a thioether bond, the reaction is recommended to set at the near neutral (pH 
6.5-7.5) conditions. An example of a maleimide-activated reagent is sulfo-SMCC. 
Hydrazide reaction (Figure 1.7D): bioconjugation via the hydrazide reaction 
requires a carbonyl (aldehyde or ketone) group, which are present on 
oligosaccharides, as a target site for cross-linking (Hermanson, 2008). This reaction 
is especially useful for controlling the orientation of antibodies as there are 
polysaccharides located at the Fc region of IgG and other antibodies. Carbonyl 
groups can be created in polysaccharides by oxidising them with sodium meta-
periodate. The activated moieties called oxidised sugars can now react with 
hydrazide reagents at pH 5-7 and create hydrazine bonds. An example of a 
hydrazine-containing reagent for bioconjugation is biotin-hydrazide. 
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Figure 1.7 Examples of covalent bonding reactions via the crosslinkers. (A), NHS ester reaction; (B), EDC coupling reaction; (C), maleimide 
reaction and (D), hydrazide reaction. (R) represents a labelling reagent or a crosslinker molecule and (P) represents a protein. 
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 Figure 1.7 (continued) Examples of covalent bonding reactions via the crosslinkers. (A), NHS ester reaction; (B), EDC coupling reaction; (C) 
maleimide reaction and (D), hydrazide reaction. (R) represents a labelling reagent or a crosslinker molecule and (P) represents a protein. 
C 
D 
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1.4.2.3.4 Bioaffinity  
Bioaffinity is a non-covalent immobilisation technique. The approach exploits 
the specific recognition between two molecules as a crosslinker (Figure 1.6D). Using 
this method, oriented and site specific immobilisation of bioreceptors can be effected, 
minimising the loss of function of bioreceptor because the binding site of the 
bioreceptor is placed in the correct orientation (Sassolas et al., 2012, Scouten et al., 
1995, Liebana and Drago, 2016). Many specific interactions can be fairly easily 
reversed. This allows the electrode surface to be regenerated, reducing the cost of 
production. Examples of common bioaffinity couples that have been widely used in 
biosensors are avidin/biotin, polyhistidine tag/chelated metal ions, and 
antibodies/antigens. 
Biotin-avidin interaction: one of the most commonly used techniques for 
bioreceptor immobilisation is via the biotin-avidin interaction. This method allows 
oriented bioreceptor immobilisation to take place conveniently. To use this method, 
both the biorecognition element and the polymer on the sensor surface need to be 
biotinylated prior to bioconjugation. During the conjugation step, avidin or one of its 
analogues such as streptavidin or NeutrAvidin, which are tetrameric biotin-binding 
proteins, are employed as a bridge connecting the biotinylated receptor molecule to 
the biotin-tagged polymer. Despite being a non-covalent bond, the biotin-avidin 
interaction has a dissociation constant (KD) of approximately 10-15 M (Liebana and 
Drago, 2016, Sassolas et al., 2012) which makes it strong and stable enough to 
support the building of biosensors. 
  The avidins are tetrametric proteins, which are stable over a wide range of pH 
and temperature. Avidin protein itself is found in egg white. The molecular mass of 
this protein is about 67 kDa. Interaction with biotinylated molecules is barely affected 
by changes in pH, temperature, organic solvents, and denaturing agents. However, 
avidin is glycosylated and has an isoelectric point (pI) of 10, which can cause non-
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specific binding. As an alternative, avidin’s analogues, namely streptavidin (from 
Streptomyces avidinii) and Neutravidin (reengineered avidin) have minimal non-
specific binding. Streptavidin is a 53 kDa protein and its isoelectric point is near 
neutral (6.8-7.5). Unlike avidin, there is no glycosylation site on streptavidin, which 
helps minimise non-specific binding to other molecules. However, with its RYD 
recognition sequence, Streptavidin tends to interact with fibronectin and other 
adhesion-related molecules (Alon et al., 1990). The other analogue of avidin is 
Neutravidin, which is a 60 kDa tetrametric protein. NeutrAvidin is a reengineered non-
glycosylated version of avidin and has its isoelectric point of 6.3. Without 
carbohydrate modifications and RYD recognition sequences, Neutravidin should 
have even left non-specific binding. Currently, both streptavidin and Neutravidin are 
used as a linker in the fabrication of biosensors. 
Biotin or vitamin H is naturally found in all living organisms. The structure of 
biotin contains two cyclic rings, a short spacer and a carboxyl functional group. This 
functional group can be modified to produce biotinylation reagents such as biotin-
NHS, biotin-maleimide and biotin-hydrazide. As the biotin is small (MW = 244.309), 
the addition of biotin to proteins does not affect their conformation, size or 
functionality to any real extent (Rusmini et al., 2007). 
Polyhistidine tag and metal ions: affinity tags enable interaction that can be 
used for biosensor applications. In general, 6-8 histidine residues are introduced to 
the N- or C-terminus of recombinant proteins as an affinity tag. The polyhistidine tag 
is placed far from the binding sites of proteins, allowing ligand binding to be 
unaffected (Rusmini et al., 2007). Histidine-rich regions in a protein are capable of 
interacting with divalent metal ions including Ni2+, Cu2+ and Zn2+. The solid support is 
initially coated with a chelating agent, typically nitrilotriacetic acid (NTA), prior to being 
loaded with divalent cations. Mostly Ni2+ is employed, but Cu2+, Mn2+ and Fe2+ have 
all been used.  Following this, recombinant proteins with polyhistidine tag attach to 
the surface via the Ni2+-NTA group.  
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The dissociation constant for this interaction is in the low affinity range of 10 
µM (Rusmini et al., 2007). The interaction can be interrupted by adding competitive 
ligands such as imidazole, histidine and ethylenediaminetetraacetic acid (EDTA). 
This is beneficial for a surface that requires regeneration. However, it is not suitable 
for sensors that need long-term storage. 
Protein A/G, and antibodies: protein A and G are surface proteins found in 
some species of pathogenic bacteria. Protein A is expressed on the cell wall of 
Staphylococcus aureus, whereas protein G is obtained from Streptococcus species 
(Liebana and Drago, 2016, Liu and Yu, 2016). These two proteins bind to the Fc 
region of immunoglobulins, contributing to oriented immobilisation of IgGs. The 
specificities of protein A and G to the Fc regions of antibodies rely on the host species 
in which antibodies are produced. Protein A recognises antibodies from cats, 
humans, guinea pigs, rhesus monkeys, and rabbits (Liebana and Drago, 2016). In 
comparison, protein G however binds specifically to antibodies from rats, goats, 
sheep and cows. Despite the strong binding of protein A and G to Fc regions, they 
can also interact with the Fab regions of antibodies. Therefore, researchers who use 
this method for antibody attachment may need to take this into account. Protein G in 
its native form is also able to bind albumin (Sjobring et al., 1989), possibly causing a 
non-specific response when applying for biosensors. Nowadays, thanks to the 
advancement of genetic engineering techniques, protein A/G, a recombinant fusion 
version of protein A and G, can be generated (Eliasson et al., 1988). The recombinant 
protein A/G is very useful since the Fc binding properties of protein A and G are 
combined. Hence, a wider range of antibodies can be used with this protein. 
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1.4.3 Applications of impedimetric biosensors 
Owing to the advantageous properties of impedimetric biosensors such as 
small device size, low sample volumes, label-free detection without sample 
preparation and low production cost, there have been a plethora of publications of 
impedimetric biosensors for detecting various kinds of analytes such as whole cells, 
proteins or peptides biomarkers for diseases and small molecules (Rushworth et al., 
2013). Some of the analytes successfully detected by impedimetric protocols are 
indicated in Table 1.1. 
According to the review of (Berggren et al., 2001), capacitive biosensors, 
based on the measurement of the electrical capacitance or impedance, were 
developed to be a tool for capturing a wide range of targets including antigens, 
antibodies, proteins, DNA fragments and heavy metal ions. Using interdigitated 
electrodes, the biosensor provided low detection limits down to 10-15 M for each kind 
of analytes. Impedimetric protocols were applied to detect different species of 
bacteria. Using a biotinylated polyclonal anti-Escherichia coli antibody and SAM 
based sensor with electrochemical impedance spectroscopy, E.coli cells were 
detected at a detection limit of 10 cfu/ml for whole cells compared to a concentration 
of 107 cfu/ml by the use of SPR (Maalouf et al., 2007). Another work was focused on 
the use of electrochemical impedance spectroscopy to detect Escherichia coli and 
Salmonella typhimurium (Laczka et al., 2008). The sensor was constructed by 
immobilising biotinylated polyclonal antibodies onto Neutravidin-coated chips and 
had a detection limit of around 104-105 cells/ml. Because of good selectivity and low 
cross-reactivity, an impedimetric biosensor was selected to detect Streptococcus 
pyogenes, a pathogenic bacterium that causes invasive and noninvasive infections 
in human (Ahmed et al., 2013). Regarding the protocol for this report, tyramine (Tyr) 
monomers were electropolymerised onto the sensor as a supporting layer and biotin-  
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Table 1.1   Applications of impedimetric biosensors for the detection of different 
types of analytes 
Analyte Electrode Transducer 
surface 
Bioreceptor Reference 
Bacteria 
E.coli Gold SAM Antibody (Maalouf et al., 
2007) 
E.coli and 
S.typhimurium 
Gold - Antibody (Laczka et al., 2008) 
S.pyogenes Gold Polytyramine Antibody (Ahmed et al., 2013) 
Viruses 
Dengue Porous 
alumina 
membrane 
Platinum Antibody (Peh and Li, 2013) 
 
Adenovirus Gold Polyaniline and 2-
aminobenzylamine 
Half antibody (Caygill et al., 2012) 
Vaccinia virus Gold Thiol-modified 
primer 
Aptamer (Labib et al., 2012) 
Proteins and peptides 
Ara-h-1 Gold SAM Antibody (Huang et al., 2008) 
Prostate 
specific 
antigen 
Carbon Polyaniline Antibody (Barton et al., 2008) 
Amyloid-beta 
oligomer 
Gold Polytyramine/3-(4-
hydroxyphenyl) 
propionic acid 
Cellular prion 
protein (PrPC) 
(Rushworth et al., 
2014) 
Myoglobin Gold 4-aminothiophenol 
SAM 
Half antibody (Billah et al., 2010) 
Human IgE Gold SAM Aptamer (Xu et al., 2005) 
Anti-myc tag 
antibody 
Gold SAM Affimer (Raina et al., 2015) 
C-reactive 
protein 
Gold SAM Affimer (Johnson et al., 
2012) 
Interleukin-8 Gold SAM  Affimer (Sharma et al., 
2016) 
Small molecules 
Ciprofloxacin Carbon Polyaniline Antibody (Tsekenis et al., 
2008) 
Uranyl ions Gold L.sphaericus JG-
A12 S-layer 
protein 
Uranyl binding 
protein 
(Conroy et al., 2010) 
Digoxin Carbon SAM/EDC/NHS Antibody (Barton et al., 2009) 
Adenosine Gold SiO2 Aptamer/nucleic  
acid 
(Zayats et al., 2006) 
Ochratoxin A Gold 4-carboxyphenyl  
monolayer 
Antibody (Radi et al., 2009) 
 
Abbreviations: SAM, self-assembled monolayer; EDC, ethyl(dimethylaminopropyl) 
carbodiimide; NHS, N-hydroxysuccinimide 
36 
 
  
tagged whole antibodies against S. pyogenes were deposited on the polymer layer.  
The detection limits of this biosensor ranged from 104-107 cells/ml of bacteria. 
Impedimetric biosensors have not only been used to detect bacteria, but also 
applied for detection and quantitation of viruses. For example, a novel impedimetric 
assay based on the use of reduced antibody fragments as biorecognition elements 
specific to a human Adenovirus 5 (Ad5) capsid protein was developed. The surface 
of the sensor chip was coated with a functionalised conducting co-polymer matrix 
consisting of polyaniline and 2-aminobenzylamine, followed by immobilisation of an 
anti-Ad5 half-antibody onto this layer. It was found that the limit of detection was 103 
virus particles/ml (Caygill et al., 2012). Proteins are one of the most common targets 
for impedimetric biosensors. An impedance biosensor for peanut protein Ara-h-1, 
which is one of the allergenic proteins found in peanut was constructed successfully 
(Huang et al., 2008). A specific antibody against Ara-h-1 protein was immobilised 
onto a self-assembled monolayer (SAM). It was estimated that this reagentless 
biosensor provided a limit of detection of less than 0.3 nM and the KD for the Ara-h-1 
protein was around 0.52 nM. As well as the allergenic protein in peanuts, a labeless 
immunosensor assay based upon an ac impedance protocol used to detect prostate 
specific antigen (PSA) was also produced (Barton et al., 2008). Biotinylated 
antibodies for prostate specific antigen (APSA) were deposited onto screen-printed 
carbon electrodes by the classical avidin-biotin affinity technique. The limit of 
detection was down to a level of sub-pM PSA. Additionally, an immunoassay based 
on an AC impedance protocol was applied for the detection of fluoroquinolone 
antibiotics in milk. For this sensor, biotinylated antibodies against ciprofloxacin were 
immobilised onto a layer of polyaniline which was electropolymerised onto 
commercial screen-printed carbon electrodes. The assay could be employed to 
detect the analyte ciprofloxacin in the range of 0.3 – 300 nM (Tsekenis et al., 2008). 
A label-free and reagentless aptamer-based sensor was developed to detect the 
small molecule adenosine (Zayats et al., 2006). Aptamer/nucleic acid duplexes were 
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coated on the sensor surface as the bioreceptors. The device had a sensitivity limit 
of 5 x 10-5 M (Zayats et al., 2006). Also, a label-free impedimetric immunosensor for 
detection of ochratoxin A was constructed (Radi et al., 2009). The ochratoxin A 
antibody was immobilised onto the stable 3-carboxyphenyl (4-CP) monolayer which 
was deposited onto a gold electrode. The sensor had a detection limit of 1.2 nM. 
 
1.5 Classification of bioreceptors 
1.5.1 Types of common bioreceptors used for fabricating 
electrochemical biosensors 
1.5.1.1 Enzymes  
Enzymes act to accelerate chemical reactions in living organisms. As a part 
of the catalytic reaction, enzymes use a binding pocket, the active site to bind their 
substrates and convert them into products. Some enzymes require cofactors or 
coenzymes to work effectively. In biosensor applications, enzymes were the first 
biorecognition elements that were successfully used to detect a target in an 
electrochemical biosensor. This platform was developed in 1962 by Clark and Lyon 
(Clark and Lyons, 1962) who used glucose oxidase (GOx) as the bioreceptor to 
monitor glucose in blood. To date, enzymatic biosensors have been developed to be 
specific for a variety of targets including glucose, lactate, glutamate, urea and 
cholesterol (Ispas et al., 2012). Enzymes that have been widely employed in 
biosensor fabrication are oxidases and dehydrogenases (Rocchitta et al., 2016) since 
they can catalyse oxidation-reduction reactions, generating electroactive species that 
can be turned into a measurable signal. The catalytic activities of enzymes strongly 
rely on pH and temperature (Xu, 1997) and the extreme pH and temperature beyond 
the optimal conditions can cause enzymatic deactivation and denaturation.   
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1.5.1.2 Antibodies 
Antibodies are one of the most widely used bioreceptors. In mammals, 
antibodies are proteins produced by B lymphocytes of the adaptive immune system 
in response to foreign antigens. Mostly, interactions between antibodies and their 
antigens are highly specific with dissociation constants (KD) in the pM – nM range 
(Kim et al., 1990, Landry et al., 2015). The specific recognition of antibodies and their 
targets takes place at the complementarity determining regions (CDR) or hyper-
variable regions. These regions show an extremely high diversity in their amino acid 
sequences as a result of gene rearrangements during B-cell development and 
somatic hypermutation (Conroy et al., 2009). The diversity of antibodies is necessary 
since different antigens require different antibodies with highly specific binding. 
Polyclonal antibodies can be produced by injecting antigens into animal hosts such 
as rabbits, goats or sheep (Byrne et al., 2009). These antibodies are a mixed 
population of antibodies from different B-cells and recognise different epitopes on 
antigens. If a recognition of a single epitope is needed, it is possible to isolate the 
particular clone responsible for that particular IgG. These antibodies, termed 
monoclonal, can be isolated using hybridoma technology (Byrne et al., 2009). Detail 
of monoclonal antibody production is described in Section 1.5.2.2.1. 
 
1.5.1.3 Synthetic binding proteins 
 Synthetic binding proteins are recently developed bioreceptors as an 
alternative to antibodies. The core structure of synthetic binding proteins can be 
derived from different core scaffolds from a range of proteins (Nygren and Skerra, 
2004, Skerra, 2007). The libraries comprising genes encoding non-antibody binding 
scaffolds with variable peptide regions are constructed in display systems such as 
phage display libraries (Conroy et al., 2009). Binders highly specific for a target of 
interest can be selected from these complex libraries using biopanning, which are 
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described in more detail in Section 1.5.2.2.2. Additionally, synthetic binding proteins 
offer properties that antibodies cannot. For example, synthetic binding proteins are 
typically highly stable, small in size and easy to immobilise onto a surface (Binz et 
al., 2005). Expression of synthetic binding proteins can be performed in E.coli and 
similar microbial systems. Up to this moment, a number of synthetic binding proteins 
have been released to the public including Affibodies (Lofblom et al., 2010), DARPins 
(Stumpp et al., 2008), Anticalins (Skerra, 2008) and Affimers (Ferrigno, 2016, Tiede 
et al., 2017). 
 
1.5.1.4 Aptamers 
Aptamers are RNAs or single-stranded DNAs that show specific interaction to 
their targets. As well as synthetic binding proteins, aptamers also provide an 
alternative to antibodies. Aptamers offer a structure which is usually stable at high 
temperature. The production of Aptamers is cost effective with great accuracy and 
reproducibility. As nucleic acids are typically not recognised by human immune 
system as foreign antigens, Aptamers are low-immunogenic to human bodies. These 
make Aptamers suitable for a variety of analytes (Song et al., 2012). The selection of 
the binders for the target of interest from a population of oligonucleotides can be 
achieved through Systematic Evolution of Ligands by Exponential enrichment 
(SELEX). In brief, a combinatorial oligonucleotide library is initially converted into 
single stranded nucleotides consisting random sequence regions. The target is then 
used to select Aptamers that bind to it before unbound Aptamers are removed. 
Polymerase chain reaction (PCR) is then used to amplify the selected 
oligonucleotides since the random region is flanked by defined primer sequence at 
each end. The steps above are repeated for a number of cycles to enrich the 
oligonucleotides that show strong binding to the target (Song et al., 2012, Darmostuk 
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et al., 2015). Aptamers have been applied for a plethora of targets, e.g. cells, 
bacteria, viruses, proteins, small molecules and ions (Wu and Kwon, 2016).  
 
1.5.1.5 Whole cells 
Whole cells have been used as bioreceptors to fabricate biosensors for 
detecting hazardous substances, contaminants and pollutants in the environments 
(Pancrazio et al., 1999, Ziegler, 2000, Lagarde and Jaffrezic-Renault, 2011, Banerjee 
and Bhunia, 2009). Both prokaryotic cells like bacteria and eukaryotic cells such as 
yeast and mammalian cells can be used since the cellular mechanisms of these 
organisms are affected or interrupted when exposed to pathogenic and toxic 
substances. In detection, receptors presenting on their cell membranes bind the 
analytes of interest. The receptors can be naturally present on the cell membranes 
or be engineered using recombinant DNA techniques (Pancrazio et al., 1999, 
Banerjee and Bhunia, 2009). The interactions between the cells and their targets 
cause changes in cell morphology and physiology, and cellular damage such as cell 
membrane leakage, pore formation, and apoptosis or cell death (Pancrazio et al., 
1999, Banerjee and Bhunia, 2009). These events can be measured by a variety of 
techniques including enzymatic, fluorescent, and impedimetric techniques (Banerjee 
and Bhunia, 2009). Although the use of cell-based biosensors has been successful 
in some circumstances, they have some limitations such as low specificity, short-term 
stability, low robustness, and high production cost, especially when working with 
mammalian cells.  
 
1.5.1.6 Molecularly imprinted polymers (MIPs) 
MIPs are artificial biorecognition elements based on highly crosslinked 
polymers. MIPs can be made of organic or inorganic substances (Dickert, 2014).  
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MIPs have also been used as biosensing elements. In the polymerisation process, 
the reaction consists of a template (analyte of interest), functional monomers, cross-
linking monomers, and a polymerisation initiator (Hussain et al., 2013). Briefly, to 
produce the MIPs, the target of interest is first imprinted in the polymer. The functional 
monomers are then polymerised to form polymer network with the target molecule. 
Prior to the removal of the target, cross-linking monomers are employed to form 
chemical bonds with functional polymer matrices and help them stay in the 
appropriate conformation (Algieri et al., 2014). As well as other bioreceptors, MIP 
based sensors can be utilised in combination with optical, piezoelectric, and 
electrochemical measurements in order to convert the binding of receptors and their 
target to a measurable signal. MIPs have gained attention in the area of biosensors 
because they not only offer the users the specificity to the target, repeated 
regeneration. Unlike most protein receptors, MIPs are more stable and resistant to 
extreme conditions such as high/low pH and temperature (Hussain et al., 2013). 
There have been applications using MIPs as receptors for detection of a number of 
analytes such as ions, neurotransmitters, proteins and whole cells (Peeters, 2015). 
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1.5.2 Antibodies and their limitations 
 
1.5.2.1 An overview of antibodies 
The immune system is a system that the human body uses to protect itself 
from bacterial and viral pathogens, and other toxins. In human beings, the immune 
system can be classified into two subtypes; the non-adaptive (innate) and adaptive 
(acquired) immune responses (Murphy, 2012). Non-adaptive immunity is always the 
first barrier to combat a variety of pathogens, but this protection is not long-lasting 
due to the lack of immunological memory and is non-specific. Cells that function in 
the non-adaptive system include phagocytes (macrophages, neutrophils, and 
dendritic cells), mast cells, eosinophils, basophils and natural killer cells. On the other 
hand, adaptive immunity is a specific immune response mediated by lymphocytes; T 
cells and B cells. While T cells normally involve cell-mediated immunity, B cells hold 
a key role in the humoral immune response by secreting specific antibodies against 
target antigens, and, in this review, only antibodies generated by B cells are focused 
on in more detail.  
In general, an antibody or immunoglobulin molecule is comprised of two pairs 
of polypeptide chains which are different in size (Figure 1.8). Two of them are heavy 
chains of Mr about 50 kDa each whereas the other two are light chains of Mr around 
25 kDa each. All four polypeptides are connected to one another by disulfide bonds. 
The heavy chains of antibodies usually contains a variable (VH) domain, and three 
constant domains, the CH1 domain, CH2 domain and CH3 domain. In contrast, the 
light chains contain two domains, a VL domain and a single CL domain. Although 
antibody molecules share the same basic structure, they display remarkable 
variability in the areas that bind specifically to the antigen.  To interact with target  
antigens,  antibodies  normally  employ  regions   called   the complementarity-
determining regions (CDRs),  which  are  present  in  both  VH and VL domains and 
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Figure 1.8  An immunoglobulin G (IgG) structure. The basic structure of an antibody 
consists of two identical heavy chains and two identical light chains connected with 
disulfide bonds. Both heavy and light chains have their hypervariable regions (CDRs) 
which play a significant role in antigen recognition. This figure is modified from Carter 
(2006).   
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located at the tips of the IgG “Y” structure. Immunoglobulins are categorised into five 
classes based on their heavy chain structure: IgA, IgG, IgM, IgD and IgE (Figure 1.9). 
The difference in structure is because during B cell development, B cells can switch 
from making one class of antibody to another, which is called class switching (Alberts 
et al., 2002). Gene recombination and somatic hypermutagenesis are two factors 
involving antibody diversity (Conroy et al., 2009). Combinatorial rearrangement of the 
VH-DH-JH segments for heavy chains and the VL-JL segments for light chains during 
B cell development leads to production of a variety of antibodies with different 
affinities to antigens. Furthermore, somatic hypermutation, mainly base substitution, 
during B cell proliferation introduces a variety of nucleotide sequences into the coding 
regions, which is beneficial for producing antibodies specific for a vast range of 
analytes. 
 
 
 
 
 
 
 
Figure 1.9  the structure of five classes of immunoglobulins. IgG, IgD and IgE 
presents as a monomer in the serum. Serum IgM exists as a pentamer whereas IgA 
can be found in both monomeric and dimeric forms. The blue lines connecting 
between IgA dimer and IgM pentamer indicate the joining (J) chains containing 
cysteine residues, resulting in the intracellular polymerisation of IgA and IgM 
monomers. 
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1.5.2.2 Production of antibodies 
Polyclonal antibodies are widely applied in different areas of research 
including biological and medical applications because they can be made simply by 
immunising an experimental animal. However, batch-to-batch variability and cross-
reactivity still limit their use in some applications that require an antibody specific to 
a single epitope, e.g., diagnostic manufacturing and therapeutic drug development. 
To overcome these limitations, several techniques have been developed to produce 
monoclonal antibodies to solve the problems. 
 
1.5.2.2.1 Monoclonal antibody production 
Hybridoma technology was first reported as a technique to be used for 
production of monoclonal antibodies in 1975 (Kohler and Milstein, 1975). Since then, 
this method has been employed for generating monoclonal antibodies against a wide 
range of antigens. Briefly, laboratory animals like mice are immunised by injection of 
a specific antigen. After several weeks, B cells are isolated from the spleen tissues 
known as splenocytes. Then, the extracted cells are immortalized by fusion with 
myeloma (B cancer cells) cells by electrofusion. The cell lines with desired binding 
specificity are isolated and then multiplied. Although hybridomas have gained an 
attention from researchers in biological and medical fields, antibodies obtained by 
this method are foreign proteins in humans. This can cause immunogenic symptoms 
to those exposed to the antibodies, initially leading to unsuccessful clinical 
applications (Carter, 2006). In order to minimise the effect of immunogenicity, 
humanised antibodies have been developed (Co and Queen, 1991, Tsurushita et al., 
2005). To produce the first generation of humanised antibodies, genes encoding 
variable domains are isolated from the mRNA of B cell hybridoma using PCR. The V 
genes are constructed into an expression vector containing genes encoding constant 
domains from human IgGs. The recombinant IgGs are expressed in mammalian 
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cells. These IgGs are called “chimaeric mAbs”. However, variable domains which are 
originally from other animals can cause immunogenic response when antibodies are 
used in humans (Co and Queen, 1991). Therefore, in the second generation, only 
complementarity-determining regions (CDRs) from other animal species are 
transferred and embedded with human IgG frameworks. IgGs made by this approach 
are known as “CDR-grafted or humanised mAbs”. As a result, immunogenicity is 
reduced. In addition, because of Fc regions originally from human IgG, the half-life of 
antibodies in serum is extended and the effector function is still retained. 
 
1.5.2.2.2 Phage display technology 
Since the first publication on phage display technology in 1985 (Smith, 1985), 
there have been other research groups further developing this techniques in order to 
adjust it to suit their work (McCafferty et al., 1990, Barbas et al., 2001). Phage display 
is an extremely useful technique that is used to display single chain variable 
fragments (scFv) or antigen-binding fragments (Fab) since it can be manipulated in 
in vitro. Additionally, this method can facilitate investigation of the human immune 
system mechanism via specific interaction of selected antibody-derived fragments 
and their targets (Hammers and Stanley, 2014). Principally, this approach starts with 
preparation of a gene library (Figure 1.10). mRNA of high quality is isolated from 
chosen cells, and then reverse transcribed to cDNA. Using sets of primers specific to 
antibody genes, the PCR products are obtained. The PCR products are then ligated 
into a phage display vector called a phagemid, resulting in the vector carrying an 
antibody gene fused to the pIII minor capsid protein gene of the M13 filamentous 
phage. Competent cells are transformed with a set of phage display vectors together 
with additional helper phage to allow complete phage production. To select 
antibodies specific to antigens, a technique called bio-panning is employed. This 
technique can allow users to enrich a small number of specifically bound phages from 
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a pool of phage with over 1010 clones (Schmitz et al., 2000). One cycle of panning 
consists of capture of phage by binding to the immobilised antigen, washing, elution, 
and then reamplification of the phage binders in E. coli. During several rounds of 
panning, the most highly specific binders are picked up from a large pool of phage. 
Then, the selected binders are once more tested by ELISA or western blotting. Phage 
from positive samples are re-amplified in E. coli for the production of monoclonal 
phage, which are then tested by phage ELISA to confirm the presence of specific 
clones binding to the target. Subsequently, the phage vectors, isolated from the 
positive clones, are sequenced, and compared to determine the variety of the genes 
selected. However, phage display still holds several limitations since it might not be 
possible to recover every antigen-specific antibody fragment using only one library. 
The scFv or Fab fragments obtained from this method may not imitate the 
immunoglobulins formed by in vivo production.  
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Figure 1.10  A schematic representation of basic phage display cycle. The diagram 
displays six key steps: (1), gene assembly and transformation; (2), protein scaffold 
display; (3), selection; (4), washing; (5), elution, and (6), re-infection into competent 
cells. The figure was modified from Mondon et al. (2008).  
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1.5.2.3 Applications of antibodies 
Antibodies have been used in a variety of areas. For proteomic studies, in 
order to investigate the relative abundance of different specific proteins, antibodies 
are used as capturing reagents to construct antibody arrays. For example, for clinical 
diagnoses, antibody arrays directed towards more than 50 biomarker proteins of 
acute ischemic stroke have been applied for high-throughput screening of patients’ 
plasma samples (Reynolds et al., 2003). Also antibody arrays have been used as an 
analytical platform for diagnosis of myocardial infarction (Wu et al., 2004, Mitchell et 
al., 2005) and screening of drugs of abuse (Buechler et al., 1992). Antibody arrays 
are a valuable tool to investigate clinical biomarker development in areas such as 
inflammatory bowel disease (Kader et al., 2005), lung and ovarian cancer (Gao et al., 
2005, Mor et al., 2005).  
In cancer therapy, tumour-specific antibodies can be conjugated to drugs. 
This method brings the benefits of selectively targeting cytotoxic drugs to tumours. 
Several antibodies are already approved by the Food and Drug Administration (FDA) 
of the USA to be used as therapeutic agents for cancer treatment. These include 
Trastuzumab (IgG1) against HER2/neu for metastatic breast cancer, Bevacizumab 
(IgG1) against vascular endothelial growth factor for metastatic chronic lymphocytic 
leukaemia, and Gemtuzumab (IgG4) against CD33 for acute myeloid leukaemia 
(Schrama et al., 2006). Antibodies can also take part in antibody-mediated liposome 
targeting for delivery systems. For instance, antibodies can be coated on the outer 
layer of liposomes via interactions e.g. the streptavidin-biotin interaction (Lee et al., 
2005). The antibody-coated liposomes can be filled with drugs, genes or fluorescent 
dyes and then delivered to the specific tissues, leading to increased efficacy of 
disease treatment (Torchilin, 2005).  
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1.5.2.4 Limitations of antibodies 
 Although antibodies offer several benefits especially their specificity, some of 
their characteristics are disadvantageous. Cost of production for antibodies is 
typically high (Ruigrok et al., 2011, Hey et al., 2005, Stumpp et al., 2008, Haurum, 
2006). This is because whole antibodies cannot be produced in microbial systems. 
The structure of antibodies comprises four polypeptide chains and post-translational 
glycosylation is required for structural stability. The complex structure of antibodies 
also requires disulfide linkages and other interactions to fold into native and functional 
domains. As a consequence, mammalian cell lines or animal hosts such as mice, 
rabbits, sheep and goats are needed as sources of antibody production. The 
production process is also time-consuming and typically small scale (Ruigrok et al., 
2011). One of the major problems of using antibodies in many applications is batch-
to-batch variation, in particular when polyclonal antibodies are employed (Haurum, 
2006, Baker, 2015, Bradbury and Pluckthun, 2015). This can be explained by the fact 
that polyclonal antibodies are a mix of antibodies produced from different B cells in 
an immunised host. With different batches of antibodies, the ratios of different 
antibodies containied in the cocktail are not identical. This can be the major problem 
with reproducibility in experiments, including biosensor research. In this area, correct 
orientation of bioreceptors is necessary when immobilising them onto the surface. 
Antibodies consist of more than one cysteine and lysine, which makes it difficult to 
modify antibodies at a specific site to control the orientation. Because of all the above, 
researchers have attempted to find other ways to overcome the drawbacks of 
antibodies and the use of alternative binding proteins are one of those approaches. 
 
 
 
 
51 
 
  
1.5.3  Antibody-derived fragments 
Because of the large size and complex structure, with four peptide chains, it 
is often difficult to develop antibodies for commercial applications. To overcome 
these limitations, the binding sites in the antibody structure have been applied to 
develop alternative antibody-derived structures (Hey et al., 2005, Ponsel et al., 2011, 
Richards et al., 2017, Chames et al., 2009). Over the past decades, there has been 
a broad spectrum of antibody fragments with desirable properties like smaller size 
and simpler structure. 
Antibody-derived fragments are a group of proteins, where structures are 
derived from a part of an antibody. Antigen-binding sites on variable domains of 
heavy and/or light chain of antibodies are retained since they are capable of 
recognising the antigen. Fab, scFv, diabodies and nanobodies are all examples of 
antibody fragments mentioned in this chapter (Figure 1.11). 
Antigen-binding fragment (Fab) is an antibody derivative. Its structure is 
comprised of one constant and one variable domains of each heavy and light chain. 
The Fc region of antibodies is excluded from the structure, which results in molecular 
mass of approximately 55 kDa (Holliger and Hudson, 2005). Fab can be generated 
through an enzymatic reaction using papain or conveniently screened from a phage 
display library (Crivianu-Gaita and Thompson, 2016). Even though the Fc region is 
removed, the capability of antigen recognition in Fab is still retained like its 
counterpart. Fab(s) have been screened via phage display technologies against such 
targets as Staphylococcal enterotoxin B (Urushibata et al., 2010), human p53 for 
monitoring colorectal cancer (Coomber et al., 1999) and B cell lymphoma (Shen et 
al., 2007). In clinical and preclinical settings, some Fab(s) have successfully been 
approved by the FDA as therapeutic agents for treatments of cardiovascular disease, 
rattlesnake bite, and overdose of digoxin (Holliger and Hudson, 2005).   
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Figure 1.11  Some examples of antibody-derived fragments. All the fragments shown 
in the figure can be selected from recombinant libraries. The size of each fragment 
is significantly smaller than a whole antibody. More examples of IgG-derived 
fragments can be found in Herrington-Symes et al. (2013) and Little et al. (2000).  
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Single-chain variable fragment (scFv) is another antibody fragment, which 
can be obtained by the screening a phage display library (Mao et al., 1999, Crivianu-
Gaita and Thompson, 2016). The basic structure of scFv consists of one variable 
region from the heavy chain and one variable region from the light chain. The two 
polypeptides are connected with a short peptide linker, which is between 10-30 amino 
acids (Crivianu-Gaita and Thompson, 2016). The linker is typically rich in small amino 
acids such as glycine, serine and threonine (Li et al., 2015). The average molecular 
size of scFv(s) is around 28 kDa (Holliger and Hudson, 2005). In therapeutic uses, 
scFv(s) are potential agents used as a part of radiation dosimetry for gastrointestinal 
malignancies (Shen et al., 2005) and drug targeting for breast cancer  (Nellis et al., 
2005). 
 Diabodies are small antibody fragments with two antigen-binding sites 
(Holliger and Hudson, 2005). Diabodies can be monospecific or bispecific depending 
on the scFv molecules that form the dimers. Dimerisation of two identical scFv 
domains results in monospecific diabodies whereas the formation of two scFv 
domains originating from different immunoglobulins provides bispecific diabodies 
(Kim et al., 2016). Two scFv domains are connected by a short peptide linker which 
contains three to five amino acids (Atwell et al., 1999, Hudson and Kortt, 1999). As a 
result, the average molecular size of diabodies is the combination of two scFv 
domains, which is roughly 50 kDa in total (Holliger and Hudson, 2005). Up until now, 
diabodies have widely been used for medical research. For example, diabodies 
showed great potential when employed as cross-linkers between E. coli β-
galactosidase and three target antigens of interest; hen-egg lysozyme, 
carcinoembryonic antigen, and HIV gp120 in enzyme immunoassays (Kontermann 
et al., 1997). A bispecific diabody recognising both EPH receptor A10 on breast 
cancer cells and CD3 expressing in cytotoxic T cells was also generated (Kamada et 
al., 2015). The researchers proposed that this diabody could potentially be applied 
for breast cancer therapy.  
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A nanobody or single domain antibody is a single domain from the camelid 
immunoglobulin family developed by Ahlynx (Ghent, Belgium). The molecular weight 
of the nanobody is only 12-15 kDa which is much smaller than a full antibody (150-
160 kDa) (Harmsen and De Haard, 2007). Nanobodies are obtained by screening via 
either phage display or ribosome display techniques (Ghahroudi et al., 1997). In 
preclinical diagnostics, nanobodies have shown potential use for the treatment of 
rheumatoid arthritis, inflammatory bowel disease and thrombosis (arterial stenosis). 
Additionally, it has been proposed to treat patients with psoriasis, solid tumours and 
Alzheimer’s disease (Hey et al., 2005). 
 
1.5.4  Non-antibody binding proteins 
In addition to engineered antibody-derived fragments, there has been 
development of alternative binding proteins whose structures have no connection to 
that of IgG. Non-antibody binding proteins are a group whose original structures are 
based on a sequence or consensus sequence of proteins from various sources. The 
core structure is required to be rigid, stable, compact and monomeric. Mostly, 
introduction of randomised amino acid regions is necessary in order to generate new 
binding sites which imitate the recognition property of antibodies. Examples of non-
antibody binding scaffolds worth describing here are monobodies, Anticalins, Kunitz 
domains, DARPins, Affilins and Affimers as follows (Table 1.2). 
A monobody or Adnectin is a human fibronectin type III domain protein, which 
can be expressed in bacteria. Since 2007, this type of protein has been developed 
by Adnexus, a part of Bristol-Myers Squibb. The structure of the Adnectin is 
comprised of 94 amino acids with a molecular weight of 10 kDa. Three distinct loops 
in the structure link six antiparallel β-sheets to the same structure. The amino acids 
in these loops are diversified to mimic the CDR loops of antibodies, allowing 
Adnectins to bind a variety of analytes (Gill and Damle, 2006, Lipovsek, 2011). It is  
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Table 1.2    Examples of some non-antibody binding protein scaffolds and their characteristics  
Scaffold name Parent structure Species origin Randomisation 
PDB 
code 
Scaffold structure Reference 
Monobody/ 
Adnectin (1) 
10th domain of 
human fibronectin 
Human 
Residues in BC, DE, 
and FG loops (loop 
library) 
3RZW 
 
(Ramamurthy et 
al., 2012) 
Monobody/ 
Adnectin (2) 
10th domain of 
human fibronectin 
Human 
Residues in C and D 
β-sheets, and DE and 
FG loops (side and 
loop library) 
3UYO 
 
(Koide et al., 
2012) 
 
Anticalin 
 
Lipocalins Human/insect 
Four loops (up to 24 
amino acids) 
1LNM 
 
(Korndorfer et 
al., 2003) 
 
Kunitz domain 
 
Protease inhibitor Human One to two loops 1KTH 
 
(Arnoux et al., 
2002) 
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Table 1.2  (continued) 
Scaffold name Parent structure Species origin Randomisation 
PDB 
code 
Scaffold structure Reference 
DARPin (1) 
Ankyrin repeat 
proteins 
Human 
Six to seven residues 
in each n-repeat  
(original library) 
2QYJ 
 
(Merz et al., 
2008) 
DARPin (2) 
Ankyrin repeat 
proteins 
Human 
Additional 13 residues 
in elongated loop  
(loop library) 
4K5C 
 
(Schilling et al., 
2014) 
 
Affilin (1) 
 
𝛾-B-crystallin Human Eight residues 2JDG 
 
(Ebersbach et 
al., 2007) 
Affilin (2) Ubiquitin Human 
Six residues in β-
sheet 
1UBI 
 
 
(Hoffmann et al., 
2012) 
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Table 1.2  (continued) 
Scaffold name Parent structure Species origin Randomisation 
PDB 
code 
Scaffold structure Reference 
Affimer 
(Adhiron) 
Phytocystatin Plant 
Two variable peptide 
loops (18 amino 
acids) 
4N6T 
 
(Tiede et al., 
2014) 
Repebody 
Leucine-rich repeat 
(LRR) modules 
Jawless vertebrates 
artificial 
Five residues in each 
LRR 
4J4L 
 
 
(Lee et al., 
2012) 
 
Fynomer 
SH3 domain of Fyn 
tyrosine kinase 
Human 
Six residues in two 
loops 
4AFQ 
 
 
(Silacci et al., 
2014) 
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expected that Adnectins will be effective in treating cancer, rheumatoid arthritis, 
psoriasis, and Crohn’s disease (TNFα) (Hey et al., 2005). Additionally, CT-322, which 
is an Adnectin selected via mRNA display technology, showed great potential to be 
an anti-tumour agent for inhibiting vascular endothelial growth factor receptor 2 
(VEGFR2) (Mamluk et al., 2010). 
Anticalins are artificial proteins derived from Pieris brassicae lipocalin. The 
protein was first developed by a team of scientists from the Technical University of 
Munich, Germany (Beste et al., 1999). The basic structure of this peptide consists of 
eight antiparallel β-strands pairwise linked by loops and an α-helix. The four 
hypervariable loops at the open end of the structure form a cup shape, which is used 
as the binding site for both small compounds and large biomolecules (Skerra, 2008, 
Richter et al., 2014). To produce Anticalins in large amounts, microorganisms such 
as bacteria and yeasts are normally used (Hey et al., 2005, Skerra, 2008). There 
have been attempts to use anticalins for diagnostic and therapeutic applications. The 
applications of this protein have been focused on drug delivery (Schlehuber and 
Skerra, 2005). For example, as a carrier for drug delivery, the ‘duocalin’, an anticalin 
possessing binding activity for doxorubicin, has been developed (Schlehuber and 
Skerra, 2001). This is an excellent strategy for drug targeting since doxorubicin is a 
tumour drug that is poorly soluble (Constantinides et al., 2004) and has severe side 
effects (Perez, 2001).  
Kunitz domains are active domains of protease inhibitors. The structure of the 
Kunitz domain consists of between 50 and 60 amino acids stabilised by three 
disulfide bonds, which results in a molecular weight of around 6 kDa. The Kunitz 
domains possess three loops that can be mutated without destabilising their structure 
and used as the binding site for targets of interest (Weidle et al., 2013, Hosse et al., 
2006). They can be selected by the use of phage display technology (Lehmann, 
2008). Kunitz domains have the potential to be used in the development of 
pharmaceutical drugs. For example, DX-88, a novel Kunitz domain, is an effective 
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and selective inhibitor of plasma kallikrein for the treatment of hereditary angioedema 
(HAE) (Williams and Baird, 2003). 
DARPins are genetically engineered binding proteins derived from natural 
ankyrin proteins. The structure of each DARPin is comprised of four or five repeat 
motifs, which are a β-turns followed by two antiparallel helices and a loop. Typically, 
the DARPins have a molecular weight of 14-18 kDa. DARPins are synthetic scaffolds 
that use their rigid secondary structure (α-helices) for recognition (Nygren and 
Skerra, 2004, Stumpp et al., 2008). Six randomised amino acids per repeat of the 
DARPins play a role in interaction with their targets (Skerra, 2007). Resulting from 
their high affinity and specificity, there have been potential medical applications of 
DARPins. For example, the designed ankyrin repeat protein, G3, was used as a 
specific binding molecule to reliably identify the amplification status of the epidermal 
growth factor receptor 2 (EGFR2) in breast cancer (Theurillat et al., 2010).     
Affilins are engineered binding proteins derived from one of two human 
proteins, 𝛾-B crystallin or ubiquitin. The structure of Affilin from the 𝛾-crystallin 
consists of two identical domains, mainly β-sheets and a molecular weight of around 
20 kDa, whereas the structure of Affilin from ubiquitin is comprised of 76 amino acid 
residues which are the building blocks of an α-helix and five β-sheet strands with a 
molecular weight of 10 kDa. The target binding regions of Affilins are located in β-
sheet structure. Six (for 𝛾-crystallin) or eight (for ubiquitin) amino acids in the binding 
sites are modified without losing structure stablility (Weidle et al., 2013).  Like the 
previous binding proteins, Affilins have been used as an alternative to antibodies in 
many applications, in particular medical research. For example, the E7 binder, an 
Affilin molecule selected against human Papillomavirus E7 protein, was used to 
inhibit the proliferation of target cells in cervical cancer (Mirecka et al., 2009).  
 Affimers are alternative binding proteins which their structure is derived from 
plant phytocystatins (Tiede et al., 2014). The core structure of Affimers is comprised 
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of a single-α-helix and four anti-parallel β-strands. Eighteen amino acid residues over 
two loops at one end of the structure are diversified in order to mimic the CDR regions 
of IgGs and use as recognition sites for the analytes. Typically, Affimers have 
molecular weight around 12-13 kDa. The selection of Affimers can be conveniently 
carried out using phage display technology (Tiede et al., 2017). Further detail of 
Affimers is provided in Section 1.5.5. 
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1.5.5 Affimers  
The BioScreening Technology Group (BSTG) at University of Leeds has 
recently developed a scaffold protein, termed the Affimer (previously known as 
Adhiron), as an alternative affinity protein framework (Tiede et al., 2014). The 
structure of the Affimer II scaffold is based on the consensus sequence of plant-
derived phytocystatins (Tiede et al., 2014) whilst the Affimer I library is derived from 
human stefin A (Stadler et al., 2011). All work in this thesis used the Affimer II 
construct and Affimer I will not be further discussed. X-ray diffraction of Affimer II 
showed a structure with a single α-helix and four anti-parallel β-strands (Figure 1.12). 
Using phage display, variants of Affimers, possessing different external loops, can 
be displayed on phage M13 as a fusion with coat protein pIII. The phage display 
Affimer II library shows a complexity of around 1.3 x 1010 individual clones, each of 
which displays 18 random residues split over two loops (2 x 9 residues). It has already 
been shown that Affimers offer an array of advantages including high thermal stability 
(some have a Tm up to 101oC), rapid production, and minimal cross-reactivity. The 
scaffolds can be expressed easily in E. coli cells. These features, especially the 
monoclonal nature of the Affimer II proteins, help users avoid the issue of batch-to-
batch variation. Another key point is that Affimers lack cysteine residues and 
cysteines can be introduced at a specific site for modification. With such interesting 
properties, Affimers have become one of the more promising alternative binding 
proteins for a wide range of applications including molecular recognition.  
To date, Affimers have been applied to a large range of research areas and 
the number of applications has been increasing from time to time (Tiede et al., 2017). 
In the field of biosensors, Affimers have been successfully used for the detection of 
several targets e.g. proteins and small molecules. In 2012, Johnson and coworkers 
reported the use of the Affimer as a receptor for impedimetric label-free assay to  
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Figure 1.12  X-ray crystal structure of an Affimer scaffold (PDB ID no. 4N6T).  The 
structure consists of a single α-helix and four anti-parallel β-strands. Two variable 
peptide sites are indicated by the brackets. 
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detect C-reactive protein (CRP) (Johnson et al., 2012). The researchers coated the 
electrodes with a  SAM  and  used  EDC/NHS  to  immobilise  the Affimer onto the 
surface. Although the Affimer bound weakly to its target on the SPR assay with the 
KD in µM range, by optimising conditions for sensor fabrication, the sensor detected 
CRP in the nM range. In 2015, the Affimer was used for the detection of anti-myc tag 
antibody (Raina et al., 2015). Using biolayer interferometry (BLI), the Affimer bound 
to its target with a KD of 360 nM. To make the sensors, the Affimer was attached to 
the SAM-coated surface via EDC/NHS and impedance was used to determine the 
binding of the receptor and its protein target. The sensors showed a detection range 
of 6.7 – 330 pM. In 2016, Sharma and the colleagues published the use of Affimer 
impedimetric biosensors to detect human interleukin-8 (IL-8) in serum with higher 
sensitivity than conventional methods (Sharma et al., 2016). BLI showed that the 
Affimer bound to IL-8 with a KD of 35 nM. The Affimer was then immobilised on the 
SAM-coated electrodes via EDC/NHS prior to impedance measurement. The 
biosensors showed a range of detection of 900 fg/ml – 900 ng/ml, which again is 
much more sensitive than conventional techniques. Affimers do not only detect 
protein targets on the biosensor platform, but they can also be used to detect small 
molecules with molecular weight less than 1 kDa. (Koutsoumpeli et al., 2017) used 
Affimers in association with quartz crystal microbalance (QCM) to detect methylene 
blue, a small compound. The researchers used QCM-D to determine the affinity of 
the Affimer to methylene blue and found that the KD was 13.7 nM. To construct the 
sensors, the Affimer was directly immobilised onto the SAM layer, which was 
previously coated on the surface. Even though the fully constructed sensors showed 
a significant change in resonance frequency (F) and dissipation (D) when exposed 
to different concentrations of the targets, the optimisation to achieve a proper 
detection range is still under investigation. Zhurauski and his colleagues developed 
an Affimer-functionalised interdigitated electrode-based biosensor to detect human 
epidermal growth factor receptor 4 (Her4), a protein biomarker of gastrointestinal 
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stromal tumours (Zhurauski et al., 2018). The researchers used non-faradaic 
impedance and evaluated sensor performance by measuring the changes in 
capacitance. The sensors showed a dynamic range from 1 pM to 100 nM of Her4 
with a limit of detection under 1 pM when the measurements were performed in both 
buffer and serum. 
 As well as applications for biosensors, Affimers have been used in other areas 
of research, for examples, as modulators to study protein-protein interactions, affinity 
histochemistry, pull-down assays, cell imaging, in vivo imaging, super resolution 
microscopy and formation of magnetic nanoparticles (Tiede et al., 2017). One 
example of studying protein-protein interaction is the use of the Affimer to inhibit the 
formation of HIF-1α/p300 complex (Kyle et al., 2015). Using competitive fluorescence 
anisotropy assay, the Affimers showed the inhibition of this interaction with a low µM 
IC50. This IC50 was found to be better than the fragments of native HIF-1α. The study 
is not only useful for dissecting signalling pathways, but also for the treatments of 
hypoxia. Affimers have also been utilised as a tool for nanoparticle synthesis. 
(Rawlings et al., 2015) screened Affimer binders that can interact with cubic 
nanoparticles. They also found that when mixing the Affimers with nanoparticle 
synthesis reaction, the shape of magnetic particles can be controlled towards a cubic 
shape. This idea is anticipated to pave the way of using alternative binding proteins 
for material synthesis. 
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1.6 Dichlorodiphenyltrichloroethane (DDT) 
Dichlorodiphenyltrichloroethane (DDT) is a synthetic organochlorine 
insecticide. The chemical structure of DDT comprises two chlorobenzene rings 
attached to a tree of three chlorine atoms (Figure 1.13). DDT is highly hydrophobic, 
which makes it almost insoluble in water. The solubility of DDT in water is found to 
be 0.025 mg/L at 25 oC (Howard and Meylan, 1997). However, DDT is soluble in fats, 
oils and most organic solvents such as dimethyl sulfoxide (DMSO) and 
dimethylformamide (DMF).   
 
 
 
 
 
 
 
 
Figure 1.13  Chemical structure of DDT. The structure consists of two chlorobenzene 
rings linked to three chlorine atoms. 
 
 DDT has been used to control the spread of malaria caused by mosquitoes. 
It has an adverse effect on insects by targeting sodium ion channels in neurons 
(Davies et al., 2007, O'Reilly et al., 2006, Du et al., 2016). DDT acts as an agonist by 
binding to the sodium channels and stabilising them in the open state. As the 
depolarization of the membrane is prolonged, the neurons fire spontaneously. As a 
consequence, this leads to paralysis and death of the insects.  
66 
 
  
 Despite its insecticidal property, DDT is now banned for use in many countries 
due to its long persistence in animal tissues and the environment. It has been 
calculated that DDT stored in adipose tissues normally takes 10 – 20 years to 
disappear from an individual (Turusov et al., 2002). As DDT is slowly degraded, it 
can be accumulated in the food chain and tissues of living organisms. The 
accumulation of DDT causes considerable thinning of the eggshell in avians (Turusov 
et al., 2002, Speich et al., 1992, Kolaja and Hinton, 1977). The effects of DDT and its 
metabolites on human health have also been studied. Even though further 
investigations are needed, some reports showed the association of abnormalities in 
people who had a long-term exposure background to DDT. For example, 
occupational exposure to DDT could adversely affect male fertility as it blocks the 
androgen receptor (Mehrpour et al., 2014, Whorton et al., 1977). In females, 
increasing concentrations of DDT in maternal serum caused decreasing probability 
of pregnancy (Rogan and Chen, 2005, Cohn et al., 2003). Exposure to DDT has also 
been associated with the occurrence of cancers including pancreatic and breast 
cancers, and neuropsychological dysfunction (Beard and Australian Rural Hlth Res, 
2006, Rogan and Chen, 2005). For these reasons, DDT is a vital indicator for 
environmental monitoring and rapid-processing assays for DDT detection are 
required. 
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1.7 Fibroblast Growth Factor Receptor 3 (FGFR3) as 
a promising biomarker for bladder cancer  
 
1.7.1 Overview of bladder cancer 
Bladder cancer is a heterogeneous disease, in which the tissues in the 
bladder multiply abnormally and spread into neighbouring muscles. An early 
symptom of this cancer is blood detected in urine without pain or painless haematuria 
(Kaufman et al., 2009, Sexton et al., 2010, Letasiova et al., 2012). An additional 
symptom that can be found alongside with haematuria is frequent and urgent 
urination (Sexton et al., 2010). Bladder cancer can be categorised into two types 
based on the tissues invaded (Knowles and Hurst, 2015). The first type is non-muscle 
invasive bladder cancer which be found inside the lining of bladder. This type is the 
most common and is not generally fatal. The latter is muscle invasive bladder cancer, 
in which the cancer cells invade beyond the lining and into the muscles surrounding. 
It is more rarely found and is often the cause of death, especially if metastasis occurs. 
In general, 70% of diagnosed patients are found to have superficial or non-muscle 
invasive bladder cancer while the remaining 30% have muscle invasive bladder 
cancer (Kaufman et al., 2009, Sexton et al., 2010). In 2012, it was reported that 
bladder cancer was ranked the ninth most common cancer found worldwide (Antoni 
et al., 2017). GLOBOCAN estimated that about 430,000 cases were newly diagnosed 
bladder patients and roughly 165,000 deaths, which three quarters were males, were 
reported in 2012. The researchers also found that Europe showed the highest 
incidence rate of bladder cancer in the world whereas Africa showed the lowest rate 
(Antoni et al., 2017). There are several risk factors involving the occurrence of 
bladder cancer. Gender and age are the first two factors to be considered. The 
incidence rate of bladder cancer was evidently higher in men than in women and 
people with the ages between 50 and 70 showed higher probability of developing 
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bladder cancer compared other age groups (Kaufman et al., 2009). Occupational 
exposures to certain chemicals can cause bladder cancer. Workers who are exposed 
to aryl amines, cyclophosphamide and phenacetin-containing substances risk 
bladder cancer development (Vlaovic and Jewett, 1999, Sexton et al., 2010). The 
most important risk factor for developing bladder cancer is tobacco smoking 
(Kaufman et al., 2009, Sexton et al., 2010). A number of chemicals contained in the 
smoke of cigarettes including 2-napthylamine, 4-aminobiphenyl and o-toluidine have 
been found to increase the risk of bladder cancer (Sexton et al., 2010, Letasiova et 
al., 2012). Being diagnosed at the early stage of cancer is necessary because this 
increases the survival rate of patients living with cancer cells since early treatment is 
enabled (Pepe et al., 2001, Budman et al., 2008, Reubsaet et al., 2009, Mazor et al., 
2010). Therefore, an efficient point of care diagnosis capable of detecting the 
development of the cancer at the earliest stage will help reduce the mortality rate and 
help patients live longer. 
 
1.7.2 Standard methods of bladder cancer diagnosis 
 Attempts have been made to establish efficient standard platforms to monitor 
the occurrence of bladder cancer in the early stages since this can affect the results 
of the treatments giving to patients. For an initial assessment, cystoscopy is known 
as the gold standard to be used for detecting bladder cancer (Kaufman et al., 2009, 
Sexton et al., 2010, Budman et al., 2008). The approach involves inserting a small 
thin camera into the bladder via the urethra, which allows the physicians to see 
abnormalities that are present. This method is invasive and makes the patients 
anxious during an operation (Budman et al., 2008). Moreover, if the malignant cells 
are flat such as carcinoma in situ, the doctors may fail to identify these abnormalities 
(Sexton et al., 2010, Budman et al., 2008). Urinary cytology is one of the widely used 
methods to detect bladder cancer cells. It is basically used in association with 
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cystoscopy. Voided urine samples are collected from patients and sent to the 
pathology laboratory to observe abnormal cells under the microscope. This approach 
is non-invasive and highly specific for bladder cancer detection (Budman et al., 2008). 
However, low sensitivity of the technique when detecting low-grade tumours is its 
major drawback.  
 Some urinary biomarkers have been researched in order to achieve detection 
of early-stage bladder cancer. Four widely used biomarker-based tests are briefly 
reviewed in this thesis. The first technique to be mentioned is bladder tumour antigen 
test (BTA) (Budman et al., 2008). The procedure is based on the use of antibodies 
for the detection of complement factor H-related protein (CFHrp) in voided urine 
(Proctor et al., 2010). This protein is secreted by tumour cells. Two commercial BTA 
kits are available in the markets. BTA stat (Polymedco) is a qualitative point-of-care 
assay using a lateral flow immunoassay to detect CFHrp whereas BTA Trak assay 
(Polymedco) is a quantitative techniques based on the ELISA. The second method 
is nuclear matrix protein 22 (NMP22) test (Budman et al., 2008). It has been found 
that the level of expressed NMP22 protein increases as an indicator of apoptosis in 
malignant urothelial cells compared to normal cells (Proctor et al., 2010). The 
detection procedure is based on the recognition of the target by antibodies. Two types 
of NMP22 test kits are available. NMP22 bladder cancer test (Alere) is an ELISA kit, 
which is a quantitative, sandwich immunoassay while the NMP22 Bladder Chek 
(Alere and Matritech) is a qualitative test strip based on lateral flow 
immunochromatography. Another widely used technique is ImmunoCyt/uCyt+ 
(Budman et al., 2008). A mixture of three antibodies tagged with fluorescent dyes is 
utilised to detect specific antigens presented on exfoliated tumour cells (Greene et 
al., 2006). M344 and LDQ10 antibodies labelled with fluorescein can recognise a 
mucin-like antigen and 19A211 antibody is specific to the glycosylated version of 
carcinoembryonic antigen (CEA). The cells are fixed on a glass slide, stained with 
antibodies and detected under a fluorescent microscope. However, this technique is 
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not a stand-alone test and needs to be used with a cytology test (Budman et al., 
2008, He et al., 2016). The last technique worth being mentioned is UroVysion 
(Budman et al., 2008). It is another fluorescent-based assay based on fluorescence 
in situ hybridisation (FISH) (Hammers and Stanley, 2014). The genetic alterations, 
namely aneuploidy for chromosome 3, 7, 17 and the loss of the 9p21 locus of 
chromosome 9, are detected using a set of oligonucleotide probes (Budman et al., 
2008, Hammers and Stanley, 2014, Dimashkieh et al., 2013). All of the four methods 
mentioned have sensitivities that are better than urinary cytology. However, using all 
the four biomarkers is still less specific than urinary cytology since they suffer from 
more false positive results (Table 1.3). Therefore, up until the present, none of 
biomarker-based assays can be used as a replacement for cystoscopy and cytology, 
and there are obviously a number of opportunities for research on new biomarker-
based techniques for bladder cancer monitoring. 
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Table 1.3   Comparison between cytology and other commercial biomarker tests for 
monitoring the occurrence of bladder cancer  
Diagnostic 
test 
Type of assay Target Sensitivity* Specificity* 
Cytology Cell-based assay Bladder 
tumour cells 
12.1 - 84.6% 78.0 - 100%  
BTA-stat Qualitative, lateral flow 
immunochromatography 
CFHrp 52.5 - 78.0% 69.0 - 87.1% 
BTA-Trak Quantitative, sandwich 
ELISA 
CFHrp 51.0 - 100.0% 73.0 – 92.5% 
NMP22 Test Quantitative, sandwich 
ELISA 
NMP22 34.6 - 100.0% 60.0 – 95.0% 
MNP22 Bladder 
Chek 
Qualitative, lateral flow 
immunochromatography 
NMP22 49.5 – 65.0% 40.0 – 89.8% 
ImmunoCyt/uCyt+ Fluorescent, cell-based 
assay 
Mucin-like 
antigen and 
CEA 
81.0 - 89.3% 62.0 - 77.7% 
UroVysion Fluorescence in situ 
hybridization (FISH) 
Chromosome 
3,7,9 and 17 
68.6 - 100% 65.0 - 96% 
*Data were obtained from (Budman et al., 2008). 
 
 
1.7.3 FGFR3 protein and its implication in bladder cancer 
Fibroblast growth factor receptor 3 (FGFR3) is a member of the FGFR protein 
family, playing an indispensable role in many biological processes, e.g. bone 
development and cell differentiation (Amizuka et al., 2004, Bolander et al., 2012). 
The structure of the protein comprises an extracellular domain (three immunoglobulin 
(Ig)-like domains), a hydrophobic transmembrane domain, and an intracellular 
tyrosine kinase domain (Figure 1.14). A previous study reported that among four 
FGFR proteins, FGFR3 showed the highest level of expression in normal urothelial 
cells, indicating that the FGFR3 could play a significant role in homeostasis of the 
urothelium (Tomlinson et al., 2005). In bladder cancer cells, both overexpression  
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Figure 1.14  Overall structure of FGFR3 protein. The FGFR3 protein consists of three 
immunoglobulin-like domains, one transmembrane domain and one split tyrosine 
kinase domain. The binding of fibroblast growth factors (FGFs) to the receptors 
causes receptor dimerisation. Transphosphorylation on several tyrosines by kinase 
enzymes then occurs, leading the activation of downstream signalling pathways. This 
figure is modified from the previous publications (Turner and Grose, 2010, Wesche 
et al., 2011). 
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and mutation of FGFR3 have been found  to  have  a  relationship  to  the  
development  of bladder  tumours. The researchers utilised immunohistochemistry to 
reveal that there was an overexpression of FGFR3 in bladder cancer cells compared 
to normal urothelium (Tomlinson et al., 2007). An increasing expression level of 
FGFR3 was especially high at the superficial stages (pTa and pT1) and grades (1 
and 2) of the cancer. As both overexpression and mutation of FGFR3 are common 
phenomena in bladder cancer, the relationship between mutational status and the 
expression level of FGFR3 has also been studied since gene mutations might result 
in the increasing level of FGFR3 proteins. It was found that approximately 85% of 
mutant tumours showed overexpression and the majority of them were classified into 
low grade or early stage cancers (Tomlinson et al., 2007). This finding was also 
supported by the research work from two different groups who also found that there 
was an increasing FGFR3 expression in bladder tumours during pTa and pT1 stages 
(Gomez-Roman et al., 2005, Mhawrech-Fauceglia et al., 2006). However, a contrary 
study reported that there was no relationship between the expression level and 
mutational status of FGFR3 at any stage or grade of bladder cancer cells (Matsumoto 
et al., 2004). Although the linkage between mutation and overexpression of the 
protein is still unclear, high expression level of FGFR3 is common in bladder cancer, 
especially at the superficial stages. There is also an evidence showing the detection 
of FGFR3 protein in urine samples. A previous study reported that using western blot 
analysis, the soluble form of FGFR3 could be detected in urine obtained from patients 
with non-invasive bladder cancer (Blanca et al., 2016). The researchers also found 
that the expression of FGFR3/Cyclin D3 proteins in urine could be a specific and 
sensitive approach for monitoring bladder cancer recurrence. There are two possible 
events that may explain the presence of soluble FGFR3 protein found in urine. The 
soluble form of FGFR3 can be generated by alternative mRNA splicing. A previous 
study reported that via mRNA splicing the secreted isoform, FGFR3 ∆8-10, was 
detected (Tomlinson et al., 2005). The C-terminus of Ig-like domain III and 
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transmembrane domain were absent in this isoform, making it be secreted as a 
soluble form. The other process generating soluble FGFR3 is ectodomain shedding 
(Degnin et al., 2011). The researchers found that the proteolytic cleavage of 
extracellular domain of FGFR3 is carried out by cathepsins and 𝛾-secretase, 
releasing the ectodomain of FGFR3 into extracellular fluids. This suggests that 
FGFR3 could become a potential biomarker for detecting early stage bladder cancer 
in urine. 
 
1.7.4 Available methods for FGFR3 detection 
In general, to detect the expression of FGFR3 in bladder cancer cells, 
immunohistochemical staining (IHC) is utilised in a clinical setting (Bodoor et al., 
2010, Guancial et al., 2014, Sung et al., 2014, Tomlinson et al., 2007). Even though 
widely used in many laboratories and hospitals, there are several drawbacks of this 
technique, making it impractical in some circumstances. IHC is less sensitive in 
detecting its target, can be susceptible to photobleaching when using fluorescent 
tags, is time consuming and has a narrow dynamic range of detection. Because of 
these complications, the technique also needs trained users to perform it. Therefore, 
the resulting interpretation is subjective and this makes the technique not an ideal 
tool for point-of-care diagnostics.  
ELISA is also one of the most widely used methods to detect protein 
biomarkers in biological fluids. At present, there are commercial ELISA kits capable 
of detecting FGFR3 in serum, plasma and biological samples for sale in the markets. 
The kits are claimed to have dynamic ranges from pM to nM (ab214027, Abcam, UK 
and LS-F6632-1, LifeSpan Biosciences, USA). However, it is known that ELISA is 
time-consuming, costly and needs a skilled user. Therefore, new techniques which 
can overcome the problems of IHC and ELISA are still required. 
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1.8 Project aims and potential applications 
The major objective of this project was to develop an impedimetric biosensor 
platform using Affimers as bioreceptors to recognise targets of interest, which could 
be small molecules or protein biomarkers of diseases. 
Dichlorodiphenyltrichloroethane (DDT) was selected to represent a small molecule 
while fibroblast growth factor receptor 3 (FGFR3) is a protein biomarker of bladder 
cancer. To complete the tasks, the project was divided into three sections as follows.  
   The first part of the project was concerned with the screening and production 
of the Affimers to be used as biorecognition elements. DDT was used as a model 
analyte for the Affimer phage display screening. The Affimers were obtained by 
selecting from a phage display library within the Leeds BioScreening Technology 
Group. The selected Affimers were then subcloned and expressed prior to further 
use. Affimers directed against FGFR3 had already been selected and subcloned as 
part of another project. 
 The aim for the second part of the thesis was to characterise the specific 
interaction of chosen Affimers with their targets. Several approaches were employed 
to check the affinity of the Affimers and the targets. Enzyme-linked immunosorbent 
assay (ELISA) was picked to confirm the binding of Affimers against DDT. Further 
analysis was not done as the DDT Affimers proved non-specific. On the other hand, 
three techniques, ELISA, surface plasmon resonance (SPR) and pull-down assay 
(immunoprecipitation) were employed to investigate the binding of Affimers to FGFR3 
protein. Affimers giving positive response to their target were then selected for 
biosensor fabrication. 
 The final section was focused on the fabrication of impedimetric biosensors 
using the Affimers selected from the first and second sections. Commercially screen-
printed gold electrodes which had three electrodes (working, counter and reference) 
were used. Two different protocols, the ELISHA ‘gluing method’ and the NeutrAvidin-
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biotin linkage-based protocol, were used to fabricate sensors to detect FGFR3. To 
establish the sensor construction protocol, the concentrations of Affimers and 
NeutrAvidin were optimised. Also, several blocking agents were investigated as an 
attempt to minimise non-specific binding background.  
 Although there have been biomarker-based tests commercially available in 
the markets at the present, none of these tests shows sufficient sensitivities to be 
used as a replacement for cystoscopy and urine cytology for bladder cancer 
detection. As a promising protein biomarker for bladder cancer, the development of 
an Affimer-based impedimetric biosensor to detect FGFR3 protein may become a 
useful analytical tool to be used as either a stand-alone test or in combination with 
other bladder cancer detection approaches for surveillance of early stage bladder 
tumours or the recurrence of cancer surgeries. If the platform is successfully 
established, it may not only be applied for bladder cancer detection, but also could 
be used to develop biosensors to monitor the emergence of other life-threatening 
diseases, in particular cancers, which affect a large number of people worldwide. 
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Chapter 2  
Materials and Methods 
2.1 Materials 
 
2.1.1  Inorganic chemicals 
 K3Fe(CN)6 (99%), K4Fe(CN)6.3H2O (98%), NaCl, and Tris were purchased 
form Fisher Scientific. NaOH and disodium tetraborate were supplied by BDH 
laboratory supplies. NaH2PO4 was purchased from Sigma-Aldrich.  
 
2.1.2  Organic chemicals 
 D-Glucose, glycine and boric acid were purchased from BDH laboratory 
supplies. Isopropyl-β-D-thiogalactopyranoside (IPTG) was purchased from 
ThermoFisher Scientific. Imidazole, biotin-maleimide, tyramine, (+)-biotin N-
hydroxysuccinimide ester (biotin-NHS) and pyromellitic dianhydride were purchased 
from Sigma-Aldrich. Glycerol was purchased from Fisher Scientific. 2-
mercaptoethanol was purchased from Bio-rad. Poly(sodium-p-styrenesulfonate) was 
obtained from Acros Organics. mPEG-biotin (5K) was supplied by NEKTAR 
Transforming Therapeutics. 
 
2.1.3  Other reagents 
 BugBuster protein extraction reagent was obtained from Novagen. Halt 
protease inhibitor cocktail, immobilised TCEP disulphide reducing gel and Pierce 
ECL western blotting substrate were purchased from ThermoFisher Scientific. Ni2+ -
NTA slurry was purchased from IBA Solutions for Life Sciences. Laemmli sample 
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buffer was purchased from Bio-rad. Quick coomassie stain was obtained from 
Generon. Tween-20 was purchased from Fisher scientific. 3,3’,5,5’-
tetramethylbenzidine (TMB) substrate (SeramunBlau® fast TMB/substrate solution) 
was purchased from Seramun. 4% (w/v) copper (II) sulfate pentahydrate and 
bicinchoninic acid were purchased from Sigma-Aldrich. Streptavidin resin was 
obtained from Genscript.   
 
2.1.4  Bacterial growth media ingredients 
 Tryptone, yeast extract and agar were purchased from Sigma-Aldrich. 
Carbenicillin was purchased from Alfa Aesar. 
 
2.1.5  Antibodies and related reagents 
 Anti-His-tag antibodies HRP (ab1187) was purchased from Abcam. Anti-
FGFR3 antibodies specific to extracellular domain (F3922) and anti-rabbit IgG 
antibodies – HRP (A0545) were purchased from Sigma-Aldrich. Pierce high 
sensitivity streptavidin-HRP was purchased from ThermoFisher Scientific. 
 
2.1.6  Bacterial and viral strains 
 E.coli cells strain ER2738 and M13K07 helper phage were supplied by the 
BioScreening Technology Group (BSTG), University of Leeds. XL1-blue E.coli 
supercompetent cells and BL21 Gold (DE3) E.coli cells were purchased from Agilent 
technologies. 
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2.1.7  Enzymes 
 NheI-HF, NotI-HF, Antarctic phosphatase, DpnI and T4 DNA ligase were 
supplied by New England BioLabs (NEB). Phusion DNA polymerase was purchased 
from ThermoFisher Scientific. Benzonase nuclease was purchased from Novagen. 
 
2.1.8  Solvents and buffers 
 Methanol was obtained from Fisher Scientific. 10x TGS (Tris/Glycine/ 
SDS) buffer was purchased from Bio-rad. Dimethyl sulfoxide (DMSO), Phosphate 
buffered saline (PBS) tablets and 10x casein blocking buffer were purchased from 
Sigma-Aldrich. 10x PBS-P+ buffer was obtained from GE Healthcare Life Sciences. 
 
2.1.9  Proteins 
 NeutrAvidin was purchased from Invitrogen. Bovine serum albumin (BSA), β-
2-microglobulin, human serum albumin and sodium caseinate were purchased from 
Sigma-Aldrich. Purified recombinant FGFR3 protein was obtained from Genscript. 
Anti-digoxin IgG was provided by the Leeds Bionanotechnology Group. 
 
2.1.10 Kits and consumables 
 NucleoSpin® gel and PCR clean-up kits were supplied by Macherey-Nigel. 
QIAprep Spin Miniprep kits were purchased from QIAGEN. Two-ml polystyrene 
columns, F96 Maxisorp Nunc-immuno plates and Zeba spin desalting columns (7K 
MWCO) were purchased from ThermoFisher Scientific. Mini-PROTEAN TGX gels (4-
15%, 10 wells) were purchased from Bio-rad. Pur-A-LyzerTM Midi 6000 dialysis tubes 
were purchased from Sigma-Aldrich. Series S sensor chips SA and polyvinylidene 
difluoride (PVDF) membranes were obtained from GE Healthcare Life Sciences. 
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2.1.11 Electrodes 
 Gold-based screen-printed electrode chips (model CX223AT) were fabricated 
by and purchased from Dropsens (Spain). Each chip (Figure 2.1) offers a three 
electrode system. This makes its application more convenient since there is no 
requirement for additional reference and counter electrodes. Two working electrodes 
are circular whereas the counter electrode has a U shape. Working and counter 
electrodes were made of gold. A reference electrode was made of Ag/AgCl. 
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Figure 2.1  A Dropsens gold screen-printed electrode chip. Each chip has two 
working electrodes, one counter electrode and one reference electrode. Four silver 
connectors at the bottom are used to connect with a potentiostat via a Dropsens 
connector. 
 
 
 
 
 
 
 
 
1 cm 
3.4 cm 
Au counter electrode 
Au working electrode x 2 
Al/AgCl reference electrode  
Silver connector  
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2.2  Methods  
2.2.1  Phage display screening for DDT-binding Affimers 
Biotinylated DDT (Hapten 2 – biotin) was synthesised and kindly provided by 
Dr. Hanafy Ismail from Liverpool School of Tropical Medicine, UK. The structure of 
biotinylated DDT is presented in Figure 2.2. Biotinylated DDT was dissolved in 80% 
(v/v) methanol at the concentration of 20 mg/ml.  Prior to use for phage display 
screening, the stock of biotinylated DDT was diluted down to 1 mg/ml. 
 
 
 
 
 
 
 
 
 
Figure 2.2  The chemical structure of biotinylated DDT. The structure contains 
(1) biotin, (2) hydrocarbon chain linker and (3) DDT moiety. 
 
The Affimer phase display selection was performed as presented in Figure 
2.3. In the first panning round, biotinylated DDT was immobilised onto a streptavidin-
coated well (ThermoFisher Scientific) for 1 h and then 5 µl of Affimer phage library 
was added and incubated on a vibrating shaker for 2 h at room temperature. The 
panning well was washed with PBST on a plate washer. Bound phage were then  
1 
2 
3 
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Figure 2.3  The schematic representation showing the brief protocol of phage display 
screening for DDT-specific Affimer selection. The procedure consisted of binding of 
the Affimer presented on phage to DDT, washing unbound phage, eluting bound 
phage and infecting E.coli cells with phage presenting the Affimer. In the second and 
third panning rounds, streptavidin-coated magnetic particles and a Neutravidin-
coated plate were used for the selection. 
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eluted from the target using 0.2 M glycine, pH 2.2 for 10 min, neutralised in 1 M Tris-
HCl, pH 9.1, then eluted using 10 mM Triethylamine for 6 min, and neutralised in 1 
M Tris-HCl, pH 7.0. Eluted phage were further employed for infecting E.coli strain 
ER2738 for 1 h at 37oC without shaking. The phage-infected E.coli cells were plated 
on LB agar plates with 100 µg/ml carbenicillin and incubated overnight at 37oC. 
Growing colonies were scraped into 5 ml of 2TY media with 100 µg/ml carbenicillin 
and infected with M13K07 helper phage (titre ca. 1014/ml). After 30 min of incubation, 
25 mg/ml kanamycin was added and the culture was left overnight with shaking at 
25oC, 170 rpm. The phage were precipitated in polyethylene glycol-NaCl solution (4% 
(w/v) PEG 8000, 0.3 M NaCl) and the pellets were resuspended in TE buffer 
containing 10 mM Tris, pH 8.0, 1 mM EDTA. 
In the second panning round, in order to pre-pan the phage, 125 µl of phage-
containing supernatant from the first panning round was mixed with 25 µl of the 
streptavidin beads (Dynabeads® MyOneTM Streptavidin T1, 10 mg/ml, Invitrogen). 
The suspension was incubated on a rotator for 1 h at room temperature prior to 
centrifugation.  The supernatant was transferred to a fresh tube and mixed with 25 µl 
of the streptavidin beads again, following by 1 h incubation and centrifugation. In the 
meantime, biotinylated DDT was coated on the streptavidin beads. Supernatant 
containing the pre-panned phage was mixed with the DDT-coated streptavidin beads. 
For competitive panning, non-biotinylated DDT was added into the suspension. The 
supernatant was allowed to incubate overnight on a rotator at room temperature. 
After competitive binding, the suspension containing the beads was washed using a 
KingFisher Flex robotic platform (ThermoFisher Scientific). Wash and elution 
protocols were identical to the first panning round. As soon as the run finished, the 
supernatant was incubated with ER2738 E.coli cells for 1 h at 37oC without shaking. 
After centrifugation, the bacterial cells were plated on LB agar plates with 100 µg/ml 
carbenicillin and left overnight at 37oC. The phage were precipitated in polyethylene 
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glycol-NaCl solution (4% (w/v) PEG 8000, 0.3 M NaCl) and the pellets were 
resuspended in TE buffer. 
In the final panning round, a NeutrAvidin coated 8-well strip (ThermoFisher 
Scientific) was used to capture biotinylated DDT. 1 µl of 1 mg/ml biotinylated DDT 
stock was added to the well and incubated for 1 h at room temperature. 100 µl of 
supernatant containing phage from the second panning round was added to the DDT-
coated well and incubated for 1 h at room temperature on a shaker. After washes, a 
solution containing 0.5 µg/µl of non-biotinylated DDT was added into the DDT-coated 
well and left for incubation on a shaker overnight at room temperature. In the 
meantime, ER2738 E.coli cells were cultured in 2TY media plus 12 µg/ml tetracycline 
and incubated overnight at 37oC, 230 rpm. The overnight ER2738 cell culture was 
diluted in 2TY media with a ratio of 1:15 and incubated for 1 h at 37oC, 230 rpm. After 
washes using a plate washer, the phage were eluted by 0.2 M glycine, pH 2.2 for 10 
min, and neutralised in 1 M Tris-HCl, pH 9.1. The phage were immediately mixed 
with the ER2738 cells. Remaining phage in the panning wells were eluted using 10 
mM triethylamine for 6 min, neutralised in 1 M Tris-HCl, pH 7.0 and transferred to the 
ER2738 cells. The mixture was left for incubation at 37oC for 1 h without shaking and 
then plated with a range of volumes (10-fold dilutions from 0.01 to 100 µl) on LB agar 
plus 100 µg/ml carbenicillin. The plates were incubated overnight at 37oC and were 
used for phage ELISA. 
 
2.2.2 Phage ELISA 
Preparation of phages: individual colonies of infected ER2738 E.coli cells 
from the final panning round were picked and grown in 200 µl of 2TY media 
containing 100 µg/ml carbenicillin in a 96-well V-bottom deep well plate for overnight 
at 37oC, with shaking at 1050 rpm. From each overnight culture, 25 µl was then 
transferred to 200 µl of fresh 2TY media containing 100 µg/ml carbenicillin and 
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incubated for 1 h at 37oC with shaking. M13K07 helper phage (titre ca. 1014/ml) were 
diluted in 2TY media with the ratio of 1:1000 and 10 µl of the dilution was added to 
fresh bacterial cultures. The cultures were incubated for 30 min at room temperature 
at a shaking speed of 450 rpm. The phage-infected cultures were added to 10 µl of 
2TY media containing 1.25 mg/ml kanamycin and incubated overnight at room 
temperature and shaking speed of 750 rpm. The culture plate was centrifuged at 
3,500 xg for 10 min. The supernatant was removed to check for binding to biotinylated 
DDT. 
 
ELISA: to begin with, biotinylated DDT was immobilised on a streptavidin-
coated 96-well plate. The plate was washed once in PBST prior to adding 10 µl of 
10x casein blocking buffer (Sigma-Aldrich) and 40 µl of phage-containing 
supernatant. The plate was incubated for 1 hr at room temperature on a shaker. After 
washing once in PBST, 50 µl of 1:1000 dilution of anti-Fd-Bacteriophage-HRP was 
added into the wells and incubated for 1 h at room temperature with shaking. The 
plate was washed 10 times in PBST before 50 µl of TMB substrate (SeramunBlau® 
fast TMB/substrate solution, Seramun) was added. The absorbance at 620 nm was 
measured after 3 min incubation. The phagemid vectors from positive clones were 
then selected and extracted for sequencing.     
 
2.2.3 Subcloning of Affimer-encoding sequences into pET11a 
plasmids 
2.2.3.1 Digestion of pET11a with NheI and NotI enzymes 
The 125 µl reaction containing 5 µg of pET11a plasmid, 1x CutSmartTM buffer, 
100 units of NheI (NEB) and 100 units of NotI (NEB) was prepared and incubated 
overnight at 37oC. 14 µl of 10x Antarctic phosphatase reaction buffer and 1 µl of 5,000 
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units/ml of Antarctic phosphatase (NEB) were added to the overnight reaction and 
incubated for 15 min at 37oC. The reaction was then heated up to 65oC for 5 min in 
order to inactivate Antarctic phosphatase. The digested pET11a vector was 
examined using 0.7% (w/v) agarose gel electrophoresis. To extract the pET11a 
plasmid from the excised gel, a NucleoSpin® gel and PCR clean-up kit (Macherey-
Nigel) was used according to the manufacturer’s instructions. The absorbance at 620 
nm was measured and the products were stored at -20oC for the further use. 
 
2.2.3.2 PCR amplification of Affimer-encoding sequences 
To amplify Affimer-encoding sequences from phagemid vectors, PCR 
reactions were set up. A 25 µl PCR reaction comprised of 1x Phusion HF Buffer 
(ThermoFisher Scientific), 200 µM dNTP mix, 3% (v/v)  DMSO, 0.8 µM forward primer 
forward shorter (5’ – ATGGCTAGCAACTCCCTGGAAATCGAAG - 3’), 0.8 µM 
reverse primer pDHIS-C-rev (5’ – TTACTAATGCGGCCGCACAAGCGTCACCA 
ACCGGTTTG – 3’), 0.02 units/µl of Phusion DNA polymerase (ThermoFisher 
Scientific) and 1 µl of phagemid DNA template. PCR was performed as follows. A 
cycle of initial denaturation was run at 98oC for 30 s, following by 30 cycles of 
denaturation at 98oC for 20 s, annealing at 54oC for 20 s and extension at 72oC for 
20 s. Finally, a cycle of final extension was performed at 72oC for 10 min. PCR 
products were purified through a Macherey-Nagel Nucleospin® gel and PCR clean-
up kit (Macherey-Nagel) according to the manufacturer’s instructions prior to further 
use. 
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2.2.3.3 Digestion of PCR-amplified Affimer sequences using 
NheI and NotI 
To digest PCR products, 60 µl reaction was prepared as follows: 1x 
CutSmartTM Buffer, 167 units/ml of NheI-HFTM (NEB), 167 units/ml of NotI-HFTM (NEB) 
and 50 µl of purified PCR products. The mixtures were incubated overnight at 37oC. 
After the incubation, 0.5 µl of DpnI enzyme (NEB) was added into the reactions in 
order to remove dam methylated phagemid DNA template. The reactions were then 
incubated for 1 h at 37oC prior to purifying with a Macherey-Nagel Nucleospin® gel 
and PCR clean-up kit (Macherey-Nagel) according to the manufacturer’s instructions. 
 
2.2.3.4 Ligation of digested Affimer-encoding sequence PCR 
fragments into the pET11a vector 
In order to ligate Affimer-encoding sequences into the pET11a expression 
vector, 20 µl ligation reactions were prepared. Each reaction contained 1x T4 DNA 
ligase buffer (NEB), 75 ng of digested pET11a vector, 25 ng of digested Affimer 
sequence DNA fragment and 20,000 units/ml of T4 DNA ligase (NEB). The mixed 
reactions were incubated overnight at room temperature prior to transformation into 
E.coli cells.  
 
2.2.3.5 Transformation of ligation products into competent cells 
In transformation, XL1-Blue E.coli supercompetent cells (Agilent 
technologies) were selected for amplification of pET11a vectors carrying Affimer-
encoding sequences. In brief, the competent cells were thawed on ice before 10 µl 
of the cells was gently mixed with 1 µl of the ligation mix. The mix was incubated on 
ice for 30 min, heated shock at 42oC for 45 s and incubated on ice again for 2 min. 
190 µl of SOC medium was then added to the mix before incubating at 37oC for 1 hr 
89 
 
  
with shaking speed of 230 rpm. After the incubation, 100 µl of the bacterial mixture 
was grown on LB agar with 100 µg/ml carbenicillin overnight at 37oC. Single colonies 
growing on the media were randomly picked into LB media plus 100 µg/ml 
carbenicillin and incubated overnight at 37oC. The subcloned plasmid DNA for each 
Affimer clone was extracted from transformed E.coli using a QIAprep Spin Miniprep 
kit (QIAGEN) according to the manufacturer’s instructions. The plasmids were 
sequenced using a T7P primer (5’ – TAATACGACTCACTATAGGG – 3’). The 
nucleotide sequences of Affimer were translated into amino acid sequences prior to 
alignment using Clustal Omega supplied by EMBL-EBI. 
 
2.2.3.6 Colony PCR 
 5 µl of sterile dH2O was aliquoted into a fresh PCR tube. A single colony of 
transformed E.coli was picked and dipped in 5 µl dH2O as a template for colony PCR. 
A 12.5 µl PCR reaction consisted of 1x Phusion HF Buffer (ThermoFisher Scientific), 
200 µM dNTP mix, 0.8 µM forward primer forward shorter (5’ – 
ATGGCTAGCAACTCCCTGGAAATCGAAG - 3’), 0.8 µM reverse primer pDHIS-C-
rev (5’ – TTACTAATGCGGCCGCACAAGCGTCACCAACCGGTTTG – 3’), 0.02 
units/µl of Phusion DNA polymerase (ThermoFisher Scientific). PCR cycling was 
performed as described previously in 2.2.3.2. The PCR products were examined 
using 1.4% (w/v) agarose gel electrophoresis in 1x TAE buffer and the gels were 
photographed under UV light using a Syngene G-BOX imager. 
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2.2.4 Expression and purification of Affimers 
2.2.4.1 Transformation of pET11a – Affimer plasmids into BL21 
Gold (DE3) E.coli  
To express the Affimers, BL21 Gold (DE3) E.coli (Agilent technologies) was 
selected as a host for Affimer production. 1 µl of plasmid DNA with an Affimer 
sequence was gently mixed with 10 µl of the competent cells. The mix was then 
incubated on ice for 30 min, heated shock at 42oC for 45 s and moved back for 
incubation on ice for 2 min.  SOC medium (180 µl) was added into the transformed 
cells and incubated at 37oC for 1 h with shaking speed of 230 rpm. The bacterial 
mixture was then plated on LB agar plus 100 µg/ml carbenicillin and inculated 
overnight at 37 oC. 
 
2.2.4.2  Affimer expression 
Single colonies growing on LB agar were randomly picked and grown in 3 ml 
of 2TY media plus 100 µg/ml carbenicillin and 1% (w/v) glucose overnight at 37oC 
and shaking speed of 230 rpm. In the meantime, 50 ml of LB was pre-warmed 
overnight at 37oC.  
Into 50 ml pre-warmed LB media, 100 µl of 50 mg/ml carbenicillin and 1 ml of 
the overnight culture were added. The culture was incubated at 37oC with shaking 
speed of 230 rpm until the OD600 reached approximately 0.8, which typically took 2.5 
h. The culture was then added with 25 µl of 1M IPTG in order to induce Affimer 
production and incubated for another 6 h at 25oC with shaking speed of 150 rpm. The 
bacterial cells were harvested using centrifugation at 3,220 xg for 30 min. The 
supernatant was discarded and the cells were air-dried for 30 min prior to storage at 
-20oC until the extraction was ready. 
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2.2.4.3  Affimer purification 
The harvested cells were lysed in 1 ml of lysis buffer containing 50 mM 
NaH2PO4, 300 mM NaCl, 30 mM imidazole, 10% (v/v) glycerol, pH 7.4, plus 1x 
BugBuster Protein Extraction Reagent (Novagen), 10 units/ml Benzonase Nuclease 
(Novagen) and 1x Halt Protease Inhibitor Cocktail (ThermoFisher scientific). The 
mixtures were initially incubated at room temperature for 20 min on a Stuart SB2 fixed 
speed rotator. In order to eliminate contaminant proteins, the mixtures were heated 
up to 50oC for 20 min. The mixtures were then centrifuged at 16,000 xg for 20 min to 
separate cell debris and unwanted insoluble components from soluble proteins. 
Simultaneously, 300 µl Ni2+-NTA slurry containing 150 µl (IBA Solutions for Life 
Sciences) was washed once in 1 ml of lysis buffer. The slurry was centrifuged at 
1,000 xg for 1 min to sediment the resin and the buffer was then removed. After 20 
min centrifugation, the supernatant containing soluble proteins was transferred into 
washed Ni2+-NTA slurry and incubated on a fixed speed rotator for 2 h at room 
temperature. The mixtures were centrifuged at 1,000 xg for 1 min to sediment the 
resin. The supernatant containing unbound proteins was transferred to a fresh tube 
and stored at -20oC. The remaining resin was added with 1 ml wash buffer containing 
50 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, 10% (v/v) glycerol, pH 7.4. To 
remove non-Affimer proteins, the resin was washed through a disposable 2 ml 
polystyrene column (ThermoFisher Scientific) until the absorbance at 280 nm 
reached < 0.09. Finally, the Affimers were eluted from the columns using elution 
buffer containing 50 mM NaH2PO4, 500 mM NaCl, 300 mM imidazole, 20% (v/v) 
glycerol, pH 7.4. SDS-PAGE was used to check the size and quantity of the Affimers. 
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2.2.4.4 Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE sample loading buffer was prepared by mixing 950 µl of 2x 
Laemmli sample buffer (Bio-rad) with 50 µl of 14.2 M 2-mercaptoethanol (Bio-rad). 
10 µl of protein sample was mixed thoroughly with 10 µl of the sample loading buffer. 
The mix was incubated at 95oC for 10 min. Subsequently, 15 µl of heated mix was 
loaded into the well in a Mini-PROTEAN TGX gel (4-15%, 10 wells, Bio-rad). SDS-
PAGE was performed in 1x TGS (Tris/Glycine/SDS) buffer (Bio-rad) with the applied 
potential of 100 V for 65 min. After the run, the gel was stained in Quick Coomassie 
Stain (Generon) for 30-40 min and de-stained in dH2O for 1-2 h. The gel was 
photographed using a Syngene G-BOX imager. 
 
2.2.4.5 Affimer dialysis 
 Prior to further use, purified Affimers were dialysed to eliminate imidazole. 
Pur-A-LyzerTM Midi 6000 dialysis tubes (Sigma-Aldrich) were equilibrated in 1x PBS 
buffer for at least 5 min. Eluted Affimers (500-800 µl) were transferred to dialysis 
tubes and then dipped in 1x PBS buffer pH 7.4 (dialysis buffer) with magnetic stirring 
for 3 h at 4oC. The buffer was changed every hour. The supernatants containing 
Affimers were removed to fresh tubes and centrifuged at 13,000 xg for 5 min to 
eliminate aggregated components before storing at -20oC for further use. 
 
2.2.5  Characterisation of Affimers against DDT using ELISA 
2.2.5.1 Preparation of NeutrAvidin-coated 96-well plates 
 1 mg/ml stock of NeutrAvidin was prepared before diluting it into 5 µg/ml in 
PBS. To immobilise NeutrAvidin on plates, 50 µl of 5 µg/ml NeutrAvidin was aliquoted 
into each well of a F96 Maxisorp Nunc-Immuno plate (ThermoFisher Scientific) and 
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incubated overnight at 4oC. Prior to use, the plates were blocked with 2x casein 
blocking buffer (Sigma-Aldrich) overnight at 37oC.  
 
2.2.5.2 ELISA to examine the binding of Affimers against 
biotinylated DDT 
 Biotinylated DDT was initially immobilised on a NeutrAvidin-coated plate. 
After 3 washes in PBST, 5 µg/ml of Affimers was added to the wells and incubated 
for 1 h with a shaking speed of 450 rpm. The plate was washed five times in PBST 
before anti-His-tag antibodies – HRP (1:1000 dilution, Abcam) were added and 
incubated for 1 h with shaking. After 5 final washes, TMB substrate was added and 
allowed to develop for 3 min. The absorbance at 620 nm was measured. 
 
2.2.5.3 ELISA to optimise concentrations of Affimers and TMB 
incubation time for competitive assay 
 The assay was performed in the same way as described previously in Section 
2.2.5.2. Concentrations of Affimers was prepared at 0, 0.04, 0.08, 0.16, 0.31, 0.63, 
1.25 and 2.5 µg/ml by two-fold serial dilution. After TMB substrate addition, the 
absorbance at 620 nm was monitored at 10, 20, 30 and 60 min to investigate the 
optimal time point for competitive ELISA assay. 
 
2.2.5.4 Competitive ELISA  
 Biotinylated DDT-coated plates were prepared as described previously. In the 
meantime, a range of DDT concentrations was prepared at 0, 0.07, 0.15, 0.31, 0.62, 
1.25, 2.5, 5 and 10 µM by two-fold serial dilution. Affimers at the concentration of 0.3 
µg/ml was mixed with different concentrations of DDT with 1:1 ratio and left for 
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incubation on a fixed speed rotator for 1 h at room temperature. After the plates were 
washed 3 times in PBST, the Affimer-DDT mixtures were added to the plates and 
incubated for 1 h with shaking. Anti-His-tag antibodies – HRP (1:1000 dilution) were 
added after 5 washes in PBST and the plates were incubated for 1 h with shaking. 
The plates were washed 5 times with PBST before TMB substrate was added. The 
absorbance at 620 nm was measured.  
 
2.2.6 Characterisation of Affimers against FGFR3 protein 
2.2.6.1 Biotinylation of FGFR3 and GFP Affimers 
Prior to biotinylation, 150 µl of each Affimer was mixed with 150 µl of 
immobilised TCEP disulfide reducing gel (ThermoFisher Scientific) on a fixed speed 
rotator for 1 h at room temperature. The supernatants were then mixed with 6 µl of 2 
mM biotin-maleimide (Sigma-Aldrich) and incubated without agitation for 2 h at room 
temperature. The mixtures were desalted using Zeba Spin Desalting Columns, 7K 
MWCO (ThermoFisher Scientific) according to the manufacturer’s instructions. The 
concentration of biotinylated Affimers was measured via BCA assay and the 
successful biotinylation was determined by ELISA and liquid chromatography-mass 
spectrometry (LC-MS). 
 
2.2.6.2 Bicinchoninic acid (BCA) assay  
BCA assay was used as a standard method to measure the concentration of 
the Affimers and protein samples used for the whole experiments. In the assay, BSA 
was employed to set a standard curve for protein concentration measurement. BSA 
at the concentrations ranging from 0 to 1 mg/ml was freshly prepared as well as the 
Affimers and protein samples. The BCA working reagent was prepared by mixing 
1:50 ratio of 4% (w/v) copper (II) sulfate pentahydrate solution and bicinchoninic acid 
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together. Into a 96-well plate, 15 µl of each protein sample including BSA was added 
to the wells, following by 120 µl of the BCA working reagent. The reactions were 
incubated at 37oC for 30 min and were then measured the absorbance at 562 nm. 
The standard curve was generated using OriginPro 8.6 software. 
 
2.2.6.3 Sandwich ELISA to investigate the binding of Affimers 
to FGFR3 protein 
To perform the sandwich ELISA, a F96 Maxisorp Nunc-Immuno plate 
(ThermoFisher Scientific) was coated with 5 µg/ml NeutrAvidin in 1x PBS buffer 
overnight at 4oC. The plate was then blocked with 2x casein blocking buffer (Sigma-
Aldrich) overnight at 37oC. After 1x wash in PBST (PBS with 0.05% Tween-20), 
approximately 40 µM of each biotinylated Affimer was added into the wells and 
incubated with the rotation speed of 450 rpm for 1 h at room temperature. The plate 
was washed twice in PBST before 45 µM of purified FGFR3 (Genscript) was added 
into the wells and left for incubation for 1 h at room temperature. After washing steps 
as described previously, 2 µg/ml of anti-FGFR3 antibodies specific to extracellular 
domain (F3922, Sigma-Aldrich) as primary antibodies was added to the plate, 
following by 2 µg/ml of anti-rabbit IgG antibodies – HRP (A0545, Sigma-Aldrich) as 
secondary antibodies. The plate was washed 6 times with PBST before TMB 
substrate (SeramunBlau® fast, Seramun) was added. After 3 min of TMB addition, 
the absorbance at 620 was measured. 
 
2.2.6.4 Surface Plasmon Resonance (SPR) 
SPR was carried out using a Biacore T200 (GE Healthcare Life Sciences, 
USA) with a series S sensor chip SA with 1x PBS-P+ (GE Healthcare Life Sciences, 
USA) as a running buffer for the entire experiments. First, biotinylated Affimers were 
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immobilised to the sensor chip via streptavidin-biotin interaction on flow cell 2-4 
whereas flow cell 1 was left empty as a reference surface. The Affimers at the 
concentration of 16.7 nM were injected into flow cells at a flow rate of 5 µl/min until 
the surface density reached 200 response unit (RU). Kinetic binding data were 
collected by injecting purified FGFR3 at the concentrations between 0 and 1000 nM 
at a flow rate of 30 µl/min and the temperature of 25oC. The contact time during the 
association phase was 300 s, following by 900 s of the dissociation phase with the 
running buffer. After each cycle of association and dissociation, the surfaces were 
regenerated using 10 mM glycine pH 2.5 for 120 s at a flow rate of 30 µl/min. To 
determine the dissociation constant (KD) of each Affimer, the SPR data were 
analysed using GraphPad Prism 7 software. 
In fact, an Affimer has only one binding site, which can bind specifically to an 
epitope on the analyte. Therefore, the most appropriate model to explain the mode 
of action when the Affimer binds to the target is a 1:1 binding model which can be 
expressed by equation 2.1.  
 
 
 
 Where :  
[R] is the concentration of bioreceptor (M),  
[L] is the concentration of ligand (M),  
[RL] is the concentration of bioreceptor-ligand complex (M),  
kon is association rate constant in M-1 s-1 unit,  
koff is dissociation rate constant in s-1 unit 
 At the start of the association phase, none of bioreceptor molecules attached 
to the chip surface is occupied. When ligand is injected into the flow cells, more and 
[R] + [L]                            [RL] …………. (2.1) 
kon 
koff 
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more binding sites on the bioreptors are occupied with ligands, resulting in a rapid 
increase of response of the sensor. As time passes the binding sites of bioreceptors 
become fully occupied and the sensor response becomes constant. At the steady 
state, the numbers of ligands binding to and dissociating from bioreceptors are equal. 
The association rate constant is governed by the concentration of free ligands and 
bioreceptors. The binding kinetics during the association period can be shown as 
equation 2.2. 
 
𝑑[𝑅𝐿]
𝑑𝑡
=  𝑘𝑜𝑛[𝑅][𝐿] − 𝑘𝑜𝑓𝑓[𝑅𝐿] ……………………… (2.2) 
Where :  
d[RL]/dt is change in receptor-ligand complex formation over time,  
[R] is bioreceptor concentration (M),  
[L] is ligand concentration (M),  
[RL] is bioreceptor-ligand complex concentration (M),  
kon is association rate constant in M-1 s-1 unit,  
koff is dissociation rate constant in s-1 unit 
 A one-site specific model was used in order to calculate the association rate 
constant (kon). The kinetic equation 2.2 is transformed to the format that can be 
resolved by computer programmes as shown in equation 2.3. The reference data and 
zero FGFR3 data were subtracted from the SPR data of each concentration of 
FGFR3. By fitting the SPR data from the association phase with this model, the kon 
values for Affimers when binding to FGFR3 protein were obtained. 
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𝑦 = 𝑦0 + 𝐴(1 − 𝑒
𝑘𝑜𝑛𝑡) ………………………………. (2.3) 
Where :  
y is binding signal (response unit),  
y0 is minimum binding signal achieved (response unit),  
A is the amount of ligand (M),  
kon is association rate constant (M-1 s-1),  
t is time (s) 
 The dissociation phase occurs when the injection of ligand is stopped. The 
solution containing ligand of interest is replaced by running buffer. Therefore, the 
ligand concentration is zero. At this stage, bound ligands dissociates from the 
bioreceptors. The rate of dissociation is governed by time and the concentration of 
ligand-receptor complex and can be described by equation 2.4. 
 
𝑑[𝑅𝐿]
𝑑𝑡
=  −𝑘𝑜𝑓𝑓 ∙ [𝑅𝐿] …………………………………. (2.4) 
Where :  
d[RL]/dt is change in receptor-ligand complex formation over time,  
[RL] is bioreceptor-ligand complex concentration (M),  
koff is dissociation rate constant in s-1 unit 
 In order to analyse the SPR data from the dissociation phase, a one phase 
decay model was used. The kinetic equation for dissociation is transformed to the 
rate equation presented in equation 2.5. By fitting the binding kinetic data with this 
model, the koff values for the binding of Affimers to FGFR3 protein were obtained. 
 
 
99 
 
  
𝑦 =  𝑦0 + 𝐴 ∙ 𝑒
−𝑘𝑜𝑓𝑓∙𝑡 ……………………………..(2.5) 
Where :  
y is binding signal (response unit),  
y0 is minimum binding signals achieved (response unit),  
A is the amount of ligand (M),  
koff is dissociation rate constant (s-1),  
t is time (s). 
 To determine the affinity of a bioreceptor for its target, the overall dissociation 
constant (KD) is normally used. The dissociation constant (KD) represents the 
concentration of ligand that saturates 50% of the binding sites of the bioreceptor. 
From this definition, the lower the KD is, the stronger the interaction between 
bioreceptors and ligands is. The apparent KD from the experiments can be calculated 
using equation 2.6. 
 
𝐾𝐷 =  
𝑘𝑜𝑓𝑓
𝑘𝑜𝑛
 ……………………………………… (2.6) 
Where :  
KD is dissociation constant (M),  
kon is association rate constant (M-1 s-1),  
koff is dissociation rate constant (s-1) 
 
2.2.6.5 Pull-down assay and western blot analysis 
 Prior to the pull-down assay, 60 µl of streptavidin resin (Genscript) was mixed 
with 60 µl of 4x casein blocking buffer (Sigma-Aldrich) and incubated for 1 h on a 
fixed speed rotator at room temperature in order to block unoccupied sites on the 
resin. The resin was washed once in 1x PBS before 20 µg of biotinylated Affimers 
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was added to the washed resin, following by 90 min incubation on a rotator at room 
temperature. After removing unbound Affimers and washing once in wash buffer, 
15.75 µg of purified FGFR3 was added to the resin coated with Affimers. The 
mixtures were incubated overnight on a rotator at 4oC. The supernatant was removed 
and the resin was washed three times in wash buffer. The extra 30 µl of 1x PBS was 
added to suspend the resin. 
 For western blot analysis, the pull-down products as well as a biotinylated 
Affimer and purified FGFR3 as positive controls for the blots were prepared and 
separated using SDS-PAGE as mentioned in Section 2.2.4.4. It should be noted that 
two identical gels are required. To begin with, polyvinylidene difluoride (PVDF) 
membranes were pre-soaked in methanol for 1 min, following by equilibrating in 
transfer buffer containing 20% (v/v) methanol, 25 mM Tris, 190 mM glycine, pH 8.3 
for at least 15 min. The gels containing protein samples were carefully packed into 
the cassettes in the following order: black side of blotting pad, 2 x filter paper, gel, 
PVDF membrane, 2 x filter paper, white side of blotting pad. The cassettes were 
moved to a tank filled with transfer buffer. An ice block was used to keep the 
temperature consistent during the transfer. The proteins in the gels were transferred 
to PVDF membranes using the applied potential of 115 V for 75 min. After transferring 
the proteins onto the membranes, the membranes were blocked in 5% (w/v) skim 
milk in PBST for 1 h on a rocker. The membranes were washed 3 times in PBST. In 
order to examine the existence of Affimers, one of the membranes was incubated in 
1:1000 ratio of streptavidin-HRP (ThermoFisher Scientific) diluted in 2% (w/v) BSA in 
PBST for 1 h at room temperature. The membrane was washed 4 times in PBST and 
3 times in 1x PBS. The results were revealed by Pierce ECL western blotting 
substrate (ThermoFisher Scientific). The membrane was then photographed using a 
Syngene G-BOX imager.  
 In the meantime, to examine the binding of Affimers to FGFR3 protein, the 
other membrane was incubated in 1:750 ratio of anti-FGFR3 antibodies (F3922, 
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Sigma-Aldrich) diluted in 2% (w/v) BSA in PBST overnight on a rocker at 4oC. The 
membrane was then washed 4 times in PBST before being incubated in 1:1000 ratio 
of anti-rabbit IgG antibodies – HRP (A0545, Sigma-Aldrich) diluted in 2% (w/v) BSA 
in PBST on a rocker for 1 h at room temperature. The membrane was washed 4 
times in PBST, following by washing three times in 1x PBS. After 1 min addition of 
Pierce ECL western blotting substrate (ThermoFisher Scientific) solution, the 
membrane was photographed using a Syngene G-BOX imager.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
 
2.2.6.6 ELISA to check the specific binding of Affimers to 
FGFR3 and other protein targets 
 10 µg/ml of each protein sample (FGFR3, β-2-microglobulin, antidigoxin IgG 
and human serum albumin) was added into the wells in a F96 Maxisorp Nunc-
Immuno plate (Thermo Scientific) and left for immobilisation overnight at 4oC. The 
plate was washed 3 times in PBST, following by blocking with 10x casein blocking 
buffer (Sigma-Aldrich) for 3 h at 37oC. After washed three times in PBST, 5 µg/ml of 
biotinylated Affimers was added into the wells and left for incubation at room 
temperature for 1 h with the shaking speed of 450 rpm. The plate was then washed 
6 times in PBST before 1:1000 ratio of streptavidin-HRP (ThermoFisher Scientific) 
was added to each well and incubated for 1 h as described previously. After 8 washes 
in PBST, TMB substrate was added and allowed to develop for 30 min. The 
absorbance at 620 nm was measured. 
 
2.2.7 Fabrication of impedimetric biosensors 
2.2.7.1  Biosensor construction using ELISHA gluing method 
 To begin with, 200 µg/ml of FGFR3-21 and GFP Affimers were prepared in 
10 mM phosphate buffer pH 7.2. The Affimers were mixed with the linking reagent 
102 
 
  
supplied by ELISHA Ltd. with 1:1 ratio and incubated on a fixed speed rotator for 1 h 
at room temperature. The reagents were stored at 4oC until use. 
 In order to immobilise Affimers onto electrodes, cyclic voltammetry was used. 
FGFR3-21 Affimer was immobilised first onto working electrode 1 with the applied 
potential of 0-1.6 V, 2 cycles and a scan rate of 100 mV/s. After washes with 100 mM 
PBS pH 7.2, GFP Affimer was deposited to working electrode 2 with the identical 
approach. The Affimer-immobilised chips were soaked in 100 mM PBS pH 7.2 until 
EIS measurement. After the baseline impedance measurement, the sensors were 
tested with FGFR3 protein over the concentration range from 10-15 to 10-8 M with 
washing in PBS in between. The data obtained were analysed using Origin Pro v8.6 
software. 
 
2.2.7.2  Biosensor construction via NeutrAvidin-biotin linkage 
- Electropolymerisation of polytyramine 
 Electropolymerisation of polytyramine was performed using NOVA 2.0.2 
software on an AUTOLAB type III electrochemical workstation (Metrohm Autolab 
B.V.; Utrecht, Netherlands). To polymerise a layer of polytyramine, cyclic 
voltammetry was used. Three types of electrodes were covered with a solution of 25 
mM tyramine (Sigma-Aldrich) dissolved in 0.3 M NaOH in Milli-Q water. The applied 
potential was cycled twice from 0 to 1.6 V and then back to 0 V at a scan rate of 200 
mV/s. After polymer deposition, the electrodes were rinsed twice and incubated in 20 
mM boric acid/disodium tetraborate buffer pH 9.0 for 20 min prior to bioconjugation. 
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- Immobilisation of Affimers 
 To immobilise Affimers, polytyramine-coated electrodes were rinsed twice in 
20 mM boric acid/disodium tetraborate buffer pH 9.0 and dried gently with tissue 
paper. To tether biotinylated Affimers to the electrode surface, NeutrAvidin-biotin 
interaction was utilised. The electrodes were incubated with 10 µl of 3 mM NHS-biotin 
(Sigma-Aldrich) for 30 min, following by 10 µl of a selected concentration of 
NeutrAvidin for 45 min with washing in PBS in between. Finally, 2 µl of a specific 
concentration of biotinylated Affimer was added onto a working electrode and left for 
1 h at room temperature. After washing in PBS, the fully constructed electrodes were 
incubated in PBS for 1 h prior to EIS measurement. 
 
2.2.7.3   Electrochemical impedance spectroscopy 
 To observe the binding of FGFR3 protein to Affimers on the electrode surface, 
electrochemical impedance spectroscopy (EIS) was performed using an AUTOLAB 
type III electrochemical workstation (Metrohm Autolab B.V.; Utrecht, Netherlands). 
The fully fabricated sensors were challenged by incubating sequentially with 
increasing concentrations of FGFR3 between 10-14 and 10-8 M for 15 min, following 
by washing in PBS in between. Impedance measurement was conducted in the 
presence of 10 mM K3[Fe(CN)6]/K4[Fe(CN)6] (1:1 ratio) in 100 mM PBS, pH 7.2. The 
measurements were recorded at an applied potential of 0 V vs Ag/AgCl over a 
frequency range of 2.5 kHz to 250 mHz with a modulation voltage of 10 mV. All of 
the experiments were replicated (n ≥ 3) with independent sensor chips.  
To analyse the sensor responses, charge-transfer resistance (Rct) obtained 
automatically from NOVA 2.0.2 software was employed. The Rct of each FGFR3 
concentration was normalised as percentage against the Rct measured without 
analyte addition. The sensor response was revealed using equation 2.7. The 
resulting data were then analysed using Origin Pro v8.6 software. 
104 
 
  
𝐶∗ = −
𝑍"
𝜔|𝑍|2
 − 𝑗
𝑍′
𝜔|𝑍|2
= 𝐶′ + 𝑗𝐶" ………………………….……..(2.8) 
 
 
 Changes in capacitance, phase shift and absolute impedance were also 
considered as alternative approaches to measure sensor performance. To 
investigate effects on capacitance, impedance data were converted into complex 
capacitance using equation 2.8 obtained from Jolly et al. (2016). 
 
 
 
 Where:  
 C’ = real part of capacitance (F) 
 C” = imaginary part of capacitance (F) 
 Z’ = real component of measured impedance (Ω) 
 Z” = imaginary part of measured impedance (Ω) 
 𝜔 = 2𝜋𝑓, angular frequency of the measurement (rad/s) 
 The real and imaginary components of capacitance were plotted against each 
other, providing Cole-Cole plots, where the capacitance values (C’) were obtained. 
The C’ for each FGFR3 concentration was normalised as a percentage against the 
C’ of the sensors without FGFR3. The calculation was done using equation 2.9. 
 
 
 
 
105 
 
  
 To analyse phase shift data, phase shift values were plotted against 
frequencies and the data at the lowest frequency showing the maximum phase shift 
were chosen for further analysis. Here, phase shift at a frequency of 7.9 Hz was used 
to see the response of the sensors. The phase shift at 7.9 Hz of each FGFR3 
concentration was normalised by subtracting the phase shift of the sensors without 
FGFR3 as presented in equation 2.10. 
 
 
 To analyse absolute impedance data (|Z|), absolute impedance values were 
plotted against frequencies and the frequency showing the maximum change in 
absolute impedance was selected. Here, absolute impedance at 0.25 Hz was used 
for further analysis. The |Z| at 0.25 Hz of each FGFR3 concentration was normalised 
as a percentage against the |Z| of the sensors without FGFR3 as shown in equation 
2.11. 
 
  
 
2.2.7.4   Optimising sensor fabrication 
- Optimisation of Affimer concentration 
 In order to examine the optimal concentration of Affimers, 4 concentrations of 
Affimers, 0.05, 0.1, 0.3 and 1 µM, were tested. The concentrations of NHS-biotin and 
NeutrAvidin were kept constant at 3 and 0.1 µM, respectively. Sensors were 
fabricated according to the protocol in Section 2.2.7.2. 
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- Optimisation of NeutrAvidin concentration 
 The optimal concentration of NeutrAvidin for sensor fabrication was also 
investigated. The sensors were constructed following the protocols as described in 
Section 2.2.7.2. While the concentrations of NHS-biotin and Affimers were fixed at 3 
and 0.3 µM, respectively, NeutrAvidin concentrations were varied at 0.033, 0.067 and 
0.1 µM. 
 
- Effects of blocking reagents on sensor performance 
 Several proteins and chemicals were introduced here in order to minimise the 
effect of non-specific binding of analytes to sensor surface. After fabricating sensors 
following the method in Section 2.2.7.2, the sensors were blocked with 10 µl of a 
specific concentration of blocking reagents (Table 2.1) for 30 min before 1 h 
incubation in PBS and EIS interrogation. 
 
Table 2.1   Lists of blocking reagents and working concentrations used in this 
experiment  
Blocking reagents Concentration 
Bovine serum albumin (BSA) 0.1 µM 
Sodium caseinate 100 µg/ml 
Pyromellitic dianhydride 10 mM 
mPEG-biotin, 5K 0.1, 1 and 3 mM 
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2.2.7.5  Modification of sensor fabrication protocol and 
optimisation 
 Sensors were made using the protocol in Section 2.2.7.2. However, previous 
blocking procedures (Table 2.1) did not prove effective as presented in Chapter 5. 
The following, new blocking procedure, modified from (Esseghaier et al., 2008) was 
tested. Briefly, after polytyramine electrodeposition on electrode surface, 3 µM NHS-
biotin and 0.067 µM NeutrAvidin were utilised to modify polytyramine-coated working 
electrodes. Prior to conjugating Affimers onto the working electrodes, three blocking 
reagents, 6.7 µM BSA, 2x casein blocking buffer (Sigma-Aldrich) and 0.2 mg/ml 
sodium caseinate, were tested for their capability to minimise non-specific binding 
effects by incubating with the sensors for 30 min. The concentration of Affimer used 
was fixed at 1 µM. After EIS measurements and data analysis, the sensor responses 
were compared to select the best blocking reagent. In this case, 6.7 µM BSA was 
selected for optimising Affimer concentration for sensor construction. 
 In order to optimise Affimer concentrations, the sensors were made layer-by-
layer using 3 µM NHS-biotin, 0.067 µM NeutrAvidin and 6.7 µM BSA. Affimers at the 
concentrations of 0.3, 1 and 3 µM were tested. The responses of the sensors were 
determined after exposing them to the analyte. 
 
2.2.7.6   Sensors tested with negative control analytes 
 Sensors were constructed using the protocols described previously in Section 
2.2.7.5. The sensors were tested against β-2-microglobulin (Sigma-Aldrich), human 
serum albumin (Sigma-Aldrich) and antidigoxin IgG. A range of negative control 
analyte concentrations was freshly prepared from 10-14 to 10-8 M by 10-fold dilution 
in 100 mM PBS pH 7.2. EIS measurements were performed as described in Section 
2.2.7.3.  
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2.2.7.7  Effect of poly(sodium-p-styrenesulfonate) on sensor 
performance 
 To construct sensors, the methods in Section 2.2.7.2 were followed. The 
concentrations of NHS-biotin, NeutrAvidin and Affimers were kept constant at 3 µM, 
0.067 µM and 1 µM, respectively. After Affimer attachment, either 1, 5 or 10 µM of 
poly(sodium-p-styrenesulfonate) was used to block the sensor chips for 30 min. The 
sensors were tested with various concentrations of FGFR3 as described in Section 
2.2.7.3.  
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Chapter 3   
Affimer screening and production 
3.1   Introduction 
In biosensing applications, biorecognition elements play a significant role in 
the overall performance of the platforms. The major prerequisite for bioreceptors is 
the specificity with which they bind to their target although the affinity with which they 
bind their target governs the sensitivity of the device. During the past decades, 
antibodies have been widely used thanks to their specific recognition nature to the 
targets. However, large size and batch-to-batch variations make antibodies 
troublesome in many biosensor applications.  
 Non-antibody binding scaffolds have been considered as an alternative to 
antibodies as they offer some advantages. They include small size, high temperature 
stability and ease of production. The Affimer is a non-antibody binding protein 
developed for a number of applications (Tiede et al., 2017). Selection of Affimers is 
conveniently conducted via phage display screening, and with the library complexity 
of > 10-10 distinct clones (Tiede et al., 2014), Affimers are applicable to a wide range 
of targets, from small molecules to large proteins (Tiede et al., 2017).  
 This section is mainly focused on the screening and production of Affimers 
via the phage display library provided by the BioScreening Technology Group 
(BSTG). Dichlorodiphenyltrichloroethane (DDT) was initially selected as a model 
analyte for Affimer screening and represents a small molecule target and remains an 
important pesticide for malaria vector control. The protein target chosen was 
fibroblast growth factor receptor 3 (FGFR3) which is a promising biomarker for 
bladder cancer (Tomlinson et al., 2007). The chosen Affimer-encoding sequences 
were subcloned into a pET expression vector to allow the Affimers to be produced in 
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E.coli. In the production steps, DDT Affimers and FGFR3 Affimers were expressed 
and purified for further use. 
 
3.2  DDT Affimer screening 
 The core structure of the Affimers is based on the consensus sequence of 
plant-derived phytocystatins (Tiede et al., 2014). To obtain Affimers recognising the 
targets of interest, the BioScreening Technology Group (BSTG) at University of 
Leeds screened the Affimer phage display library with the complexity of 
approximately 1.3 x 1010 distinct clones presenting two variable peptide regions with 
18 random amino acid residues (Tiede et al., 2014). 
 
3.2.1  Preparation of biotinylated DDT as a target for phage display 
screening 
 In this section, dichlorodiphenyltrichloroethane (DDT), a widely used 
insecticide for agriculture and malaria control, was chosen as the target of interest 
for Affimer screening. Basically, the targets of interest are required to be biotinylated 
first in order to allow immobilisation by streptavidin-biotin interaction prior to the 
screening steps.  
 Biotinylated DDT was synthesised and provided by Dr. Hanafy Ismail from the 
Liverpool School of Tropical Medicine. The original structure of DDT does not contain 
any functional groups that are useful for further modification and a carboxylic group 
was introduced into the structure of DDT. Then, a short spacer and biotin were linked 
to the DDT analogue. The resulting biotinylated DDT analogue was then attached to 
streptavidin-coated surfaces (Figure 3.1). 
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Figure 3.1  A schematic representation of Affimer screening. DDT is biotinylated prior 
to use for Affimer selection. The selection can be performed via phage display 
screening. 
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3.2.2  Phage display screening 
 DDT was selected as an analyte to screen for the Affimers in this study. 
Biotinylated DDT was immobilised onto a streptavidin-coated plate before phage 
presenting Affimers were added. After incubation for one hour, unbound phage were 
washed out and only phage with the Affimers binding to the DDT moiety still 
remained. Acid and alkaline buffers were then used to elute the remaining phage. In 
order to elute the remaining phage, it was suggested that the non-biotinylated form 
of analytes could be used, allowing Affimers binding specifically to the analytes to be 
selected. An example of this type of elution is using imidazole to elute His6-tagged 
proteins from Ni2+-NTA coated resin as presented in Section 2.2.4. However, 
because of the fact that DDT is insoluble in water, it is impossible to prepare high 
concentration stock of DDT in water-based solvents such as PBS to be used as 
elution buffer. These phage were then used to infect E.coli strain ER2738, which 
allows the phagemid to amplify exponentially. The E.coli cells were then infected with 
M13K07 helper phage. This step is vital since the helper phage provides the 
necessary components for phage assembly and secretion. Three panning rounds 
were performed. However, during the second and final panning rounds, non-
biotinylated DDT was added to perform competitive selection. The reason for the use 
of competitive selection is the strong binders with fast association and slow 
dissociation for the target of interest can be picked from a pool of other binders. After 
the final panning, 48 colonies of E.coli were randomly selected for the phage ELISA 
(Figure 3.2). 
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Figure 3.2  ER2738 E.coli cells growing on LB-carbenicillin (carb) plates after the 
third competitive panning for DDT Affimer selection. The LB carb plates were spread 
with (A) ER2738 cells without infection with phage, (B-F) ER2738 cells inoculated 
with 0.1, 1, 10, 100 µl and remaining suspension of selected phage, respectively. 
Forty eight colonies from the plates in C, D and E were randomly picked and used in 
the phage ELISA step. 
 
 
 
 
 
 
 
 
A B C 
D E F 
114 
 
  
3.2.3 Phage ELISA 
 Forty eight single colonies of E.coli containing phagemid vectors were 
randomly picked and cultured. They were then infected with M13K07 helper phage 
to help form the phagemid presenting Affimers specific for DDT.  To do phage ELISA, 
biotinylated DDT was captured on a streptavidin-coated plate, following by phage-
containing suspension. The binding between biotinylated DDT and Affimers 
presented on the phage was examined using anti-Fd-bacteriophage-HRP. The 
results were revealed after adding a solution of 3,3’,5,5’-tetramethylbenzidine, which 
is a substrate for HRP enzyme. Figure 2.5 shows the ELISA 96-well plate, where 
wells A1 to H6 with biotinylated DDT were immobilised and wells A7 to H12 were 
negative controls. The Affimer in well A1 had a negative control in well A7 and 
similarly for the other Affimers.  Out of 48 selected clones, 46 clones showed specific 
binding to biotinylated DDT and none of the clones showed non-specific binding in 
the control wells (Figure 3.3). The clones showing positive results were selected and 
prepared for sequencing. 
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Figure 3.3  Phage ELISA results showing 46 out of 48 clones of Affimers presenting 
on the coat of M13 phage bound specifically to biotinylated DDT. (A) The ELISA 96-
well plate after TMB substrate was added, the blue product was generated in the 
wells with phage presenting Affimers capable of binding to biotinylated DDT.  
(B) Absorbance at 620 nm showing the binding of 48 selected Affimers to biotinylated 
DDT. 
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3.2.4 Affimer sequencing and sequence alignment 
 The phagemid vectors of the 46 positive clones of DDT Affimers were 
prepared and sent for sequencing with the assistance of GENEWIZ Genomics, UK. 
The nucleotide sequences were obtained and translated to amino acid sequences 
using ExPASy translate tool (https://web.expasy.org/translate/). Amino acid 
sequences of each Affimer clone were aligned using Clustal Omega available on 
EMBL-EBI. 
 Out of 46 positive clones, 34 clones contained full-length functional 
sequences (the core structure and the variable peptide regions). The 34 functional 
clones showed 16 different patterns of amino acid sequence in the variable peptide 
loops. Interestingly, amongst the 16 unique patterns found, only clone H25 contained 
two variable peptide regions whereas the other Affimers showed only one inserted 
variable peptide loop (Figure 3.4 and 3.5). In order to produce the Affimers, eight 
clones, H8, H10, H18, H23, H25, H27, H38 and H39, were selected for further 
experiments. The clone selection was based on the variation in types of amino acids 
(non-polar/neutral, polar/neutral, acid/polar and basic/polar) found within the binding 
loop(s). For example, if two Affimers clones showed a similar pattern in the types of 
amino acid, one was arbitrarily selected as similar interactions of both Affimers with 
DDT could be expected. However, if two Affimers presented a different pattern of 
amino acid types in the binding loop(s), both of them were chosen for further 
investigation. By this means of selection, a workable number of eight Affimers was 
obtained.   
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 Figure 3.4  Nucleotide and amino acid sequences of H25 Affimer.  H25 is selected as a representative to show the full-length Affimer sequence as 
it is the only selected Affimer presenting two variable peptide regions. The sequences highlighted in blue represent insertion region 1 and the ones 
highlighted in red show insertion region 2. 
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Figure 3.5  Amino acid sequences of 16 selected Affimers against DDT. The figure shows the amino acid sequences at two variable peptide regions. 
Only the H25 Affimer has two complete loops whereas the others have one loop. The number of identical clones for each Affimer is also presented. 
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3.3 Subcloning of anti-DDT Affimer-encoding 
sequences into pET11a expression vector 
 The phagemid vectors containing Affimer-encoding sequences cannot be 
used for protein expression in E.coli. The Affimer-encoding sequences needed to be 
subcloned into an expression vector such as pET11a in order to enable efficient 
expression of the Affimers in bacteria. 
 
3.3.1 Digestion of pET11a with NotI/NheI restriction enzymes 
 The pET system is a powerful system developed for subcloning and 
expression of proteins of interest in E.coli. The pET11a vector used in this study 
contains the pBR322 origin of replication, which allows it to replicate in E.coli cells 
(Figure 3.6). It also has an ampicillin resistance gene, which can be used as a 
selectable marker for identifying the E.coli cells accepting the pET11a vectors. 
Finally, there is a T7 promoter site which is the recognition site for T7 RNA 
polymerase and a His8 tag encoding region that allows purification of the Affimers 
conveniently, using Ni2+-NTA resin. 
 The pET11a vector was digested with two restriction enzymes, NotI and NheI 
before separating with 0.7% (w/v) agarose gel electrophoresis (Figure 3.7). In the 
lane of uncut pET11a, there were three bands of plasmid appearing on the gel. This 
is because the open circular or nicked form of plasmid migrates slowly. Therefore, it 
appeared on the top of the gel. The plasmid can also exist in supercoiled form. As 
the nature of supercoiled plasmids is compact, this makes them migrate faster than 
the open circular ones. Thus, the supercoiled forms (the lowest band in pET11a uncut 
lane) were visualised below the nicked circle form (the highest band in pET11a uncut 
lane). The middle band in pET11a uncut lane represents the plasmid in its linear form, 
which could be due to nuclease contamination or harsh treatment during the 
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purification process. In the NheI/NotI digested plasmid lane, two bands appeared. 
With excess plasmid before digestion, the restriction enzymes could not digest the 
plasmid completely. The digested plasmids are linear, which allows them to migrate 
more rapidly than the intact, circular form of the plasmids. The digested pET11a band 
was excised from the gel and purified to use for the further steps of subcloning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  The map of pET11a expression vector. The vector contains NotI and 
NheI restriction sites, T7 promoter for T7 RNA polymerase, eight histidine residue 
region, and ampicillin resistance gene for selection and pBR322 origin of replication. 
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Figure 3.7  The pET11a plasmid digested with NotI and NheI enzymes. The digested 
products were separated using 0.7% (w/v) agarose gel electrophoresis in 1x TAE 
buffer system. The DNA marker in the first lane is 2-log ladder marker (NEB). The 
arrow () indicates the digested pET11a vector, which was cut out for the further 
use. 
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3.3.2 Polymerase chain reaction (PCR) amplification of Affimer-
encoding sequences 
 PCR was used to multiply Affimer-encoding sequences selected previously 
from the phage display technique. In the PCR reaction, phagemid vectors for eight 
selected clones of Affimers against biotinylated DDT were used as DNA templates. 
The forward primer was designed using the nucleotide sequence located at the 
upstream region of the Affimer sequence including NheI restriction site on the 
phagemid vector whereas the reverse primer was positioned covering NotI restriction 
site. Additionally, the codon for cysteine was introduced into the reverse primer in 
order to introduce a specific site for chemical modifications.  
 The PCR products were examined using 0.7% (w/v) agarose gel 
electrophoresis as shown in Figure 3.8.  The bands with the molecular size > 1000 
bp represented the phagemid templates in both circular and supercoiled forms. The 
bands with the molecular sizes < 500 bp were PCR fragments of Affimer-encoding 
sequences, which were used in further experiments. 
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Figure 3.8  PCR products before the reactions were treated with NotI/NheI and DpnI 
enzymes. The products were separated using 0.7% (w/v) agarose gel 
electrophoresis in 1x TAE buffer system and stained with ethidium bromide. The DNA 
marker is 2-log ladder marker (NEB). The red arrow indicates Affimer-encoding 
sequence PCR fragments. The blue bracket indicates phagemid vector templates. 
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3.3.3 Digestion of PCR fragments using NotI/NheI and DpnI 
enzymes 
 Prior to ligation with the pET11a vector, the Affimer-encoding PCR fragments 
needed to be digested with the same restriction enzymes used to prepare the 
digested pET11a plasmid. PCR products were digested with NotI and NheI overnight 
to ensure that both ends of the PCR fragments were able to link with the sticky ends 
of the pET11a vector. After NotI/NheI digestion of PCR fragments, it was essential 
for the reactions to be treated with DpnI enzyme. This enzyme has the unique 
property of digesting dam methylated DNA templates. In this research, during the 
PCR amplification, the concentrated and diluted (1:30 ratio) phagemid vectors were 
studied as the appropriate templates for PCR. Figure 3.9 showed that when using 
the concentrated phagemid templates for PCR, DpnI was not able to digest all of the 
template and there was remaining template left in the reactions. However, when the 
phagemid template was diluted before PCR, the DpnI digestion was complete and 
none of the template was left. This is an important step since the remaining phagemid 
fragments could possibly compete with the Affimer sequence fragments during 
ligation, resulting in the expression vectors with unexpected sequences. Therefore, 
the digested PCR fragments amplified from the diluted template reactions were used 
for ligation. 
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Figure 3.9  PCR products after the reactions were treated with NotI/NheI and DpnI. 
The phagemid templates were completely digested by DpnI when 1:30 dilution of the 
template was used. The products were separated using 1.4% (w/v) agarose gel 
electrophoresis in 1x TAE buffer system. The DNA marker is 2-log ladder marker 
(NEB). The red bracket indicates the remaining phagemid template after digestion. 
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3.3.4 Ligation and transformation 
 Ligation was performed in order to join a fragment of PCR product and a 
plasmid vector together. Prior to ligation, digested pET11a vector and PCR fragments 
of Affimer-encoding genes were run through a 1.4% (w/v) agarose gel to see if correct 
products were present (Figure 3.10). The band of 6000 bp on the second lane 
indicated the digested pET11a plasmid whereas the bands with molecular size 
around 300 bp in lanes 3-8 indicated the Affimer sequence fragments. In the ligation 
reaction, a PCR product and the pET11a vector were mixed with the ratio of 1:3 (w/w) 
(Figure 3.11). After the overnight ligation, the ligated pET11a vectors containing 
Affimer-encoding sequences were transformed into XL1 Blue E.coli competent cells 
using the heat-shock method. The transformed cells were grown overnight on LB 
agar media added with carbenicillin as an antibiotic for the selection. The colonies 
growing on the plates (Figure 3.12) were randomly selected for colony PCR and 
sequencing to check the successful ligation of expression vectors. 
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Figure 3.10  Digested pET11a vector and PCR products of genes encoding Affimers 
prepared for ligation. The products were separated using 1.4% (w/v) agarose gel 
electrophoresis in 1x TAE buffer system. The DNA marker is 2-log ladder marker 
(NEB). The arrow () indicates Affimer encoding fragments. 
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Figure 3.11  A schematic representation of ligation and transformation of a pET11a 
expression vector containing an Affimer-encoding sequence. Both pET11a vector 
and Affimer fragment are digested with NheI and NotI in order to allow the ligation 
between the vector and the PCR fragment. The resulting pET11a vector containing 
an Affimer sequence is transformed into an XL1 Blue E.coli cell using heat-shock 
method. 
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Figure 3.12  XL1 Blue E.coli cells containing Affimer-encoding genes growing on LB 
carb plates. The plates were spread with (A) E.coli without pET11a vector (negative 
control) and (B – G) E.coli transformed with pET11a vector containing the sequences 
of Affimer H8, H10, H18, H25, H27 and H39, respectively. Three colonies for each 
clone were randomly selected for colony PCR to check the success of insertion of 
Affimer-encoding gene fragments into pET11a vectors. 
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3.3.5 Colony PCR 
 To confirm the successful insertion of Affimer-encoding sequences into the 
pET11a expression vector, colony PCR was conducted. Five single colonies of 
transformed E.coli for each clone of Affimers were randomly picked as templates for 
PCR. The primers used for the PCR reaction were the same as in the subcloning 
step. The PCR products were separated using 1.4% (w/v) agarose gel 
electrophoresis and stained with ethidium bromide. Figure 3.13 revealed that out of 
all the bacterial colonies picked from the plates, some colonies had the pET11a 
vector containing Affimer sequences, in which 300-bp fragments were visualized. 
However, the other colonies did not show 300-bp bands, suggesting that there was 
no inserted Affimer sequence.  
 In order to confirm the correct Affimer sequences and the successful addition 
of a cysteine residue, sequencing was required. The bacterial cells showing positive 
detection on colony PCR were cultured in LB media containing carbenicillin and the 
plasmids were then extracted from the cells. The plasmids were sent for sequencing 
by GENEWIZ Genomics, UK. 
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Figure 3.13  Colony PCR was performed in order to check the success of inserting 
Affimer-encoding sequences into pET11a vectors. The PCR products were 
separated using 1.4% (w/v) gel electrophoresis in 1x TAE buffer. The 300-bp PCR 
bands representing the Affimer-encoding genes are indicated by the arrows (). The 
positive colonies were selected for sequencing. The DNA marker is 2-log ladder 
marker (NEB). 
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3.3.6  Sequencing and alignment 
 Sequencing and alignment were the approaches used to confirm the correct 
nucleotide and amino acid sequences. The nucleotide sequences obtained from 
GENEWIZ Genomics, UK were translated to amino acid sequences using the 
Translate tool supplied by ExPASy. The amino acid sequences were then aligned 
with the same Affimer-encoding sequences from phagemid vectors using online 
Clustal Omega supplied by EMBL-EBI. Figure 3.14 shows the result of amino acid 
sequence alignment of H25 Affimer sequences from pET11a vector compared with 
the same Affimer from the phagemid vector. The core structure of the Affimer was 
almost identical except for the addition of a cysteine residue and the missing amino 
acids at N-terminus of the Affimer from the phagemid, which represents a part of the 
DsbAss signal sequence. The additional cysteine was useful because it provides a 
single –SH group for further modifications so that the orientation of the Affimers can 
be controlled.  
 To this point, the pET11a expression vectors carrying the nucleotide 
sequences for H8, H10, H18, H23, H25, H27, H38 and H39 Affimers were 
constructed. Affimer clone H25 contains two variable peptide regions whereas the 
others have only one inserted loop (Table 3.1). The expression vectors containing 
Affimer sequences were used for Affimer production which was described in the 
following sections. 
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Figure 3.14  Sequence alignment of H25 Affimer obtained from pET11a vector and the H25 Affimer obtained from phagemid vector. The red-
highlighted region indicates the variable peptide loop 1 whereas the blue-highlighted region indicates the loop 2. The green arrow () shows the 
position of the introduced cysteine addition. 
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Table 3.1   Amino acid sequences at variable peptide loops 1 and 2 of eight selected 
Affimers against DDT. Only H25 contains two complete loops whereas 
the other clones have one inserted loop. 
 
Clone number Sequence of loop 1 Sequence of loop 2 
H8 NIYMDYERN - 
H10 PDSRSDLYN - 
H18 EFLDGPYST - 
H23 AHPARYEKN - 
H25 WTEYKPVYA AKHVHLLTQ 
H27 YFVTNSETN - 
H38 RYPLRSEKN - 
H39 YFNSDVEQN - 
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3.4  Production of Affimers against DDT 
 As well as other alternative binding protein scaffolds, one of the advantages 
of Affimers that make them an alternative to antibodies is that production can be 
carried out in bacterial system. By doing this, any batch-to-batch variation issues can 
be minimised. The results of anti-DDT Affimer production are described in the 
following section. 
 
3.4.1 Affimer expression 
Affimer expression was carried out using an established protocol developed 
by the BioScreening Technology Group (BSTG) at Leeds as described in Section 
2.2.4. BL21-Gold (DE3) E.coli competent cells, a T7 promoter-driven expression 
system, were selected for Affimer production.  pET11a plasmids carrying Affimer-
encoding sequences were transformed into the E.coli cells. A single colony growing 
on a LB media plate containing carbenicillin was picked for making a start-up culture. 
The overnight culture containing bacteria was then transferred to 50 ml LB media 
containing carbenicillin to make a fresh culture of bacteria for induction. After 2.5 
hours of incubation, the induction was started by adding 0.5 mM IPTG into the 
growing bacterial culture and incubation continued for 6 h. The E.coli cells containing 
Affimer were then harvested by centrifugation at 3,220 xg for 30 min and the Affimers 
were then extracted and purified. 
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3.4.2 Affimer purification 
 By following the procedure in Section 2.2.4.3, purification of the Affimer was 
conducted using Ni2+-NTA chromatography as the Affimers contain eight consecutive 
His residues at the C-terminus. The harvested bacterial cells were lysed in lysis buffer 
comprising 50 mM NaH2PO4, 300 mM NaCl, 30 mM imidazole, 10% (v/v) glycerol, 
pH 7.4, plus 1x BugBuster Protein Extraction Reagent, 10 units/ml Benzonase 
Nuclease and 1x Halt Protease Inhibitor Cocktail to allow protein release. The lysates 
were then centrifuged to remove cell debris and insoluble proteins. The supernatant 
containing Affimer was mixed with Ni2+-NTA resin. The resin mix was washed several 
times with wash buffer containing 50 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, 
10% (v/v) glycerol, pH 7.4 to eliminate remaining unbound proteins using gravity flow. 
The Affimers were subsequently eluted from the resin using elution buffer containing 
50 mM NaH2PO4, 500 mM NaCl, 300 mM imidazole, 20% (v/v) glycerol, pH 7.4.  
 In order to confirm the presence of Affimer after purification, SDS-PAGE was 
used (Figure 3.15). For each Affimer, five consecutive eluted fractions containing 
Affimers were run through a 4-15% (w/v) SDS-PAGE gel, alongside cell lysate and 
an unbound protein fraction. The data showed the migrated protein bands in lanes 
E1 to E5 with Mr between 10 – 15 kDa, indicating the correct Affimer size. Other 
proteins could not be detected in the lanes of Affimers, suggesting that the purity of 
the Affimer was sufficient for use in further experiments. The Affimer was then 
dialysed as recommended in Section 2.2.4.5 to eliminate imidazole before use. 
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Figure 3.15  SDS-PAGE gels of purified anti-DDT Affimers. (A) – (H) the gels showing H8, H10, 
H18, H23, H25, H27, H38 and H39 Affimers, respectively. The protein markers are SpectraTM 
multicolour broad range protein ladder (ThermoFisher Scientific) in kDa unit. (Lys) is lysate 
fraction, (UB) is unbound protein fraction, (E1-E5) are purified Affimer fractions 1-5, respectively. 
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3.5   Production of Affimers against FGFR3 
 In addition to DDT Affimers, Affimers specific to FGFR3 were also produced. 
FGFR3 is a protein in fibroblast growth factor receptor (FGFR) family, whose 
overexpression appears to be correlated with bladder cancer occurrence. The 
production of Affimers specific to FGFR3 may be beneficial for the researchers who 
would like to study the potential of FGFR3 as a biomarker for detection bladder 
cancer at the early stages. The FGFR3 Affimers were previously selected and 
subcloned by Dr. Nidhi Lal as part of another project. 
 
3.5.1 Affimer screening from the phage display library 
 The selection of Affimers from the phage library against FGFR3 protein was 
carried out by Ms. Anna Tang using the standard method established by the BSTG. 
Purified recombinant FGFR3 protein, which was the extracellular domain of the 
protein (Figure 1.14), was used for Affimer selection. FGFR3 was biotinylated before 
use in order for the target protein to use streptavidin-biotin interaction for Affimer 
selection. Initially, biotinylated FGFR3 was captured on a streptavidin-coated plate 
before phage-presenting Affimers were allowed to bind to the FGFR3 protein. 
Unbound phage were then removed during washing steps. Subsequently, bound 
phage were eluted using acid and alkaline buffers prior to infecting E.coli strain 
ER2738 for phagemid amplification. The E.coli cells were infected with M13K07 
helper phage, contributing to phage-presenting Affimers production. Three 
biopannings were performed. The first panning round was the standard panning 
whereas the second and third rounds were the competitive panning. After the third 
panning, the E.coli colonies were randomly picked for phage ELISA and positive 
clones were sequenced. Out of all the clones sequenced, 7 different patterns of 
amino acid sequence were revealed (Figure 3.16).  
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Figure 3.16  Amino acid sequences of 7 selected Affimers against FGFR3. The figure shows the amino acid sequences split over two variable 
peptide loops. Only FGFR3-21 Affimer possesses one inserted loop while the others have two inserted loops. 
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3.5.2 Anti-FGFR3 Affimer sequence and alignment 
Seven anti-FGFR3 Affimer-encoding sequences from the phagemid vectors 
were subcloned into a pET11a expression vector by Dr. Nidhi Lal (School of 
Chemistry, University of Leeds). This was to allow the selected Affimers to be 
expressed in BL21 (DE3) E.coli cells. In accordance with the preliminary 
characterisation of the selected anti-FGFR3 Affimers, the experimental data from 
biolayer interferometry (Dr. Nidhi Lal) and immunofluorescence staining assay (Dr. 
Darren Tomlinson) suggested that out of 7 selected Affimers against FGFR3, clones 
FGFR3-8, FGFR3-14 and FGFR3-21 showed higher levels of binding to FGFR3 
protein, compared to the other clones. Therefore, in this research, three anti-FGFR3 
Affimers, FGFR3-8, FGFR3-14 and FGFR3-21, were studied alongside with a GFP 
Affimer as a negative control. pET11a vectors containing FGFR3 and GFP Affimer 
sequences were kindly provided by Dr.Nidhi Lal and Dr. Paul Beales (School of 
Chemistry, University of Leeds). Initially, the sequences of four Affimers were 
checked by sequencing via GENEWIZ Genomics, UK. The nucleotide sequences of 
the Affimers were translated before alignment using online Clustal Omega (EMBL-
EBI). Figure 3.17 showed that all the four Affimers have the identical core structure 
and only vary in the sequences at the two peptide loop regions. Three Affimers, 
FGFR3-8, FGFR3-14 and GFP, contain two inserted loops whereas FGFR3-21 
Affimer has only one variable peptide loop. 
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Figure 3.17  Amino acid alignment of FGFR3 and GFP Affimers. The regions highlighted in red are variable peptide loop 1 whilst the blue regions 
are variable loop 2. The green arrow () indicates the added cysteine residue. 
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3.5.3 Anti-FGFR3 Affimer expression and purification 
 In order to produce the Affimers, the protocol established by the BSTG as 
described in Section 2.2.4 was followed. After the elution step, the purified Affimers 
were examined alongside with cell lysates and unbound protein fractions. Figure 3.18 
shows the results of SDS-PAGE gels of purified Affimers FGFR3-8, FGFR3-14, 
FGFR3-21 and GFP. In elution fractions E1 to E5, protein bands with the Mr around 
12.5 kDa, consistent with the size of an Affimer, were seen.  
 Although using this expression protocol resulted in expression yields of up to 
3 mg/ml for FGFR3-21 and GFP Affimers, yields for FGFR3-8 and FGFR3-14 
Affimers were under 1 mg/ml, causing difficulties for further experiments.  
Re-considering the original expression protocol from the BSTG, subsequently 
heating cell lysates at 50oC was avoided. Originally, heating the cell lysates is to 
remove non-specific (non-Affimer) proteins since Affimers are typically stable at 
higher temperatures. However, some Affimers tend to be degraded when the 
temperatures rise over 50 oC. By excluding heating to 50 oC, the expression yields of 
FGFR3-8 and FGFR3-14 Affimers increased to 2-3 mg/ml. 
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Figure 3.18  SDS-PAGE gels of purified Affimers against FGFR3. (A) – (D) the gels 
showing anti-FGFR3-8 FGFR3-14, FGFR3-21 and anti-GFP Affimers, respectively. 
The protein markers are SpectraTM multicolour broad range protein ladder 
(ThermoFisher Scientific) in kDa unit. (Lys), lysate fraction; (UB), unbound protein 
fraction; (E1-E5), purified Affimer fractions 1-5, respectively.  
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3.6  Discussion 
 The main focus of this chapter was to screen for, and produce, Affimers 
against DDT. The screening was successfully done using the Affimer-phage display 
library where 16 different clones of Affimers were obtained from the screening. The 
majority of the clones (15 out of 16 clones) possess one variable peptide loop 
whereas only the clone H25has two variable peptide loops. The small size of the 
target, DDT, may only require a small number of amino acid residues for the 
interaction. Antigens such as proteins present multiple epitopes, which are large, so 
they can form a number of bonds with Affimer binding sites. Therefore, it is common 
that the Affimers selected against proteins e.g. yeast SUMO (Tiede et al., 2014) and 
anti-myc tag antibodies (Raina et al., 2015) possess two inserted peptide loops. On 
the other hand, when the targets are small organic compounds such as 2,4,6 – 
trinitrotoluene (TNT), some of the isolated Affimers possess one variable peptide loop 
(Tiede et al., 2017). This indicates selection of these Affimers from a minor population 
of the original phage display library. 
 After subcloning anti-DDT Affimer-encoding sequences into the pET 
expression vector system, Affimer production was carried out in E.coli cells alongside 
with the production of anti-FGFR3 Affimers. Mostly, the yield of purified Affimers was 
between 1 mg/ml and 4 mg/ml, which was acceptable. However, two FGFR3 Affimer 
clones, FGFR3-8 and FGFR3-14, provided the yields below 1 mg/ml when using the 
original purification protocol, making them impractical for the further work. Eliminating 
the cell lysate heating step to 50oC improved the yield of the two FGFR3 Affimers up 
to 2-3 mg/ml. Aggregation is a common problem that researchers working with 
Affimers may experience. The unique properties of the Affimer scaffold, plus the two 
loops which contribute to around 25% of the total mass, and the addition of cysteine 
residues can be causes of aggregation. It is recommended that to prevent Affimers 
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from precipitation, stabilising agents such as glycerol should be added in the storage 
buffer (Raina, 2013). However, users may need to take into account that the 
additional agents may interfere with the further assays or applications. In the next 
section, all the selected Affimers were checked for their specific binding to the targets 
prior to using them in biosensor applications. 
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Chapter 4  
Affimer characterisation 
4.1  Introduction 
 In an application requiring biorecognition, specific binding of the bioreceptor 
to its target dominates the successful outcome of the assay. When working with 
synthetic binding proteins, it is essential for users to confirm that the selected 
bioreceptor is specific to the target of interest. A number of approaches have been 
developed in order to determine the affinities between two or more biomolecules. 
Some techniques are suitable for equilibrium measurement or at a steady state such 
as enzyme-linked immunosorbent assay (ELISA), isothermal titration calorimetry 
(ITC), immunoprecipitation (pull-down) assay and fluorescence anisotropy. However, 
methods such as surface plasmon resonance (SPR) and biolayer interferometry (BLI) 
can be used to study the binding kinetics in real time and also provide steady state 
data. A combination of different methods can help scientists select the best 
bioreceptor for their assays. 
 In this chapter, the main focus is on characterisation of the selected Affimers 
from Chapter 3. Two model analytes, DDT (a small molecule) and FGFR3 (a 
macromolecular protein), were studied. The work in this chapter was divided into two 
parts. To study the binding of Affimers to DDT, ELISA was used as a tool to determine 
the affinities between the Affimers and DDT. On the other hand, specific interaction 
between the Affimers and FGFR3 protein are confirmed using several approaches 
including ELISA, SPR, and immunoprecipitation assay. At the end of the 
characterisation, none of Affimers against DDT showed binding to free DDT, whereas 
Affimers against FGFR3 performed well on specifically binding to the target and were 
selected for biosensor construction, as will be described in Chapter 5.  
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4.2  Characterisation of Affimers against DDT 
 Although phage ELISA showed the success of binding between the Affimers 
presented on the phage pIII and biotinylated DDT, it was necessary to confirm that 
binding ability of the selected Affimers could be retained whilst not displayed on 
phage. Direct and competitive ELISAs were employed to check the binding between 
selected Affimers and DDT itself.  
 
4.2.1  ELISA to check the binding of Affimers to biotinylated DDT 
 The ELISA is a common immunoassay that is widely used to study interaction 
between bioreceptors (mostly antibodies) and targets of interest. In this section, a 
direct ELISA was used to evaluate the binding of eight Affimers to DDT. Biotinylated 
DDT was initially captured on a NeutrAvidin-coated Nunc-immuno plate via 
NeutrAvidin-biotin interaction. Each Affimer was used as the primary recognition 
element, following by anti-His6 tag antibodies – HRP (at 1:1000 dilution) as the 
secondary detection agent (Figure 4.1A). 
 Out of eight Affimers previously selected, six binders, clones H10, H18, H23, 
H27, H38 and H39, showed strong binding to biotinylated DDT whereas clones 
numbered H8 and H25 did not bind to DDT captured on the plate (Figure 4.1B). Three 
replicates were included in each experiment and two independent experiments were 
repeated. The results from the two experiments were indentical. An anti-GFP Affimer, 
which was used as a negative control, was unable to bind DDT, suggesting that the 
binding between the six positive Affimers and biotinylated DDT was specific. 
Therefore, the six Affimers which bound to biotinylated DDT were chosen for 
competitive ELISA, which is described in the following section. 
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Figure 4.1  Direct ELISA to examine the binding of Affimers to biotinylated DDT 
immobilised on a NeutrAvidin-coated plate. (A) schematic showing ELISA platform 
and (B) the result of ELISA showing the binding between nine Affimers to biotinylated 
DDT. Six Affimers, H10 to H39, showed positive results on the assay. The error bars 
represent mean of n = 3 ± SEM. 
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4.2.2  Optimisation of Affimer concentration for competitive 
ELISA 
 The optimal concentration of the biorecognition elements is a key factor for 
success in competitive ELISA. In this section, a range of Affimer concentrations were 
studied to determine the optimal concentration used for further competitive ELISA. 
H10 and H23 Affimers were selected as representatives for this study. Initially, 
biotinylated DDT was immobilised to a NeutrAvidin-coated plate. Then the Affimers, 
which varied in concentration from 0 to 2.5 µg/ml, were added and allowed to bind to 
the biotinylated DDT. Anti-His6 tag antibodies – HRP conjugate was used to develop 
the ELISA as described previously. For each experiment, three replicates were 
included. Two independent experiments were repeated in order to confirm the 
results. The optimal concentration of Affimer is the minimum concentration of Affimer 
where the generation of blue product after TMB substrate addition can still be 
visualised, compared to the Affimers absent (negative control). Figure 4.2A shows 
that an Affimer concentration (both H10 and H23) around 0.3 µg/ml was the minimum 
point where the blue product could be defined while concentrations lower than this 
showed a lower response which was not sufficient for competitive ELISA. 
In the meantime, the optimal incubation time for colour development and 
A620 measurement was also investigated. After TMB addition, the absorbance at 
620 nm was measured at different time points, from 10 min to 60 min. It was observed 
that after 30 min, the absorbance values changed slowly and was defined at 60 min 
(Figure 4.2B). Therefore, to conduct the competitive ELISA, an Affimer concentration 
of 0.3 µg/ml and an incubation time of 30 min after TMB substrate addition were 
chosen. 
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Figure 4.2  Optimisation of Affimer concentration and incubation time point for competitive ELISA. (A) 96-well plates showing the ELISA 
after 30 min of TMB addition. (B) Absorbance at 620 nm of ELISA upon the binding of H10 and H23 Affimers to biotinylated DDT. Affimer 
concentrations and incubation times were varied as shown. The error bars represent mean of n = 3 ± SEM. 
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4.2.3 Competitive ELISA to study the binding of Affimers to free 
DDT 
 In the previous section, it was confirmed that some of the selected Affimers 
bound to biotinylated DDT. However, it was important to prove whether the Affimers 
were able to bind free DDT as well. Competitive ELISA is a standard and easy 
method to study the interaction between two molecules and was chosen to examine 
the interaction between the Affimers and free DDT. To set up the competitive assay, 
biotinylated DDT was immobilised onto a NeutrAvidin-coated plate. Six Affimers, 
H10, H18, H23, H27, H38 and H39, at 0.3 µg/ml were individually mixed with free 
DDT concentrations ranging from 0 to 10 µM. The mixture of Affimers and free DDT 
was then transferred to the biotinylated DDT coated plate to allow the free DDT to 
compete with biotinylated DDT for Affimer binding. The Affimers that have a strong 
interaction with free DDT should not be dissociated from free DDT whereas weaker 
binders should be more easily dissociated from the free DDT and bind to the 
biotinylated DDT instead. Bound Affimers were detected using anti-His6 tag 
antibodies – HRP as described previously. For each experiment, three replicates 
were included. Two independent experiments were repeated so as to confirm the 
results. 
 The results from competitive ELISA showed that none of the six Affimers 
could bind to free DDT (Figure 4.3). All six Affimers were capable of binding to 
biotinylated DDT on the plate, which can be seen from the absorbance values from 
the wells containing Affimers, biotinylated DDT and free DDT, compared to the wells 
without Affimers or biotinylated DDT (negative controls). However, no increasing 
trend of A620 could be observed when allowing the Affimers to bind to different 
concentrations of free DDT, suggesting that the binding between the Affimers and 
free DDT did not occur with any appreciable affinity. During the phage display 
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screening, biotinylated DDT consisting of biotin, spacer and DDT moiety was used 
as a target for Affimer selection. It is assumed that as the biotin group was captured 
by NeutrAvidin on the plate, the Affimers may recognise the DDT moiety and a part 
of spacer (Figure 4.4). Without a short spacer on free DDT, the Affimers were unable 
to tightly bind DDT. 
 However, as seen in Figure 4.3B and 4.3F, the absorbance at 620 nm for 
Affimers H18 and H39 was lower compared to the other Affimers. As a result, the 
success of competitive binding of Affimers H18 and H39 to free DDT is still 
ambiguous. This may be because the optimal concentration of Affimer obtained from 
Section 4.2.2 is not suitable for all the Affimers tested. Therefore, optimisation of 
Affimer concentration for each Affimer clone should be a better approach to achieve 
a competitive ELISA. 
Selecting Affimers against small molecule targets is a challenging task. 
Recently, an established method of Affimer screening for organic compounds from 
the BSTG has been released. The explosive 2,4,6-trinitroluluene (TNT) was chosen 
as a target to screen for Affimers from the phage library (Tiede et al., 2017). Counter 
selection was performed and the TNT analogue, 2,4,6-trinitrobenzene sulphonic acid 
(TNBS) was conjugated to ovalbumin and IgG to act as an epitope for Affimer 
selection. The phage presenting Affimers were screened against TNBS-ovalbumin 
and TNBS-IgG conjugates as well as ovalbumin and IgG in order to select strong and 
specific binders. With this approach, four clones of Affimer specific to TNT were 
ultimately obtained. This method could be used as a model to select Affimers for 
other small molecules including DDT. Since TNT has three polar nitro groups, it may 
be a more amenable target than DDT which is much more hydrophobic. 
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H10 Affimer H18 Affimer H23 Affimer 
H27 Affimer H38 Affimer H39 Affimer 
Figure 4.3  Competitive ELISA to examine the binding between six Affimers to free DDT.  Panels A to F represent the binding between free DDT 
and (A) H10, (B) H18, (C) H23, (D) H27, (E) H38 and (F) H39, respectively. Free DDT was not able to compete at binding of the respective Affimers 
to the immobilised biotin-DDT. The error bars represent mean of n = 3 ± SEM. 
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Figure 4.4  Hypothetical scheme showing the binding of the Affimer to the DDT 
moiety and spacer. It is hypothesised that the binding site of the Affimer may 
recognise DDT and part of spacer region in biotinylated DDT. Therefore the Affimer 
failed to bind free DDT molecule with high affinity. 
 
 
 
 
 
155 
 
 
 
4.3  Characterisation of Affimers against FGFR3 
4.3.1  Biotinylation of Affimers via biotin-maleimide 
 One advantage of using Affimers is an additional cysteine can be introduced 
into the Affimer structure to provide a specific site for oriented modification as there 
are no cysteine residues in Affimers normally. The addition of a cysteine at the C-
terminus of the Affimers was performed previously by PCR as described in Chapter 
2. As the characterisation techniques to prove the binding of the selected Affimers 
and FGFR3 protein relied on avidin-biotin interaction, the Affimers were biotinylated 
before use. The benefit of using avidin-biotin linkage is correct orientation of the 
Affimers can be achieved on the solid surface, allowing the analyte to access the 
binding site of the Affimer. 
 Biotinylation of the Affimers can be carried out via maleimide chemistry. 
However, as a cysteine was added into the Affimer structure, during storage the 
Affimers dimerise via formation of a disulfide bond. Before biotinylation, Affimer 
dimers were cleaved using TCEP gel, providing a free thiol group to react with the 
maleimide group on biotin-maleimide (Figure 4.5). To confirm successful biotin 
labelling of the Affimers, ELISA and liquid chromatography – mass spectrometry (LC-
MS) were employed. The ELISA data indicated successful biotinylation as shown in 
Figure 4.6. In addition, LC-MS was performed to compare the molecular size of the 
Affimers before and after biotinylation. The resulting LC-MS spectrum of the Affimer 
before biotinylation showed two distinct peaks (Figure 4.7). The peak representing 
the lower mass indicated the monomeric Affimers whereas the peak at twice the 
mass showed the Affimer dimers. After biotinylation of the Affimers, only one peak 
can be seen (Figure 4.8). This is because once modified with biotin-maleimide, the 
thiol group is unavailable to react and form a disulfide bond. The difference of the 
molecular mass between a monomer and a biotinylated version of each Affimer is 
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almost equal to the molecular mass of biotin-maleimide (MW = 451.54) (Table 4.1), 
indicating the success of the biotinylation process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5  Biotinylation of an Affimer via biotin-maleimide. The process can be done 
using the maleimide reaction. 
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Figure 4.6  ELISA to check the success of Affimer biotinylation. (A) shows the ELISA 
setup. Biotinylated Affimer was coated on the plate and detected with streptavidin – 
HRP conjugate. (B) shows ELISA data. One µl of biotin-tagged Affimer was placed 
in row A and serial 0.1x and 0.01x dilution into row B and C, respectively. 
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 Figure 4.7  LC-MS spectrum of a FGFR3-8 Affimer prior to biotinylation. Two distinct peaks can be observed. Peak A represents the monomeric  
Affimer and peak B represents Affimer dimer, respectively. 
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Figure 4.8  LC-MS spectrum of a FGFR3-8 Affimer after biotinylation.  A, a distinct peak representing biotinylated Affimer monomer can be detected. 
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Table 4.1   Comparison of molecular mass of the Affimers before and after 
biotinylation  
 
Affimers Non-biotinylated form (Da) Biotinylated 
form (Da) 
Non-biotin 
monomer – 
Biotin form 
Monomer Dimer 
FGFR3-8 12389.60 24779.20 12840.00 450.40 
FGFR3-14 12449.60 24898.40 12902.40 452.80 
FGFR3-21 11218.40 22436.80 11669.60 451.20 
GFP 12590.40 25180.80 13040.80 450.40 
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4.3.2  Double-sandwich ELISA to check the binding between 
Affimers and FGFR3 
 To determine which selected Affimers have the highest affinity to FGFR3 
protein, a double-sandwich ELISA was chosen as to confirm the binding between 
each Affimer and FGFR3. In brief, biotinylated Affimers were initially immobilised onto 
an ELISA 96-well plate via NeutrAvidin-biotin interaction (Figure 4.9A). Three 
Affimers, FGFR3-8, FGFR3-14 and FGFR3-21, previously screened against FGFR3, 
were tested whereas anti-GFP Affimer was used as a negative control. The captured 
Affimers on the ELISA plate were then challenged with purified FGFR3. To 
investigate successful binding, anti-FGFR3 antibodies were applied as primary 
antibodies, following by anti-rabbit IgG antibodies – HRP as secondary antibodies. 
Colourimetric detection using TMB substrate was finally utilised to report the binding 
of the Affimers to their FGFR3 target. For each experiment, three replicated were 
included. Two independent experiments were carried out and the results were 
indentical. The result from the ELISA revealed that FGFR3-14 Affimer showed the 
highest binding ability to FGFR3 protein, following by FGFR3-21 Affimer. The binding 
between FGFR3-8 Affimer and FGFR3 protein could be detected but the level of the 
binding was not as strong as with FGFR3-14 and FGFR3-21 Affimers. As expected, 
the anti-GFP Affimer was unable to bind FGFR3 protein (Figure 4.9B). 
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A B 
Figure 4.9  Double-sandwich ELISA test to check the binding of Affimers and FGFR3 protein. (A) A schematic of ELISA setup. (B) The result of the 
ELISA showing positive binding when the Affimers screened against FGFR3 were used. The absorbance was measured at 620 nm. The error bars 
represent mean of n = 3 ± SEM. 
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4.3.3  Binding kinetics study using surface plasmon resonance 
(SPR) 
 As high sensitivity and specificity of biosensors are required and rely 
principally on the affinity between a bioreceptor and its target, the binding kinetics 
between the selected Affimers and FGFR3 were investigated using surface plasmon 
resonance (SPR). SPR is an optical biosensor where the basic principle of the 
measurement is based on a change in refractive index resulting from the binding 
between bioceptors and their target. The sensorgrams obtained provide useful 
information for studying protein-ligand interactions. A typical sensorgram offers real 
time binding data during association and dissociation phases that can be used to 
investigate binding parameters (Figure 4.10). 
 
 
 
 
 
 
 
 
 
Figure 4.10  A typical SPR binding sensorgram showing association and dissociation 
phases. The association data are collected after the injection of the analyte. The 
dissociation data, on the other hand, are measured and recorded after stopping 
analyte injection and replacing by running buffer. 
 
164 
 
 
 
  To set up the experiment, a streptavidin-coated SPR chip containing four flow 
cells was used. Biotinylated FGFR3-8, FGFR3-14 and FGFR3-21 Affimers were 
immobilised in flow cells 2 to 4, whereas flow cell 1 was left empty as a reference 
cell. The chip was then exposed to a series of FGFR3 concentrations ranging from 0 
to 1000 nM. At each FGFR3 concentration, the cycle started with association phase 
for 300 sec, following by 900 sec of dissociation. As anticipated, the change in 
refractive index increased as the concentration of FGFR3 added to flow cells 
increased (Figure 4.11), indicating that the binding between Affimers and FGFR3 
protein had occurred. The real time SPR data showed that FGFR3-14 and FGFR3-
21 Affimers could bind to FGFR3 (Figure 4.11A and 4.11B) while FGFR3-8 Affimer 
failed to bind its target (Figure 4.11C). These data agreed with the double-sandwich 
ELISA which previously revealed that the binding of FGFR3-14 and FGFR3-21 to 
FGFR3 protein were somewhat higher than for FGFR3-8 (Figure 4.9B). However, the 
evidence from immunofluorescence staining experiments showed that FGFR3-8 was 
able to bind FGFR3 upon cell-based assays (Dr. Darren Tomlinson - personal 
communication). This suggested that immobilisation of FGFR3-8 Affimer onto a solid 
surface may negatively affect its binding ability to the target. 
The SPR data showing the affinity between the selected Affimers and FGFR3 
protein were analysed using the approach presented in Section 2.2.6.4. Due to the 
limited stock of purifired FGFR3 protein, the SPR experiment could be conducted 
only once. The KD for the interaction between the FGFR3-14 Affimer and FGFR3 
protein was 327 pM while the KD for the FGFR3-21 Affimer and FGFR3 was 18.5 pM 
(Table 4.2). Typically, the KD values of antibody-antigen interaction range from pM to 
nM (Kim et al., 1990, Landry et al., 2015). It has earlier been reported that the KD for 
a monoclonal anti-FGFR3 antibody is 16.2 pM (ab133644, Abcam, UK). This means 
that the affinity of the selected Affimers is comparable to anti-FGFR3 antibody and 
they could be promising reagents for biosensor fabrication. 
165 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11  SPR sensorgrams showing the changes of refractive index in response 
units (RU). The sensors were immobilised with (A) FGFR3-8, (B) FGFR3-14 and (C) 
FGFR3-21 Affimers before challenged with FGFR3 protein concentration ranging 
from 0 to 1000 nM.  
 
A 
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Figure 4.12  The results of SPR data fitting with a one-site binding model available 
on Graphpad Prism 7 software. (A) is the fitting for FGFR3-14 Affimer and (B) for 
FGFR3-21 Affimer. The black curves represent experimental data from SPR assays 
whereas the red curves represent the fitting results which are overlaid. The 
association phase was fitted with a one-site specific binding model while the 
dissociation phase was analysed using a one-phase decay exponential model. 
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Table 4.2   Fitting SPR data from a one-site binding model. The results showed the 
excellent fit as shown in Figure 4.12.  
 
Affimer clones FGFR3-14 FGFR3-21 
kon (M-1 s-1) 1.60 × 108 4.49 × 108 
koff (s-1) 5.24 × 10-2 8.31 × 10-3 
KD (pM) 327 18.5 
R2 0.955 0.976 
2 1.610 1.071 
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4.3.4  Immunoprecipitation assay  
 Immunoprecipitation or pull-down assay is a well-known and widely used 
technique to isolate an analyte or protein of interest out of solution. The technique 
relies on the specific interaction between antibody and antigen. In this study, Affimers 
were used as an antibody replacement to bind FGFR3 in order to test their specificity. 
The experiment was set up as shown in Figure 4.13A.  Biotinylated Affimers were 
immobilised to streptavidin-coated resin, and as the amount of the Affimers was 
excess, unbound Affimers were then removed using wash buffer. The Affimers 
coated onto the resin were incubated with FGFR3 protein overnight before unbound 
FGFR3 was removed by several washing steps. The pulled-down fractions were 
heated to 95oC for 5 min in order to release the Affimers and FGFR3 protein from the 
resin. SDS-PAGE was used to separate the Affimers and FGFR3. Two identical gels 
were prepared to check the presence of both Affimers and FGFR3 protein. Proteins 
on both gels were transferred to PVDF membrane in order to carry out western 
blotting. The first membrane was probed with streptavidin-HRP to detect biotin 
tagged Affimers. If biotinylated Affimers are successfully coated on streptavidin resin, 
they can be recognised by streptavidin-HRP.  As seen in Figure 4.13B, all three 
Affimers, FGFR3-14, FGFR3-21 and GFP, used in this experiment were detected on 
the PVDF membrane, indicating successful immobilisation of Affimers onto 
streptavidin. The biotinylated Affimer used as a positive control was also detected in 
the first lane. In order to check whether the Affimers are able to bind FGFR3, the 
other membrane was probed with anti-FGFR3 antibodies (primary antibodies), 
following by anti-rabbit IgG antibodies – HRP (secondary antibodies). As presented 
in Figure 4.13C, pull-down products for FGFR3-14 and FGFR3-21 Affimers showed 
positive detection on the membrane, indicating the binding ability of FGFR3-14 and 
FGFR3-21 Affimers to FGFR3 protein. However, GFP Affimer, which was used as a 
negative control, did not bind to FGFR3 in this assay as pull-down product for GFP 
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Affimer did not show any detected signal. Purified FGFR3 protein, which was used 
as a positive control, also showed positive detection as expected. The result from the 
immunoprecipitation assay confirmed the results from double-sandwich ELISA and 
SPR that FGFR3-14 and FGFR3-21 Affimers were the two Affimers capable of 
binding to FGFR3 protein and could be used for biosensor fabrication. 
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Figure 4.13  Immunoprecipitation assay showing the binding of the Affimers to FGFR3. (A) A schematic showing a pull-down platform. A molecule 
of Affimer is coated via avidin-biotin interaction before testing with FGFR3. (B) Western blotting showing the successful immobilisation of Affimers 
onto streptavidin resin after probing with streptavidin-HRP and (C) Western blotting showing the pull-down products of the Affimers after probing with 
anti-FGFR3 antibodies and anti-rabbit IgG antibodies – HRP. BiotAff = Biotinylated Affimer; FGFR3 = purified FGFR3 protein; No Aff = No Affimer;  
FG14 = FGFR3-14 Affimer; FG21 =  FGFR3-21 Affimer; GFP = GFP. Affimer; Marker = SpectraTM multicolour broad range protein ladder 
(ThermoFisher Scientific). 
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4.3.5  ELISA to check the specificity of Affimers to FGFR3 protein 
 Non-specific binding is a common problem for immunoassays. There are a 
number of factors that may cause non-specific interaction between biomolecules, 
including interaction with scaffold of the bioreceptors. In order to prove whether the 
Affimers can bind specifically to FGFR3 protein, ELISA was utilised. In the assay, the 
selected Affimers against FGFR3 (FGFR3-14 and FGFR3-21) and GFP, were tested 
with different analytes including FGFR3, β-2-microglobulin, anti-digoxin IgG and 
human serum albumin. To set up the assay, each analyte was immobilised on an 
ELISA plate (Figure 4.14A) and then biotinylated Affimers were added and allowed 
to bind. After removing unbound Affimers, streptavidin-HRP was used to reveal 
whether binding had occurred. For each experiment, three replicates were included. 
Two independent experiments were repeated in order to confirm the results. 
 As presented in Figure 4.14B, FGFR3-21 Affimer had strong binding to 
FGFR3 protein but not to any of the other proteins. Affimer FGFR3-14 showed 
binding to FGFR3 but not as strongly as FGFR3-21. However, the results from 
double-sandwich ELISA, SPR and immunoprecipitation described previously showed 
that the strength of the binding between FGFR3-14 Affimer and FGFR3 protein was 
comparable as FGFR3-21 Affimer and FGFR3. It is assumed that the epitope on 
FGFR3 protein which was recognised by FGFR3-14 Affimer may form the 
interactions with the ELISA plate, preventing the Affimer from accessing the epitope. 
This may cause significantly lower level of detection of FGFR3 protein by this Affimer. 
As expected, the GFP Affimer, as a negative control showed no binding to FGFR3 
protein.  
 The specificity of the selected Affimers to the FGFR3 protein is still unclear in 
this assay. The limitation of this experiment is that the assay could not distinguish 
between the wells with no protein and with non-FGFR3 proteins (β-2-microglobulin, 
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anti-digoxin IgG and human serum albumin). Although proteins can typically form 
hydrophobic interaction with polystyrene surfaces such as a 96-well plate it is still 
necessary for users to prove that the proteins are truly deposited on the surface. My 
recommendation is that antibodies specific to β-2-microglobulin, anti-digoxin IgG and 
human serum albumin can be used to detect their analytes, which are initially 
captured on the surface, via ELISA. By doing this, the specificity of the Affimers to 
only FGFR3 protein can be confirmed. 
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Figure 4.14  ELISA to confirm the specific binding of Affimers to FGFR3. (A) A 
schematic presenting the ELISA setup. (B) ELISA result upon the measurement of 
the absorbance at 620 nm showing anti-FGFR3-21 and FGFR3-14 Affimers bind to 
FGFR3 protein but do not bind to the other proteins tested. The error bars represent 
mean of n = 3 ± SEM. 
A 
B 
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4.4   Discussion 
The main focus of this chapter is to characterise the specific binding 
properties of Affimers selected from the phage display library against their targets, 
DDT and FGFR3. Several methods including ELISA, SPR and immunoprecipitation 
were employed to check the binding of the Affimers in soluble form to their analytes. 
As different analytes, a small molecule (DDT) and a protein (FGFR3), were used as 
the targets for the Affimers, the discussion will be split into two sections. 
 
4.4.1   Affimers against DDT 
ELISA was used to determine the binding between the selected Affimers and 
DDT. Even though the Affimers showed binding ability to biotinylated DDT attached 
onto a solid surface, they failed to bind DDT in its original form in a competitive ELISA. 
It was assumed that the Affimers recognised the DDT plus the spacer between DDT 
and biotin. Therefore the DDT moiety alone cannot interact strongly with the Affimers. 
One issue that we need to take into account is the methods used in phage display 
screening. Previously, the standard protocol for phage display screening 
recommended by BSTG required a biotinylated target and three panning rounds. 
However, this protocol may be suitable for larget analytes displaying multiple 
epitopes such as proteins, but not for small molecules like DDT. Recently, a protocol 
for Affimer screening against small molecules has been released (Tiede et al., 2017). 
In brief, counter selection was used to select Affimers against TNT. TNT was 
conjugated to two carrier proteins, ovalbumin and IgG. The competitive pannings 
were performed using TNT-ovalbumin and TNT-IgG conjugates as well as ovalbumin 
and IgG. With this method, Affimers specific to TNT could be obtained. The protocol 
could be applied to select Affimers against DDT, but one issue to be considered is 
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the hydrophobic nature of DDT which makes it fairly insoluble in water. The 
conjugation of DDT to carrier proteins can be more difficult than for water-soluble 
small molecules.  
 
4.4.2   Affimers against FGFR3 
 To characterise the binding of Affimers selected against FGFR3 protein, 
sandwich ELISA, immunoprecipitation (pull-down assay) and SPR were utilised. The 
sandwich ELISA and immunoprecipitation are both qualitative methods that are 
useful for studying protein-protein interactions. In the ELISA, anti-FGFR3-14 and 
FGFR3-21 Affimers showed strong binding to FGFR3 protein, which agreed with the 
performance of FGFR3-14 and FGFR-21 Affimers in the pull-down assay. The 
FGFR3-8 Affimer showed the lowest level of binding to FGFR3 compared to the other 
two Affimers according to the result from the ELISA. It was assumed that the 
immobilisation of the FGFR3-8 Affimer may affect its binding ability since in the 
immunofluorescence staining assay (Dr. Darren Tomlinson - personal 
communication) showed a high  binding level of FGFR3-8 Affimer to FGFR3 protein 
similar to that shown by FGFR3-14 and FGFR3-21 Affimers. 
 Surface plasmon resonance (SPR) is an optical sensing platform widely used 
to study binding kinetics parameters. SPR revealed that among the three selected 
Affimers, FGFR3-14 and FGFR3-21 were able to bind FGFR3 protein whilst FGFR3-
8 failed to do so in this system. This supported the outcome of sandwich ELISA and 
immunoprecipitation methods. SPR provides a dissociation constant (KD), which 
gives the strength of affinity between the receptor and ligand. The SPR data for both 
FGFR3-14 and FGFR3-21 Affimers were found to fit well to a one site binding model 
as expected because each Affimer contains one binding site and should have 
recognised one epitope on the protein. However, the KD values obtained from the 
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fitting software were pM to nM (KD for FGFR3-14 Affimer = 327 pM and KD for FGFR3-
21 Affimer = 18.5 pM), which seem to be overestimated as compared to the KD of 
Affimers against other targets (Tiede et al., 2014, Raina et al., 2015, Sharma et al., 
2016). At least three independent repeats for the SPR experiment should be 
performed in order to ensure the consistency of the measurement.  Furthermore, KD 
determination using other approaches such as radiolabelled ligand binding assay and 
fluorescence anisotropy should be performed in order to have confidence in the KD 
values determined. 
 In this chapter, ELISA also used to examine the specificity of the Affimers to 
different types of analytes. In addition to FGFR3, Affimers were tested for their non-
specific binding to β-2-microglobulin, anti-digoxin IgG and human serum albumin. It 
was found that anti-FGFR3-21 and FGFR3-14 Affimers showed binding to FGFR3 
protein whereas the anti-GFP Affimer did not bind to FGFR3 protein. However, the 
evidence showing whether the Affimers bind to other proteins (β-2-microglobulin, 
anti-digoxin IgG and human serum albumin) is still needed to confirm the presence 
of the proteins on an ELISA plate. The data obtained from different characterisation 
methods suggested that either FGFR3-14 or FGFR3-21 Affimer could be used as the 
Affimer specific to FGFR3 protein for biosensor construction. 
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Chapter 5  
Biosensor fabrication 
 
5.1  Introduction 
 Impedimetric biosensors are known for their high sensitivity in detecting 
biological events. The technique is label-free, cost effective, easy to operate and 
applicable for different types of biorecognition elements such as enzymes, 
antibodies, synthetic peptides and oligonucleotides. During the past decades, an 
increasing number of impedimetric biosensors capable of monitoring a wide range of 
targets have been released. In general, multiple steps are involved in impedimetric 
biosensor fabrication. It is important that the sensor performance needs to be stable 
and reproducible. To achieve the highest efficiency of the sensors, strict and careful 
optimisation for the sensor construction protocol is required in order to minimise any 
variations that commonly occur during the construction processes. 
 The main focus of this chapter was to apply the Affimers obtained from 
Chapter 3 and Chapter 4 as bioreceptors for constructing impedimetric biosensors to 
detect FGFR3 protein. Two sensor construction protocols, the ELISHA “gluing 
method” and NeutrAvidin-biotin based procedure, were studied. As commonly 
known, a number of factors can govern the sensor performance and these affect the 
reproducibility of the sensors. We developed a NeutrAvidin-biotin interaction protocol 
where Affimer concentration, NeutrAvidin concentration, and effects of different 
blocking agents on sensor performance were investigated to establish an optimum 
protocol for biosensor fabrication.  
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5.2  Construction of impedimetric biosensors using 
ELISHA gluing method 
 The ELISHA “gluing method” is a protocol for fabricating impedimetric 
biosensors with Affimers. The protocol was developed by ELISHA Ltd. Selected 
Affimer binders were prepared using a mixture containing 5 mM octopamine and a 
bifunctional linker supplied by the company. This method allows control of the correct 
orientation of the Affimers when immobilised onto the sensor surface, thus allowing 
the optimum accessibility of the analyte (FGFR3) to the binding site on the Affimer.  
 In Figure 5.1, the construction overview of a sensor in accordance with 
ELISHA gluing method is presented. An anti-GFP Affimer was used as a negative 
control receptor and immobilised onto working electrode 1. Anti-FGFR3-21 Affimer 
was selected as the specific receptor to FGFR3 protein and immobilised onto working 
electrode 2. In order to immobilise both Affimers to a sensor chip, cyclic voltammetry 
was utilised as stated in Section 2.2.7.1. During the polymerisation of octopamine 
together with the Affimer-linker conjugates, a cyclic voltammogram was obtained 
(Figure 5.2). In the first cycle, there was a small peak representing the oxidation of 
octopamine at 0.65 V. However, the event could not be detected during the second 
CV scan. These data showed that octopamine has self-limiting growth property as 
with other non-conducting polymers e.g. tyramine (Ahmed et al., 2013, Losic et al., 
2005).  After the immobilisation, it was expected that the Affimers were tethered onto 
a layer of polyoctopamine via the bifunctional linker shown in Figure 5.1.  
 The fully constructed sensors were tested with FGFR3 protein in PBS buffer 
over the concentrations range from 10-15 to 10-8 M. The response of the sensors 
showed  that  the impedance  signal  represented  by  Nyquist  plots  decreased  as  
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Figure 5.1  Schematic representation of a sensor constructed following the ELISHA 
“gluing” method. The Affimer was immobilised onto the polymer layer via a specific 
linker provided by ELISHA Ltd prior to FGFR3 addition. 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  A cyclic voltammogram of polyoctopamine and Affimer deposition onto a 
Dropsens gold screen-printed electrode. The CV was performed for 2 cycles from 0-
1.6 V at a scan rate of 100 mV/s. (A) is an oxidation peak at 0.65 V whereas (1) and 
(2) are CV scan cycles. 
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FGFR3 concentrations increased (Figure 5.3A). Sensor response was reported via 
the charge transfer resistance (Rct) which was automatically calculated by NOVA 
software. Data were normalised by subtracting Rct for each FGFR3 concentration 
with Rct at the baseline (PBS buffer) and transformed to percent change in Rct. The 
data showed that decrease in Rct from 20% - 40% was found when exposing FGFR3-
21 sensors to FGFR3 protein over the concentrations of 10-15 – 10-14 M, but beyond 
this range the Rct value was almost constant (Figure 5.3B). In anti-GFP Affimer 
sensors which served as a negative control, a shift in impedance between -20% and 
-35% could be observed over the same FGFR3 range. This effect occurred because 
of non-specific binding of FGFR3 protein to the sensor surface, leading to a decrease 
in impedance on both FGFR3-21 and GFP Affimer sensors. It is plausible that the 
ELISHA gluing method was not suitable for making sensors to detect FGFR3 protein. 
However, the ELISHA gluing method has been successfully used to fabricate 
impedimetric biosensors to detect carcinoembryonic antigen (CEA) as a biomarker 
for colorectal cancer (Mrs. Shazana Shamsuddin - personal communication). 
Different target proteins have distinct properties thanks to their amino acid patterns 
and post-translational modifications. For example, CEA protein has over 60% 
glycosylation by mass, which may prevent non-specific binding to the modified 
surface on the electrode. Therefore, other sensor fabrication methods were 
considered in order to construct impedimertric biosensors for FGFR3 detection. 
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Figure 5.3  Sensor response after cumulative addition of FGFR3 concentrations. (A) 
Nyquist plots of impedance represent a PBS buffer baseline and a fully constructed 
FGFR3-21 Affimer-based sensor after exposing to 10-15 – 10-8 M FGFR3, 
respectively. (B) Calibration of the Affimer-based sensors for detecting FGFR3 
protein (n = 4 ± SEM). The response of the sensors was displayed in term of ΔRct(%). 
Inset is the Randles’ equivalent circuit model for this system where Rs is solution 
resistance, Rct is charge transfer resistance and CPE is constant phase element. 
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5.3   Biosensor fabrication via NeutrAvidin-biotin 
linkage of the Affimers 
5.3.1  Overview of sensor fabrication 
 The avidin-biotin interaction is known as the strongest non-covalent 
interaction used for bioconjugation with a dissociation constant (KD) of approximately 
10-15 M provided the bioreceptor is tethered by a specific residue. This type of 
interaction can offer specific orientation when attempting to tether a protein receptor 
onto the solid surface. In the work in this thesis, NeutrAvidin, a reengineered avidin 
which has no glycosylation, was used. Previously, avidin-biotin linkages were used 
to set up ELISA, SPR and immunoprecipitation assays in order to study specific 
binding between the Affimers and FGFR3 protein. A positive response resulting from 
Affimers-FGFR3 interaction was observed through all the three assays. Therefore, a 
NeutrAvidin-biotin interaction was also employed for impedimetric biosensor 
construction as well. 
  To fabricate a sensor chip for electrochemical impedance measurement, a 
layer-by-layer sensor construction protocol previously described (Ahmed et al., 2013, 
Rushworth et al., 2014) was modified. As presented in Figure 5.4, a molecule of 
biotinylated Affimer was immobilised onto polytyramine-coated gold surface via the 
NeutrAvidin-biotin interaction. At each step of immobilisation, polytyramine, NHS-
biotin, NeutrAvidin and biotinylated Affimer were respectively deposited on working 
electrodes with washing in PBS in between as stated in Section 2.2.7.2. 
 The stability of the polymer layer is one of the most indispensable factors 
contributing to the sensitivities and specificities of biosensors. Polytyramine has been 
widely used in biosensor applications (Ahmed et al., 2013, Pournaras et al., 2008, 
Rushworth et al., 2014, Wu et al., 2005, Yang et al., 2012)  
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Figure 5.4  Schematic illustration of a fully-constructed Affimer-based sensor. The 
gold surface on an electrode chip was initially coated with polytyramine. Then a high 
affinity “NeutrAvidin-biotin linkage” allowed biotin-tagged Affimer to be tethered to the 
surface in an oriented fashion. 
 
because  it  offers high stability, less or no conductivity and capabilities of self-
controlling thickness and porosity (Ahmed et al., 2013, Losic et al., 2005). In this 
work, tyramine was prepared in 0.3 M NaOH in dH2O prior to electropolymerisation. 
Typically there was a small peak evident at 0.5 V vs Ag/AgCl, indicating oxidation of  
the tyramine during the first cycle of CV while this event could not be seen in the 
second cycle (Figure 5.5). This confirmed polytyramine’s self-limiting property during 
polymerisation. The Nyquist plots showed that after electropolymerisation of 
polytyramine on the gold surface, the impedance increased, indicating successful 
polymer deposition (Figure 5.6). In the previous publications, tyramine was generally 
prepared in 0.3 M NaOH in absolute methanol (Ahmed et al., 2013, Pournaras et al., 
2008, Rushworth et al., 2014). However, it was found here that using methanol as a 
solvent may cause an insufficient thickness of polytyramine layer coated as a base 
layer for Affimer-based sensors, leading to  the  inconsistency  of  the  baseline   
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Figure 5.5  Cyclic voltammogram of polytyramine deposition. Cyclic voltammetry was 
performed in 25 mM tyramine in dH2O with 0.3 M NaOH. The CV scan was run for 
two cycles from 0-1.6 V at a scan rate of 200 mV/s. 
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Figure 5.6  Nyquist plot showing layer-by-layer construction of an FGFR3-21 Affimer-
based biosensor. The measurement was performed in a solution of 100 mM PBS pH 
7.2 containing 10 mM K3Fe(CN)6/K4Fe(CN)6 over a range of frequencies from 2.5 
kHz to 250 mHz. Nyquist plots were generated when using bare gold surface, 
polytyramine-coated surface, surface coated with biotin-NeutrAvidin and sensor with 
biotin-tagged FGFR3-21 Affimer immobilised. 
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and  the  responses when exposing sensors to the target. Changing the solvent to 
0.3 M NaOH in dH2O resulted in an increase of resistance and capacitance of the 
polymer layer (Figure 5.7), indicating increasing thickness of the polytyramine layer. 
As a result, the overall responses of the sensors were more consistent and 
reproducible. 
 After electropolymerisation of polytyramine, NHS-biotin and NeutrAvidin were 
introduced sequentially to the polytyramine-coated electrodes. NeutrAvidin was used 
as a bridge to tether biotinylated Affimers to the biotinylated transducer surface. As 
expected, there was a large shift in impedance after NHS-biotin and NeutrAvidin 
additions since deposition of large molecules can hinder the transfer of charge 
components to the transducer surface, resulting in an increase in resistance and  
decrease in capacitance   (Figure 5.6).    As   each    electrode    chip    contains    two   
working electrodes, anti-GFP Affimer was immobilised on working electrode 1 as a 
negative control receptor whilst FGFR3-21 Affimer was captured on working 
electrode 2. However, the introduction of the Affimer to the functionalised surface 
resulted in decrease in impedance (Figure 5.6), implying that the binding of 
biotinylated Affimers to NeutrAvidin caused increased conductivity of the sensor 
surface. 
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Figure 5.7  Nyquist plot showing two fully constructed FGFR3-21 Affimer-based 
biosensors with the polytyramine layer prepared in different solvents. The sensor 
deposited with polytyramine prepared in 0.3 M NaOH in MeOH and the sensor 
prepared using polytyramine dissolved in 0.3 M NaOH in dH2O are compared. The 
measurement was performed in a solution of 100 mM PBS pH 7.2 containing 10 mM 
K3Fe(CN)6/K4Fe(CN)6 over a range of frequencies from 2.5 kHz to 250 mHz. 
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5.3.2  Electrochemical impedance spectroscopy for detection of 
FGFR3 
 In this study, prior to incubating the fully constructed biosensors with FGFR3 
protein, four consecutive impedance measurements were performed to set the 
baseline (PBS buffer) for data normalisation. As presented in Figure 5.8, the 
impedance signal for the baseline was almost constant after the 4th measurement, 
indicating that the sensors were ready for testing with FGFR3 protein. The sensors 
were then incubated with increasing concentrations of FGFR3 protein in PBS buffer  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8  Impedance spectra showing the stability of baseline before a sensor was 
tested with a range of FGFR3 concentrations. Four consecutive impedance 
measurements were performed after a fully constructed sensor was incubated in PBS 
buffer for 1 h. The measurement was performed in a solution of 100 mM PBS pH 7.2 
containing 10 mM K3Fe(CN)6/K4Fe(CN)6 over a range of frequencies from 2.5 kHz to 
250 mHz. 
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varying from 10-14 M to 10-8M with washes in between.  The sensors were immersed 
in 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator to perform EIS measurement. The 
EIS Nyquist plots from a representative sensor with FGFR3-21 Affimer immobilised 
are presented in Figure 5.9. It was observed that there was a decrease in impedance 
with the increasing FGFR3 concentrations. Mostly, in previous publications binding 
of analyte to its bioreceptor leads to an increase in impedance (Ahmed et al., 2013, 
Billah et al., 2010, Caygill et al., 2012, Millner et al., 2012). However, it has also been 
reported that the binding between synthetic proteins and their analytes sometimes 
causes a decrease in impedance (Goode et al., 2016, Rushworth et al., 2014). This 
observation can also be supported by the recent finding using Affimers to detect 
carcinoembryonic antigen (CEA), a glycoprotein biomarker for colorectal cancer 
where a decrease in impedance was found after exposing the Affimer sensors to 
CEA analyte (Mrs. Shazana Shamsuddin - personal communication). Nanobodies 
derived from camelid single chain antibodies in (Goode et al., 2016) are similar in 
size to the Affimers used in this study. Therefore, the decrease in impedance 
detected here could be explained by a similar mechanism. It has been suggested 
that the unexpected decrease in impedance happens owing to stresses in the 
polymer layer from the interaction of a large analyte with its small bioreceptor (Goode, 
2015). The coated polymer on electrodes is semi-solid, making it quite mobile and 
flexible like a sponge (Bartlett and Cooper, 1993). When larger analytes bind to 
smaller bioreceptors tethered on the polymer layer, the immediate change of mass 
may cause a polymer shift on the surface, generating pinholes which let charged 
components pass through the polymer layer to contact with gold surface underneath. 
This process is known as the ‘pinholing effect’ and the reduction of the barriers to 
charge transfer process leads to the increasing conductivity across the sensor 
surface (Bharathi et al., 2001, Goode, 2015). This means that the resistance and 
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capacitance on the sensor interface are lowered, resulting in the decreasing 
impedance that was observed. 
 
 
 
 
 
 
 
 
 
 
Figure 5.9  Impedance spectra after cumulative addition of FGFR3 concentrations 
ranging from 10-14 M to 10-8 M to a fully constructed sensor. Nyquist plots of 
impedance represent a baseline (PBS buffer) and a fully constructed FGFR3-21 
Affimer sensor after exposing to 10-14 – 10-8 M FGFR3, respectively. The 
measurement was performed in a solution of 100 mM PBS pH 7.2 containing 10 mM 
K3Fe(CN)6/K4Fe(CN)6 over a range of frequencies from 2.5 kHz to 250 mHz. Inset is 
the Randles’ equivalent circuit model for this system, where Rs = solution resistance, 
Rct = charge-transfer resistance, and CPE = constant phase element. 
 
 In this thesis, Rct values were initially used for monitoring the performance of 
fully fabricated sensors in response to FGFR3 protein as most faradaic impedance 
biosensors rely on the change in the Rct as the analyte binds (Billah et al., 2010, 
Rushworth et al., 2014, Barton et al., 2008, Ahmed et al., 2013, Johnson et al., 2012). 
However, as seen in Figure 5.9, the limitation of using the Rct is that approximately 
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half of semi-circular shape of a Nyquist plot was obtained from the impedance 
measurement, possibly resulting in inaccuracy in Rct calculation when the data were 
fitted with the Randles’ equivalent circuit model. Therefore, other alternatives were 
considered for presenting our sensor performance. 
 Change in capacitance is another way of showing the response of 
impedimetric biosensors. A shift in real part of capacitance was employed to monitor 
the binding of the targets to the modified surface (Jolly et al., 2015, Jolly et al., 2016, 
Weiss et al., 2005). However, it should be noted that their work relied on non-faradaic 
impedance measurement. To obtain the real component of capacitance, the 
impedance data were first converted into complex capacitance using Equation 2.8 as 
presented in Section 2.2.7.3. The real part of capacitance was plotted on the X-axis 
against the imaginary part of capacitance on the Y-axis, and this is called a Cole-
Cole plot. Figure 5.10 shows the Cole-Cole plot of a representative of FGFR3-21 
Affimer sensors after exposing to a range of FGFR3 concentrations. Only slight 
change in the real part of capacitance (C’) could be seen here as the concentration 
of FGFR3 increased, indicating stable and thick layers on the electrode surface, 
which is unaffected by the biorecognition events. Significant changes, however, could 
be detected at the low frequencies of the impedance measurements. These are 
known as low frequency relaxations (Weiss et al., 2005). The sensors were highly 
resistive due to the thick layers of material deposited on them. The changes observed 
here indicated the binding of FGFR3 protein to the immobilised Affimers, which 
occurred beyond the thick layers on the electrode and did not affect the capacitance 
(Weiss et al., 2005). However, the small changes in capacitance were tried as the 
alternative to Rct to montor the sensor reponse in this work. To analyse the response 
of the sensor, the real part of capacitance at the far end of the semicircular curve was 
used and will be described in the next section.  
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Figure 5.10  The typical Cole-Cole plot showing complex capacitance of a FGFR3-
21 Affimer biosensor before and after exposing to FGFR3 protein from 10-14 M to 
10-8 M (A) is the plot showing the full semicircular curves with low frequency 
relaxations whereas (B) is the zoomed-in area indicated by the red arrow () in (A). 
A 
B 
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Phase shift is another approach that has been employed to evaluate the 
biorecognition events in impedance biosensor platforms. The phase shift is typically 
measured at a specific low frequency (0.1 Hz) to monitor the binding between the 
Affimers and the target analytes on the electrode surface (Sharma et al., 2016, Raina 
et al., 2015). However, again their sensor systems were non-faradaic. In this thesis, 
phase shift was plotted against a range of frequencies as shown in Figure 5.11. The 
lowest frequency presenting the maximum phase shift in this work was at 7.9 Hz. 
Therefore, the phase shift at this frequency was picked for further analysis and will 
be described in the next section. 
 The other method worth using to evaluate the response of biosensors is the 
change in absolute impedance (|Z|). The absolute impedance was used to present 
the impedance sensor response in the previous studies (Dapra et al., 2013, Park et 
al., 2018). The absolute values of impedance measured were plotted against a range 
of frequencies as shown in Figure 5.12. The data at 0.25 Hz were selected to be used 
for further analysis as the largest changes were observed at this point and will be 
described in the next section. 
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Figure 5.11  The plot showing the relationship between phase shift and frequencies 
of a FGFR3-21 Affimer biosensor. (A) shows the change in phase angle of the sensor 
before and after exposing to different concentration of FGFR3 and (B) is the close-
up area as indicated by the red arrow () in (A). 
A 
B 
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Figure 5.12  The plot showing the relationship between absolute values of 
impedance and frequencies of a FGFR3-21 Affimer biosensor. (A) shows the change 
in the absolute impedance of the sensor before and after exposing to different 
concentration of FGFR3 and (B) is the close-up area as indicated by the red arrow 
() in (A). 
 
A 
B 
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5.3.3  Optimisation of methods for biosensor fabrication 
 Until now, there has been no electrochemical platform to detect FGFR3 
protein in biological samples from human sources. The detection of FGFR3 in human 
fluids can be performed using an FGFR3 ELISA kit which is commercially available 
(ab214027, Abcam, UK). The reported dynamic range of detection is typically pM to 
nM, which has been used as a reference for developing impedimetric biosensors for 
FGFR3 detection because, as yet, there are no reports on the pathological levels of 
FGFR3 in biological samples, e.g. urine and serum. To achieve the construction of 
sensitive and specific biosensors to any analyte, a number of factors apart from the 
specificity of bioreceptors to the target are involved in sensor performance, 
reproducibility and stability. In this work, Affimer concentrations, NeutrAvidin 
concentrations and the effect of blocking agents were studied. 
 
5.3.3.1  Optimising concentration of Affimers 
 One of the most critical factors to be taken into account is the optimum 
concentration of bioreceptors immobilised on the surface of the sensor electrode. 
This is because too high concentration of bioreceptors may lead to a high packing 
density of material on the surface, resulting in steric hindrance and the possibility of 
non-specific binding of unwanted components. In contrast, in the case of an 
insufficient amount of bioreceptors, the sensors may not generate sufficient response 
upon the binding of the analyte. 
 In this section, a range of Affimer concentration, from 0.05 to 1 µM, were 
examined while the concentrations of NHS-biotin and NeutrAvidin were fixed at 3 and 
0.1 µM, respectively. Anti-GFP Affimer was used as a negative control on working 
electrode 1 whilst anti-FGFR3-21 Affimer was immobilised on working electrode 2. 
After consecutive 15 min incubations in the solution containing FGFR3 protein 
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ranging from 10-14 to 10-8 M, with washing in PBS in between, EIS measurements 
were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. To 
evaluate the performance of the sensor after testing with FGFR3 protein, four 
different approaches, namely changes in charge-transfer resistance, capacitance, 
phase shift and absolute values of impedance, were used to analyse the impedance 
data.  
The first procedure used to analyse the sensor response is the changes in 
Rct. At 0.05 µM Affimer, it can be observed that although different responses on the 
negative control (GFP Affimer) and FGFR3-21 Affimer sensors can be seen, there 
was no significant change in Rct upon increasing the FGFR3 concentrations (Figure 
5.13A). When the concentration of Affimers was increased up to 0.1 µM, a significant 
decrease of %Rct was detected with an increase of FGFR3 concentrations on the 
specific sensors as the response on the negative control sensors remained constant 
with a slight drop at higher FGFR3 concentrations (Figure 5.13B). However non-
specific binding was detected, causing a 5-20% change in Rct on negative control 
sensors. At an Affimer concentration of 0.3 µM, a steady decrease in %Rct was 
observed on the FGFR3-21 Affimer sensor whilst no change in Rct responses can be 
seen on control sensors (Figure 5.13C). Finally, at 1 µM Affimers applied to the 
sensors, the decrease in Rct can be seen on both FGFR3-21 and anti-GFP (negative 
control) sensors (Figure 5.13D). This may be due to the transducer surface being 
overcrowded at high concentration of bioreceptors, causing a steric hindrance effect. 
Conclusively, the optimal concentration of biotinylated Affimers used for the 
construction of biosensors here was 0.3 µM. 
 Another method used to show the sensor performance is the changes in real 
part of capacitance (C’). At the Affimer concentration of 0.05 µM, the capacitance 
increased 2% for FGFR3-21 Affimer sensors and 3% for GFP Affimer at 10-14 M 
before  decreasing  to  -1%  (FGFR3-21 Affimer)  and  0%  (GFP Affimer)  at  10-8 M  
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 A 0.05 µM Affimer 
B 0.1 µM Affimer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.13  Optimisation of Affimer concentration for impedimetric biosensors with 
data analysis based on the Rct values. The figures on the left panel are Nyquist plot 
representatives of a FGFR3-21 Affimer sensor and the figures on the right panel are 
calibration curves of the biosensors for detecting FGFR3 in PBS buffer. Four different 
concentrations of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 
µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± SEM), were tested. The sensors were 
challenged with cumulative concentrations of FGFR3 ranging from 10-14 M to 10-8 M 
with PBS washes in between. The EIS measurements were performed in the 
presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the 
sensors was displayed as ΔRct(%). 
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Figure 5.13 (continued) Optimisation of Affimer concentration for impedimetric 
biosensors with data analysis based on the Rct values. Four different concentrations 
of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 µM, (C, n = 3 ± 
SEM), and 1 µM, (D, n = 3 ± SEM), were tested. 
 
 
 
C 0.3 µM Affimer 
D 1 µM Affimer 
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FGFR3. There was no significant difference between the response on the FGFR3-
21 Affimer and control sensors (Figure 5.14A). The concentration of Affimers was 
then increased to 0.1 µM. At this concentration, the ∆C’ values were increased to 2% 
(FGFR3-21 Affimer) and 3.5% (GFP Affimer) at 10-14 M FGFR3 and decreased to 
around -2% (both Affimers) at 10-8 M FGFR3. Again, the sensors could not distinguish 
between specific and non-specific response (Figure 5.14B). At 0.3 µM Affimer, the 
∆C’ for FGFR3-Affimer sensors increased about 2% at 10-14 M FGFR3 but remained 
stable at 0% for GFP Affimer sensors. The decrease in ∆C’ was seen for both Affimer 
sensors until reaching 10-8 M FGFR3 with the ∆C’ of -4% (Figure 5.14C). The sensors 
failed to show the signal from specific interaction of FGFR3 and the Affimer. At an 
Affimer concentration of 1 µM, the increase in ∆C’ to 2% for both FGFR3-21 and GFP 
Affimer sensors was seen when challenging the sensors with 10-14 – 10-13 M FGFR3 
before the decrease in ∆C’ at higher concentrations of FGFR3 (Figure 5.14D). At  
10-8 M FGFR3, the ∆C’ dropped to -2% for FGFR3-21 Affimer sensors and -3% for 
control sensors. As the trends for FGFR3-21 and GFP Affimer sensor performance 
were similar, specific response could not be seen. From the above results, using the 
changes in capacitance proved ineffective for use to show the response of our 
fabricated Affimer-based impedimetric biosensors. Hence, other approaches will be 
considered here. 
 The changes of phase angle is another method used to monitor the binding 
of the Affimers and FGFR3 protein on biosensors in this thesis. At an Affimer 
concentration of 0.05 µM, the phase angles were almost unchanged for both specific 
Affimer and control sensors with phase shift between 0o to -1o as the concentration 
of FGFR3 increased (Figure 5.15A). The response from specific interaction of FGFR3 
and the Affimer could not be seen at this Affimer concentration. As the concentration 
of Affimers was changed to 0.1 µM, a decrease of phase angles was observed on 
both  specific  Affimer  and  control  sensors with the a between  0o  and  -5o  as  the  
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Figure 5.14  Optimisation of Affimer concentration for impedimetric biosensors with 
data analysis based on the capacitance values. The figures on the left panel are 
Cole-Cole plots of a FGFR3-21 Affimer sensor and the figures on the right panel are 
calibration curves of the biosensors for detecting FGFR3 in PBS buffer. Four different 
concentrations of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 
µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± SEM), were tested. The sensors were 
challenged with cumulative concentrations of FGFR3 ranging from 10-14 M to 10-8 M 
with PBS washes in between. The EIS measurements were performed in the 
presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the 
sensors was displayed as ΔC’(%). 
 
A 0.05 µM Affimer 
B 0.1 µM Affimer 
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Figure 5.14 (continued) Optimisation of Affimer concentration for impedimetric 
biosensors with data analysis based on the capacitance values. Four different 
concentrations of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 
µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± SEM), were tested. 
 
 
 
 
C 0.3 µM Affimer 
D 1 µM Affimer 
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Figure 5.15  Optimisation of Affimer concentration for impedimetric biosensors with 
data analysis based on the phase shift. The figures on the left panel are phase shift-
frequency plots of a FGFR3-21 Affimer sensor and the figures on the right panel are 
calibration curves of the biosensors for detecting FGFR3 in PBS buffer. Four different 
concentrations of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 
µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± SEM), were tested. The sensors were 
challenged with cumulative concentrations of FGFR3 ranging from 10-14 M to 10-8 M 
with PBS washes in between. The EIS measurements were performed in the 
presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the 
sensors was displayed as phase shift (o). 
 
A 0.05 µM Affimer 
B 0.1 µM Affimer 
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Figure 5.15 (continued) Optimisation of Affimer concentration for impedimetric 
biosensors with data analysis based on the phase shift. Four different concentrations 
of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 µM, (C, n = 3 ± 
SEM), and 1 µM, (D, n = 3 ± SEM), were tested. 
 
 
 
C 0.3 µM Affimer 
D 1 µM Affimer 
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concentration of FGFR3 increased (Figure 5.15B). However, the sensors could not 
distinguish specific from non-specific response.  As the concentration of Affimer was 
increased to 0.3 µM, the phase shift was detected between 0o and -2o over an 
increasing range of FGFR3 concentrations (Figure 5.15C). The sensors still could 
not be used to show the signal from specific binding of FGFR3 to the Affimer. At 1 
µM Affimers, the decrease of phase shift was seen on both FGFR3-21 and GFP 
Affimer sensors. The phase angle decreased to -1.5o for both Affimer sensors at  
10-13 M FGFR3, but the response of phase shift for these two Affimer sensors showed 
differences at higher concentrations of FGFR3 (Figure 5.15D). At FGFR3 of 10-8 M, 
the phase shift for FGFR3-21 Affimer sensors was about -6o whilst that for control 
sensors was -4o. However, these changes were still not sufficient to distinguish 
specific from non-specific response. This suggested that the phase shift is not 
suitable to use as a method to see the sensor performance in our work. 
 The last approach for monitoring the binding of FGFR3 to Affimers in our work 
is the change in absolute values of impedance (|Z|). At an Affimer concentration of 
0.05 µM, as the concentration of FGFR3 increased, the ∆|Z| for control sensors was 
almost stable with a shift between 0% and -2% whilst the ∆|Z| for FGFR3-21 Affimer 
sensors remained in the range of -5% to -10% (Figure 5.16A). At 0.1 µM Affimer 
concentration, a decrease in ∆|Z| was detected on both FGFR3-21 Affimer and 
control sensors. The decrease of ∆|Z| from 0% to -10% was seen on the control 
sensors whereas the ∆|Z| for the FGFR3-21 Affimer sensors dropped continually to -
20% (Figure 5.16B). Although the difference of specific and non-specific response 
could be seen, the change was insufficient for further use, especially in the case of 
biological sample tests with high background noise. Finally, as the concentration of 
Affimers was increased to 0.3 µM, the ∆|Z| for control sensors was almost stable 
between 0% and -4% whereas the ∆|Z| for FGFR3-21 Affimer sensors decreased 
from 0% to -8% when the concentration of  FGFR3  was  increased  (Figure 5.16C). 
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Figure 5.16  Optimisation of Affimer concentration for impedimetric biosensors with 
data analysis based on the absolute values of impedance. The figures on the left 
panel are absolute impedance-frequency plots of a FGFR3-21 Affimer sensor and 
the figures on the right panel are calibration curves of the biosensors for detecting 
FGFR3 in PBS buffer. Four different concentrations of Affimer, 0.05 µM, (A, n = 4 ± 
SEM); 0.1 µM, (B, n = 4 ± SEM); 0.3 µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± 
SEM), were tested. The sensors were challenged with cumulative concentrations of 
FGFR3 ranging from 10-14 M to 10-8 M with PBS washes in between. The EIS 
measurements were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 
redox mediator. The response of the sensors was displayed as ∆|Z| (%). 
 
A 0.05 µM Affimer 
B 0.1 µM Affimer 
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Figure 5.16 (continued) Optimisation of Affimer concentration for impedimetric 
biosensors with data analysis based on the absolute values of impedance. Four 
different concentrations of Affimer, 0.05 µM, (A, n = 4 ± SEM); 0.1 µM, (B, n = 4 ± 
SEM); 0.3 µM, (C, n = 3 ± SEM), and 1 µM, (D, n = 3 ± SEM), were tested. 
 
 
 
 
C 0.3 µM Affimer 
D 1 µM Affimer 
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The signal obtained was not large enough to distinguish specific from non-specific 
binding response. At 1 µM Affimer, the ∆|Z| for GFP Affimer sensors decreased from 
0% to -17% as increasing FGFR3 whilst the ∆|Z| for FGFR3-21 Affimer sensors 
decrease to almost -30% (Figure 5.16D). Although the shifts for the FGFR3-21 
Affimer and the sensors were different, the effect of non-specific binding on the 
control sensors was very large. Comparing the sensor response trend for the ∆|Z| to 
that for the changes in Rct (Figure 5.13), even though similar patterns of the sensor 
reponse could be observed, using Rct provided larger changes than using |Z|, 
assisting in data analysis.   
 Amongst the four techniques used to analyse the impedance data, the 
change in Rct was proven to be the best alternative for monitoring the binding of the 
Affimers to FGFR3 protein in our biosensor platform. Although 0.3 µM seemed to be 
the optimal concentration for the making of biosensors, the change in Rct on FGFR3-
21 Affimer sensors, corresponding to the overall performance of the sensors, is 
modest, with a 23% change at the highest concentration of FGFR3 (Figure 5.13C). 
As presented in Figure 5.6, after functionalising the polytyramine-coated surface with 
biotin-NeutrAvidin, there was a massive shift of impedance, indicating that there was 
a large barrier deposited on the polymer layer. This could potentially interfere with 
the charge transfer process, making the binding between the Affimers and the target 
analyte less detectable. Thus it was decided that the concentration of NeutrAvidin as 
a linkage between the polytyramine-coated surface and biotin-tagged Affimers was 
needed to be optimised. This will be presented in the next section. 
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5.3.3.2  Optimising the concentration of NeutrAvidin 
 Even though NeutrAvidin was utilised as a linker between the biotinylated 
transducer surface and biotinylated Affimers, the fairly large size of NeutrAvidin can 
potentially interfere with the transfer of charged components to the transducer 
surface, resulting in the loss of impedance signal. In this section, the optimal 
concentration of NeutrAvidin was investigated. Sensors were constructed as 
described in Section 5.3.1. During the construction, the concentrations of NHS-biotin 
and Affimers were kept constant at 3 and 0.3 µM. Three concentrations of 
NeutrAvidin, 0.1, 0.067 and 0.033 µM, were tested. After fabrication, the sensors 
were challenged with FGFR3 concentrations from 10-14 M to 10-8 M as with previous 
optimisation studies. 
 The results for optimisation of NeutrAvidin concentration are shown in Figure 
5.17. At a NeutrAvidin concentration of 0.1 µM, although the decrease of Rct over the 
increase of FGFR3 concentrations can be observed on the FGFR3-21 based Affimer 
sensors, the shift in Rct values with the increasing FGFR3 was detected on the control 
sensors (Figure 5.17A). These data were surprising because the condition for 
fabricating the sensors was identical to the sensors in Figure 5.17C. The only 
different issue was the electrodes used came from different batches. It was assumed 
that even though the manufacturer uses the same procedure to produce electrode 
chips, there is still variation in the manufacturing processes causing batch to batch 
variation. This can result in decreased reproducibility when electrodes are used for 
functionalisation and impedance measurement. When the concentration of 
NeutrAvidin was reduced to 0.067 µM, the decrease in impedance with the increasing 
concentrations of FGFR3 on the FGFR3-21 Affimer sensors can still be seen. 
However, on the control sensors, a -30% shift in Rct response was detected at 10-14 
M FGFR3 and this response remained consistent until 10-8 M FGFR3 (Figure 5.17B). 
It was assumed that the impedance shift detected here may be due to non-specific 
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interaction of the analyte with the surface. At the lowest NeutrAvidin concentration of 
0.033 µM, although non-specific response showing by the shift of impedance on the 
control sensors was decreased, the Rct response on the FGFR3-21 Affimer sensors 
also dropped (Figure 5.17C). Therefore, amongst the three concentrations of 
NeutrAvidin tested, 0.067 µM seemed to be the most suitable choice for constructing 
the sensors. However, non-specific binding resulting in impedance shift on the control 
sensors was still problematic. In the next section, the effect of some blocking agents 
was investigated in order to minimise non-specific interactions and improve the 
efficiency of the sensors. 
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Figure 5.17  Optimisation of Neutravidin concentration for impedimetric biosensors 
with data analysis based on the Rct values. The figures on the left panel are Nyquist 
plots of a FGFR3-21 Affimer sensor and the figures on the right panel are calibration 
curves of the biosensors for detecting FGFR3 in PBS buffer. Three different 
concentrations of NeutrAvidin, 0.1 µM, (A, n = 3 ± SEM); 0.067 µM, (B, n = 3 ± SEM), 
and 0.033 µM, (C, n = 4 ± SEM), were examined. The sensors were challenged with 
cumulative concentrations of FGFR3 ranging from 10-14 M to 10-8 M with PBS washes 
in between. The EIS measurements were performed in the presence of 10 mM 
K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the sensors was displayed 
as ΔRct(%). 
A 0.033 µM Neutravidin 
B 0.067 µM Neutravidin 
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Figure 5.17  (Continued) Optimisation of Neutravidin concentration for impedimetric 
biosensors with data analysis based on the Rct values. Three different 
concentrations of NeutrAvidin, 0.1 µM, (A, n = 3 ± SEM); 0.067 µM, (B, n = 3 ± SEM), 
and 0.033 µM, (C, n = 4 ± SEM), were examined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 0.1 µM Neutravidin 
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5.3.3.3  Effect of blocking agents on sensor performance 
 Mostly, in immunoassays, blocking agents are used in order to minimise non-
specific background, allowing the specific interaction to be monitored. In the previous 
experiments, non-specific binding was problematic as detected by the shift of 
impedance on control sensors. Attempts in this section were to discover the methods 
of reducing or eliminating non-specific background. Several agents that might have 
surface blocking properties were tested. Those were 0.1 µM bovine serum albumin 
(BSA), 10 mM pyromellitic dianhydride (PMDA), 100 µg/ml sodium caseinate, 0.1, 1 
and 3 mM of mPEG-biotin. The sensors were fabricated using the method previously 
described in Section 5.3.1. During the construction, NHS-biotin, NeutrAvidin and 
biotin-tagged Affimers were fixed at 3, 0.067 and 0.3 µM, respectively. In the last 
step, blocking agent was applied to the sensors prior to cumulative additions of 
FGFR3 protein. 
 Comparing with the performance of the sensors without any blocking agent 
(Figure 5.18A), when using BSA, PMDA and sodium casienate to block the sensor 
surface, non-specific binding can still be detected, as shown in Figure 5.18B, C  
and D. Moreover, reproducibility of the sensor performance was problematic since 
the SEM values representing the variation among different chips were very large. 
This indicated that BSA, PMDA and sodium caseinate were not suitable to be used 
as blocking agents. mPEG-biotin was another choice of blocking agents used to 
mininise non-specific binding in this study. It was assumed that mPEG-biotin can bind 
to unoccupied binding sites on NeutrAvidin that were left after adding biotinylated 
Affimers. It was found that mPEG-biotin at a concentration of 1 µM, a decrease in Rct 
response over the increasing concentration of FGFR3 on  
FGFR3-21 Affimer sensors can be observed whereas the response on control 
sensors was around at 0% irrespective of the concentration of FGFR3 (Figure 5.18F). 
However, when the concentration of mPEG-biotin was decreased to 0.1 mM (Figure 
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5.18E) or increased to 3 mM (Figure 5.18G), suppression of non-specific binding was 
much less effective. This indicated that the optimal concentration of mPEG-biotin as 
a blocking is 1 mM as it is best in eliminating non-specific binding effect. Accordingly, 
it was included as the last step of sensor fabrication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
215 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18  Effect of blocking agents on biosensor performance with data analysis 
based on the Rct values. The figures on the left panel are Nyquist plots of a FGFR3-
21 Affimer sensor and the figures on the right panel are calibration curves of the 
biosensors for detecting FGFR3 in PBS buffer.  Prior to testing with FGFR3 protein, 
the sensors were blocked with different blocking agents. Sensors without blocking 
agent was used as a control, (A, n = 3 ± SEM), following by sensors blocked with 0.1 
µM BSA, (B, n = 3 ± SEM); 10 mM pyromellitic dianhydride, (C, n = 3 ± SEM); 100 
µg/ml sodium caseinate, (D, n = 3 ± SEM); 0.1 mM mPEG-biotin, (E, n = 3 ± SEM); 
1 mM mPEG-biotin, (F, n = 3 ± SEM), and 3 mM, mPEG-biotin (G, n = 3 ± SEM). The 
sensors were challenged with cumulative concentrations of FGFR3 ranging from 10-
14 M to 10-8 M with PBS washes in between. The EIS measurements were performed 
in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the 
sensors was displayed as ΔRct(%). 
A No blocking 
B 0.1 µM BSA 
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Figure 5.18 (continued) Effect of blocking agents on biosensor performance with 
data analysis based on the Rct values. Prior to testing with FGFR3 protein, the 
sensors were blocked with different blocking agents. 
C 10 mM pyromellitic dianhydride 
D 100 µg/ml sodium caseinate 
E 0.1 mM mPEG-biotin 
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Figure 5.18 (continued) Effect of blocking agents on biosensor performance with 
data analysis based on the Rct values. Prior to testing with FGFR3 protein, the 
sensors were blocked with different blocking agents. 
 
 
 
 
 
F 1 mM mPEG-biotin 
G 3 mM mPEG-biotin 
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5.3.3.4  Specificity of the sensors for the analytes 
 One of the requirements for any sensor is the specificity to the target of 
interest. Even though the sensors immobilised with FGFR3-specific Affimers showed 
binding of FGFR3 protein, it was necessary to test them with other non-related 
proteins to confirm the specificity. The sensors were fabricated using the same 
method as described in Section 5.3.1 and then blocked with 1 µM mPEG-biotin to 
minimise non-specific background. In addition to FGFR3 protein, β-2-microglobulin 
(β2M) and human serum albumin (HSA) were selected as non-related analytes to 
test. This is because β2M is used as a predictive biomarker for acute kidney injury 
(Vaidya et al., 2008). β2M is basically filtered by the glomerulus and almost totally 
reabsorbed and demolished by the proximal tubular cells (Vaidya et al., 2008, Miyata 
et al., 1998). Dysfunction of the proximal tubular cells can cause elevated levels of 
intact β2M in urine, indicating renal failure. HSA, on the other hand, is the most 
abundant protein in plasma which plays a role in controlling oncotic pressure in 
plasma and carrying other components such as fatty acids in bloodstream (Fanali et 
al., 2012). In the case of kidney dysfunction, HSA is one of the first proteins released 
into urine. As the presence of β2M and HSA in urine may interfere with the binding 
of anti-FGFR3 Affimers and FGFR3 on sensors, both of them were selected to test 
for sensor specificity to the target. 
 The results of specificity test for the fully constructed Affimer sensors are 
presented in Figure 5.19. When the sensors were tested with FGFR3 protein, a 
continuous decrease of Rct over a range of FGFR3 concentrations was seen on 
FGFR3-21 Affimer sensors whereas the response with control sensors was almost 
constant with the change between 0 and -10% (Figure 5.19A). However, when the 
sensors were exposed to β-2-microglobulin (Figure 5.19B) or human serum albumin  
(Figure 5.19C),   non-specific   binding    to   the   sensors   can   be   observed.  
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Figure 5.19  Specificity of biosensors to the analytes with data analysis based on the 
Rct values. The figures on the left panel are Nyquist plots of a FGFR3-21 Affimer 
sensor and the figures on the right panel are calibration curves of the biosensors for 
detecting FGFR3 in PBS buffer. The sensors were blocked with 1 µM mPEG-biotin 
prior to exposing to analytes. The sensors were challenged with cumulative 
concentrations of analytes ranging from 10-14 M to 10-8 M with PBS washes in 
between. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-microglobulin, (B, 
n = 3 ± SEM), and human serum albumin, (C, n = 3 ± SEM). The EIS measurements 
were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 redox mediator. The 
response of the sensors was displayed as ΔRct(%). 
A FGFR3 
B β-2-microglobulin 
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Figure 5.19  (continued) Specificity of biosensors to the analytes with data analysis 
based on the Rct values. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-
microglobulin, (B, n = 3 ± SEM), and human serum albumin, (C, n = 3 ± SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
C Human serum albumin 
221 
 
 
 
The decrease of Rct was seen on both the sensors functionalised with FGFR3-21 
Affimer and anti-GFP Affimer. The effect of non-specific binding of the non-related 
analytes on FGFR3-21 Affimer sensors was higher than that with anti-GFP Affimer. 
As previously mentioned in 4.3.5, the ELISA showed that only the Affimers 
screened against FGFR3 bound FGFR3 protein. None of the tested Affimers showed 
binding to β-2-microglobulin and human serum albumin (Figure 4.14).  
Non-specific binding detected when challenging the sensors with different types of 
analyte could be from the interaction between the analyte and the functionalised 
surface. In this experiment (Figure 5.19), mPEG-biotin had been used as a blocking 
agent in order to minimise the effect of non-specific binding. The antifouling 
properties of polyethylene glycol (PEG) to resist the adsorption of proteins to the 
surface are well recognised (Liu et al., 2013, Ostuni et al., 2001, Furuya et al., 2006). 
However, the ability of PEG to bind to proteins has been reported as well. In a 
previous study by (Ogi et al., 2009), PEG was found to interact non-specifically with 
human immunoglobulin G (IgG) although it was used as a blocking agent for the 
system. These data were also supported by a finding by (Riquelme et al., 2016). 
These researchers found that PEG can enhance the attachment of Staphylococcus 
intermedius to a PEG-functionalised gold surface. The binding between PEG and 
BSA protein has also been studied (Rawat et al., 2010). The researchers suggested 
that the binding of PEG and BSA occurs through a strong physical adsorption of PEG 
to the hydrophobic region of BSA, leading to the stabilisation of the protein structure. 
Different proteins have unique properties, resulting from amino acid patterns. 
Therefore the interaction of different proteins to an antifouling agent can be various 
and unpredictable. PEG could be used to minimise non-specific binding of FGFR3 
but not for some proteins. In the next section, attempts were made to find more 
suitable agents other than mPEG-biotin to reduce non-specific background.   
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5.3.4  Modification of sensor construction protocol to mininise 
non-specific signal 
 In immunoassays including ELISA, western blotting and even biosensors, 
bovine serum albumin (BSA) has been commonly used as a blocking agent. In this 
work, BSA was previously used to block the sensor surface in section 5.3.3.3. 
However, blocking the sensor surface with 0.1 µM BSA after Affimer immobilisation 
did not minimise non-specific binding from FGFR3 on control sensors (Figure 5.12B). 
It was proposed that the choice of blocking agents should be based on the molecular 
size of biorecognition elements (Riquelme et al., 2016). If a small bioreceptor is 
utilised, using BSA or large molecule as an antifouling agent may interfere with 
specific recognition events between the bioreceptor and the target (Riquelme et al., 
2016). This could explain the inability of BSA to eliminate non-specific binding when 
applied after Affimer attachment.  
 In 2008, Esseghaier and co-workers revealed a method of making 
impedimetric biosensors using NeutrAvidin-biotin interaction as a linkage between 
the gold surface and a recognition element (Esseghaier et al., 2008). The researchers 
trapped NeutrAvidin molecules into a polypyrrole (PPy) layer using cyclic 
voltammetry. Prior to immobilising biotinylated anti-triazine Fab fragments, 
PPy/NeutrAvidin-modified electrodes were blocked with BSA. Interestingly, the 
concentration of BSA used was much higher than that of NeutrAvidin. With this 
fabrication protocol, specific responses of the sensors could be observed. In this 
section, the protocol for fabricating the sensors described in Section 5.3.3 was 
modified as presented in Figure 5.20. Sensors were constructed step-by-step by 
starting with polytyramine deposition. The sensors were then functionalised with 
NHS-biotin, following by NeutrAvidin as usual. However, prior to immobilising 
biotinylated Affimers, the sensors were blocked with BSA. The concentration of BSA 
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used in this study was 6.7 µM, which was 100 times higher than the concentration of 
NeutrAvidin (0.067 µM). After Affimer immobilisation completed, the sensors were 
ready to test with FGFR3 protein. 
 
 
 
 
 
 
 
 
 
 
Figure 5.20  Schematic representation of Affimer sensor construction according to 
the modified protocol. The modification was suggested by the report of Esseghaier 
et al. (2008). After NeutrAvidin attachment, the sensor was blocked with BSA before 
biotinylated Affimers were attached to the electrode. 
 
 
 
 
 
 
 
224 
 
 
 
5.3.4.1  Optimisation of Affimer concentration in sensors blocked with 
BSA at high concentration 
 As the sensor construction protocol has been modified, in order for the 
sensors to achieve the highest level of their performance, the optimal concentration 
of biorecognition elements is required. Blocking NeutrAvidin-coated surfaces with 
BSA before immobilising Affimers may reduce the possibility of biotinylated Affimers 
to interact with NeutrAvidin because BSA could block the binding sites of NeutrAvidin 
or cause a steric hindrance effect, resulting in interference with NeutrAvidin-
biotinylated Affimer interactions. Optimal concentration of Affimers may help the 
Affimers access the NeutrAvidin binding sites, improving a number of Affimers 
successfully immobilised on the sensor surface. 
 In this section, three concentrations of Affimers were tested. The sensors 
were fabricated following the modified version of the protocol as mentioned in 5.3.4. 
Polytyramine-modified electrodes were functionalised with 3 µM NHS-biotin and 
0.067 µM NeutrAvidin. Then, 6.7 µM BSA was employed to minimise non-specific 
binding events prior to immobilising different concentrations of Affimers. Anti-GFP 
Affimer was used as a control receptor. As shown in Figure 5.21, three concentrations 
of the Affimers showed similar patterns of sensor performance. However, on sensors 
with 1 µM of Affimer, non-specific background on negative control (GFP Affimer) 
sensors was the lowest (between 0% and -12%) whereas the response of Rct on  
FGFR3-21 Affimer sensors was found to decrease continually as the concentration 
of FGFR3 increased (Figure 5.21B). At the Affimer concentration of 0.3 µM (Figure 
5.21A) and 3 µM (Figure 5.21C), even though the decrease in Rct over the increasing 
concentration of FGFR3 was detected, approximately -20% shift of impedance 
indicating non-specific binding effect can be seen. Taken the data together, an 
Affimer concentration of 1 µM was selected as the optimal concentration for the 
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Figure 5.21  Optimisation of Affimer concentration for impedimetric biosensors 
subject to the modified sensor construction protocol. The figures on the left panel are 
Nyquist plots of a FGFR3-21 Affimer sensor and the figures on the right panel are 
calibration curves of the biosensors for detecting FGFR3 in PBS buffer. The sensors 
were blocked with 6.7 µM BSA prior to Affimer immobilisation. Three concentrations 
of Affimers, 0.3 µM,  (A, n = 3 ± SEM); 1 µM, (B, n = 3 ± SEM), and 3 µM, (C, n = 4 
± SEM), were tested. The sensors were exposed to FGFR3 concentrations from  
10-14 to 10-8 M. The EIS measurements were performed in the presence of 10 mM 
K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the sensors was displayed 
as ΔRct(%). 
A 0.3 µM Affimer 
B 1 µM Affimer 
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Figure 5.21 (continued) Optimisation of Affimer concentration for impedimetric 
biosensors subject to the modified sensor construction protocol. Three 
concentrations of Affimers, 0.3 µM,  (A, n = 3 ± SEM); 1 µM, (B, n = 3 ± SEM), and 3 
µM, (C, n = 4 ± SEM), were tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 3 µM Affimer 
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modified version of the sensor fabrication protocol. 
In order to confirm that the positive response on FGFR3-21 Affimer sensors 
was from binding of the Affimers to FGFR3 protein, another Affimer clone selected 
against FGFR3 protein, the FGFR3-14 Affimer, was used instead of FGFR3-21 
Affimer. The sensors were constructed as before. The concentrations of NHS-biotin, 
NeutrAvidin, BSA and Affimers were kept constant at 3, 0.067, 6.7 and 1 µM, 
respectively. Anti-GFP Affimer was used as a control on working electrode 1 and 
FGFR3-14 Affimer was immobilised on working electrode 2. Comparison of the 
sensors using FGFR3-21 and FGFR3-14 Affimers is shown in Figure 4.15. Compared 
to GFP/FGFR3-21 Affimer sensors (Figure 5.22A), GFP/FGFR3-14 Affimer sensors 
showed similar responses. The Rct shift on control anti-GFP Affimer sensors was 
found to fall between 0% to -10% whereas a continuous decrease in Rct was detected 
on FGFR3-14 Affimer sensors increasing FGFR3 (Figure 5.22B). These data 
confirmed that the Affimers can be used to sense the presence of FGFR3 protein in 
PBS buffer when being used in corporation with an electrochemical sensor platform. 
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Figure 5.22 Effect of different clones of the FGFR3-specific Affimer on the sensor 
performance. The figures on the left panel are Nyquist plots of a FGFR3-specific 
Affimer sensor and the figures on the right panel are calibration curves of the 
biosensors for detecting FGFR3 in PBS buffer. The sensors were blocked with 6.7 
µM BSA prior to Affimer immobilisation. The sensors were immobilised with 1 µM of 
GFP and FGFR3-21 Affimers,  (A, n = 3 ± SEM) and, GFP and FGFR3-14 Affimers, 
(B, n = 3 ± SEM). The sensors were exposed to FGFR3 concentrations from 10-14 to 
10-8 M. The EIS measurements were performed in the presence of 10 mM 
K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the sensors was displayed 
as ΔRct(%). 
A GFP/FGFR3-21 Affimers 
B GFP/FGFR3-14 Affimers 
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5.3.4.2  Effect of BSA and casein at high concentrations as blocking 
agents on sensor performance 
 Although BSA showed the best effect on blocking non-specific binding of 
FGFR3 to the sensor surface, there are other blocking agents such as casein that 
are commonly used in bioimmunoassay applications. In addition to BSA, two forms 
of casein were tried for their ability to minimise non-specific background and 
compared with BSA. The electrodes were modified with polytyramine, NHS-biotin 
and NeutrAvidin, respectively. Different blocking agents, 6.7 µM BSA, 2x casein 
blocking buffer (Sigma-Aldrich) and 0.2 mg/ml sodium caseinate, were used to block 
the functionalised surface before biotin-tagged Affimers were added. In this 
experiment, anti-GFP Affimer was used as the control receptor with FGFR3-21 
Affimer as the specific receptor. 
 As shown in Figure 5.17, using BSA as a blocking agent minimised non-
specific binding on negative control sensors with little shift of Rct (approximately -12% 
at the highest FGFR3 concentration tested) whilst the decrease in impedance on 
FGFR3-21 Affimer sensors was still retained (Figure 5.17A). However, when using 
either 2x casein blocking buffer (Figure 5.17B) or sodium caseinate (Figure 5.17C) 
as a blocking solution, non-specific interactions of FGFR3 protein to the sensor 
surface can still be seen on control sensors. The data presented here showed that 
BSA was the best alternative to be used as an antifouling agent to minimise non-
specific binding for this sensor platform. 
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A 6.7 µM BSA 
B 2x casein blocking buffer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.23  Effect of blocking agents on sensor performance subject to the modified 
protolcol. The figures on the left panel are Nyquist plots of a FGFR3-21 Affimer 
sensor and the figures on the right panel are calibration curves of the biosensors for 
detecting FGFR3 in PBS buffer. The sensors were blocked with either 6.7 µM BSA, 
(A, n = 3 ± SEM); 2x casein blocking buffer from Sigma-Aldrich, (B, n = 3 ± SEM), or 
0.2 mg/ml sodium caseinate, (C, n = 3 ± SEM) prior to Affimer immobilisation. The 
sensors were exposed to FGFR3 concentrations ranging from 10-14 to 10-8 M. The 
EIS measurements were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 
redox mediator. The response of the sensors was displayed as ΔRct(%). 
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C 0.2 mg/ml sodium caseinate 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.23 (continued)  Effect of blocking agents on sensor performance subject to 
the modified protolcol. The sensors were blocked with either 6.7 µM BSA, (A, n = 3 
± SEM); 2x casein blocking buffer from Sigma-Aldrich, (B, n = 3 ± SEM), or 0.2 mg/ml 
sodium caseinate, (C, n = 3 ± SEM) prior to Affimer immobilisation. 
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5.3.4.3   Specificity of high BSA concentration blocked sensors to the 
analytes 
 To test whether the high BSA concentration blocked anti-FGFR3 Affimer 
sensors so that they only recognised FGFR3 protein, the sensors were challenged 
with FGFR3, β-2-microglobulin and antidigoxin IgG. The sensors were fabricated 
using the modified method in Section 5.3.4.1. The gold surface was deposited with 
polytyramine, following by functionalising with 3 µM of NHS-biotin and 0.067 µM of 
NeutrAvidin. The modified surface was then blocked with 6.7 µM BSA prior to Affimer 
attachment. One µM of GFP (control) or FGFR3-21 Affimer was immobilised onto the 
surface before the sensors were tested with different proteins. 
 The results presented in Figure 5.24 showed that even though the presence 
of FGFR3 can be detected by FGFR3-21 Affimer sensors with almost no change in 
Rct response on control sensors (Figure 5.24A), non-specific binding was still a 
problem when testing the sensors with the other analytes. As shown in Figure 5.24B, 
non-specific binding of β-2-microglobulin could be found on both control and FGFR3-
21 Affimer sensors, yet the response patterns were different. With the increasing of 
β-2-microglobulin concentrations, the shift of Rct between 0 and 20% was detected 
on control sensors whereas a continuous decrease of Rct from 0 to nearly -40% was 
displayed for FGFR3-21 Affimer sensors. In the same way, when testing the sensors 
with antidigoxin IgG, non-specific binding can be seen (Figure 5.24C). Although the 
shift in Rct could not be seen when GFP Affimer (control) sensors were exposed to 
antidigoxin IgG, a decrease in Rct was observed on FGFR3-21 Affimer sensors, 
indicating the non-specific binding event. Specific response of the sensors is 
presented in Figure 5.24D. To calculate the specific response, ΔRct(%) of FGFR3-
21 Affimer sensors were subtracted with ΔRct(%) of anti-GFP  Affimer  sensors  and  
plotted  against  a range of FGFR3 concentrations. The subtracted response for the  
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A FGFR3 
B β-2-microglobulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.24  Specificity of biosensors to the analytes with data analysis subject the 
modified construction protocol. The figures on the left panel are Nyquist plots of a 
FGFR3-21 Affimer sensor and the figures on the right panel are calibration curves of 
the biosensors for detecting FGFR3 in PBS buffer. The sensors were blocked with 
6.7 µM BSA prior to Affimer attachment. The sensors were challenged with 
cumulative concentrations of analytes ranging from 10-14 M to 10-8 M with PBS 
washes in between. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-
microglobulin, (B, n = 3 ± SEM), and antidigoxin IgG, (C, n = 3 ± SEM). The EIS 
measurements were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 
redox mediator. The response of the sensors was displayed as ΔRct(%). (D) is 
subtracted data (ΔRct(%) for FGFR3-21 Affimer - ΔRct(%) for GFP Affimer) to 
determine specific response of the sensors. 
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Figure 5.24  (continued) Specificity of biosensors to the analytes with data analysis 
subject the modified construction protocol. The sensors were challenged with 
cumulative concentrations of analytes ranging from 10-14 M to 10-8 M with PBS 
washes in between. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-
microglobulin, (B, n = 3 ± SEM), and antidigoxin IgG, (C, n = 3 ± SEM). (D) is 
subtracted data (ΔRct(%) for FGFR3-21 Affimer - ΔRct(%) for GFP Affimer) to 
determine specific response of the sensors. 
 
 
C antidigoxin IgG 
D subtracted response of the sensors 
235 
 
 
 
sensors tested with increasing FGFR3 was between 0% and -27% whilst the sensor 
responses for β-2-microglobulin and antidigoxin IgG were in the range of 0% - 45% 
and 0% - 43%, respectively (Figure 5.24D).  
 As well as FGFR3-21 Affimer, the FGFR3-14 Affimer was tested for its 
specificity for FGFR3 protein with anti-GFP Affimer as a control again. The sensor 
performance data are presented in Figure 5.25. As the sensors were tested with 
FGFR3 protein, a decrease in impedance (from 0% to -40%) over increasing 
concentrations of FGFR3 can be seen on FGFR3-14 Affimer sensors while a shift in 
impedance for control sensors was not observed (Figure 5.25A). However, when 
testing the sensors with β-2-microglobulin, a decrease in impedance (from 0% to 
approximately -30%) with increasing concentration of the analyte can be found on 
both FGFR3-14 and anti-GFP Affimer sensors (Figure 5.25B). Similarly, challenging 
the sensors with increasing concentrations of antidigoxin IgG showed a decrease in 
impedance (from 0% to -45%) on both FGFR3-14 and control sensors (Figure 5.25C). 
Subtracted ΔRct(%) data to show specific response of the GFP/FGFR3-14 Affimer 
sensors are presented in Figure 5.25D. A continuous decrease of subtracted 
ΔRct(%) from 0% to -40% can be seen when the sensors were tested with increasing 
concentration of FGFR3. On the other hand, the subtracted ΔRct(%) data for the 
sensors exposed to β-2-microglobulin and antidigoxin IgG were almost constant with 
little shift between 15% and -10% as the concentration of analyte increased. This 
means that the effect of non-specific binding could be minimised by subtraction of its 
values in order to obtain only the response from specific interaction. However, as the 
non-specific Affimer (GFP Affimer) used for the data in Figure 5.24 and Figure 5.25 
was identical, the sensor responses we anticipated to see should have been similar. 
Different responses of the sensors may be caused by any step of sensor assembly, 
leading to variation of sensor performance. Therefore, further optimisations are 
required in order to make sensors work consistently. 
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Figure 5.25  Specificity of biosensors to the analytes with data analysis subject the 
modified construction protocol. The figures on the left panel are Nyquist plots of a 
FGFR3-14 Affimer sensor and the figures on the right panel are calibration curves of 
the biosensors for detecting FGFR3 in PBS buffer. The sensors were blocked with 
6.7 µM BSA prior to Affimer attachment. The sensors were challenged with 
cumulative concentrations of analytes ranging from 10-14 M to 10-8 M with PBS 
washes in between. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-
microglobulin, (B, n = 3 ± SEM), and antidigoxin IgG, (C, n = 3 ± SEM). The EIS 
measurements were performed in the presence of 10 mM K3Fe(CN)6/K4Fe(CN)6 
redox mediator. The response of the sensors was displayed as ΔRct(%).The 
response of the sensors was displayed as ΔRct(%). (D) is subtracted data (ΔRct(%) 
for FGFR3-14 Affimer - ΔRct(%) for GFP Affimer) to determine specific response of 
the sensors. 
A FGFR3 
B β-2-microglobulin 
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Figure 5.25  (continued) Specificity of biosensors to the analytes with data analysis 
subject the modified construction protocol. The sensors were challenged with 
cumulative concentrations of analytes ranging from 10-14 M to 10-8 M with PBS 
washes in between. The analytes tested were FGFR3, (A, n = 3 ± SEM); β-2-
microglobulin, (B, n = 3 ± SEM), and antidigoxin IgG, (C, n = 3 ± SEM). (D) is 
subtracted data (ΔRct(%) for FGFR3-14 Affimer - ΔRct(%) for GFP Affimer) to 
determine specific response of the sensors. 
 
 
C antidigoxin IgG 
D Substracted response of the sensors 
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5.3.4.4  Effect of polystyrene sulfonate as a blocking agent on sensor 
performance 
 Charge on the transducer could be one source of non-specific interactions as 
it would allow oppositely charged molecules to bind. In this study, polytyramine was 
used as a supporting layer, providing amines as functional groups for chemical 
modification. However, at neutral pH when using PBS buffer, these amine groups are 
protonated. This means that the overall charge on the surface becomes positive. It 
was assumed that the positive charge surface can cause non-specific binding 
because the majority of the proteins have an isoelectric point (pI) below 7.0, making 
them negative. Therefore, changing the transducer surface charge to be negative 
may be the way of removing non-specific binding. 
 Polystyrene sulfonate is a polyanionic polymer. It was used in this study to 
modify the sensor surface as its charge may help minimise non-specific binding of 
most proteins in urine. In the normal way, electrode surface was sequentially 
deposited with polytyramine, 3 µM NHS-biotin, 0.067 µM NeutrAvidin and 1 µM biotin-
tagged Affimer, and then polystyrene sulfonate at a concentration of 1 µM, 5 µM and 
10 µM was tested for reduction of non-specific binding. The sensors were finally 
tested with a range of FGFR3 concentrations. Figure 5.26 shows a schematic of the 
sensor fabrication steps including the application of polystyrene sulfonate as a 
blocking agent.  
 At 1 µM polystyrene sulfonate (Figure 5.27A), the shifts of Rct over the 
increasing concentrations of FGFR3 on control (GFP Affimer) and FGFR3-21 Affimer 
sensors were similar, indicating that 1 µM polystyrene sulfonate was unable to 
eliminate non-specific binding. Changing the concentration of polystyrene sulfonate 
to 5 µM reduced some non-specific binding of FGFR3 on control sensors (Figure 
5.27B)  with   the   decrease  of  Rct  with  increasing  FGFR3  concentrations   on 
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Figure 5.26  Schematic representation of Affimer sensor construction. The sensor was blocked with polystyrene sulfonate after biotinylated Affimers 
were attached to the electrode. Polystyrene sulfonate presenting negative charge was used to neutralise positive charge on polytyramine surface. 
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FGFR3-21 sensors. However, a significant level of non-specific binding still 
remained. As the concentration of polystyrene sulfonate was increased to 10 µM, 
non-specific interaction on negative control sensors was not eliminated though the 
Rct decrease for FGFR3-21 Affimer sensors was observed (Figure 5.27C). The 
results obtained from these experiments suggested that polystyrene sulfonate could 
not be employed as an effective blocking agent for this impedimetric biosensor 
platform. It is recommended that new antifouling agents should be tested for their 
blocking properties or searching for a proper washing buffer could be an alternative 
of minimising the non-specific binding events. 
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Figure 5.27  Effect of polystyrene sulfonate as a blocking agent on sensor 
performance. The figures on the left panel are Nyquist plots of a FGFR3-21 Affimer 
sensor and the figures on the right panel are calibration curves of the biosensors for 
detecting FGFR3 in PBS buffer.  The sensors were blocked with different 
concentrations of polystyrene sulfonate, which were 1 µM, (A, n = 4 ± SEM); 5 µM, 
(B, n = 3 ± SEM), and 10 µM, (n = 3 ± SEM). The sensors were challenged with 
cumulative concentrations of FGFR3 ranging from 10-14 M to 10-8 M with PBS washes 
in between. The EIS measurements were performed in the presence of 10 mM 
K3Fe(CN)6/K4Fe(CN)6 redox mediator. The response of the sensors was displayed 
as ΔRct(%). 
A 1 µM polystyrene sulfonate 
B 5 µM polystyrene sulfonate 
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Figure 5.27  (continued) Effect of polystyrene sulfonate as a blocking agent on 
sensor performance. The sensors were blocked with different concentrations of 
polystyrene sulfonate, which were 1 µM, (A, n = 4 ± SEM); 5 µM, (B, n = 3 ± SEM), 
and 10 µM, (n = 3 ± SEM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
C 10 µM polystyrene sulfonate 
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5.4   Discussion 
 Impedimetric biosensors have been proved as a valuable tool to investigate 
the binding events between biorecognition elements and their target analytes 
(Rushworth et al., 2014, Ohno et al., 2013, Goode et al., 2016). In addition to 
bioreceptors, the method of sensor construction is one of the most important factors 
for sensor efficiency. Several approaches including adsorption, entrapment, covalent 
bonding via cross-linkers and bioaffinity can be used to immobilise bioreceptors to 
the transducer electrodes (Liebana and Drago, 2016). 
 In this chapter, two methods were used to attach Affimers to the sensor 
surface. The first one was ELISHA “gluing method”, which depended on covalent 
bonding via a cross-linker. It was expected that the cross-linker connecting between 
the polymer layer and Affimers could help control correct orientation of the Affimers, 
allowing the analyte to access the binding site of the Affimers. However, non-specific 
binding on sensors was observed (Figure 5.3B). As mentioned in the methodology 
section 2.2.7.1, a mixture of Affimer, linker and monomer was simultaneously 
deposited on a working electrode via cyclic voltammetry. Some molecules of Affimer 
may be placed on the polymer surface in the upright position, which allowed them to 
bind the target analytes. However the rest of the Affimer molecules could be trapped 
between the polymer layers, hampering access to the analytes. Moreover, neutral pH 
buffer such as PBS, amine functional groups on the polymer surface are protonated. 
As the majority of bodily proteins have an isoelectric point (pI) below 7.0, the overall 
charge on the proteins is negative. At this stage, the proteins can bind to the polymer 
surface via electrostatic forces, causing non-specific binding events that can be seen 
by a shift in charge transfer resistance (Rct). Thus, an alternative method for sensor 
fabrication was introduced. 
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 The other method relied on a non-covalent bonding for surface modification, 
NeutrAvidin-biotin interaction. This interaction is extremely strong with the 
dissociation constant (KD) down to 10-15 M (Liebana and Drago, 2016, Sassolas et 
al., 2012). Using this type of linkage, correct orientation of bioceptors can be 
controlled. The Affimer-based impedimetric biosensor construction was successful 
as seen from the increase in impedance signal during each step of construction. After 
testing the sensors with the analyte (FGFR3 protein), a decrease in impedance 
values was observed. In general, the increase in impedance as the concentration of 
analyte increases is a common event (Billah et al., 2010, Esseghaier et al., 2008, 
Ohno et al., 2013). This is because more deposited materials on the sensor surface 
can cause the sensor more resistive and capacitive (Rushworth et al., 2013). 
However, in some circumstances when the binding between two molecules causes 
changes in the physical or chemical properties of the surface, a decrease in 
impedance can also be detected (Rushworth et al., 2013). The decrease in 
impedance is often seen when synthetic binding peptides are used as a 
biorecognition element and the difference of size between receptors and targets is 
significantly large (Rushworth et al., 2014, Goode et al., 2016). It was proposed that 
‘pinholing effect’ from the binding of a small receptor and a large analyte lets the 
charge components transfer through the multiple layers of polymer and contact with 
transducer surface underneath (Goode, 2015). This effect results in the decrease in 
impedance that can be detected as exemplified in this work. 
 In this work, the performance of the sensors was determined using four 
different analytical approaches to the electrochemical data. Similar to the majority of 
previous publications (Ahmed et al., 2013, Barton et al., 2008, Caygill et al., 2012, 
Johnson et al., 2012), the change in Rct was initially used to monitor the change upon 
the interaction of the Affimers and FGFR3 protein. Despite the large shift observed, 
fitting the impedance data with the Randle’s equivalent circuit model may cause an 
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erroneous calculation of the Rct since only half of a complete Nyquist plot was 
obtained from the measurement (Figure 5.9 in Section 5.3.2). Other alternatives were 
applied and compared to changes seen in the Rct data. The percent change in 
capacitance values was successfully used to detect mRNA as a biomarker of tumours 
on the non-faradaic impedance biosensor platform (Jolly et al., 2016). However, 
applying this approach to our biosensor platform was not effective since the 
capacitance values of the sensors when detecting FGFR3 barely changed. Our 
results were similar to the previous publication (Weiss et al., 2005). In the study, the 
binding of avidin, following by biotinylated anti-haemoglobin IgG, to biotinylated SAM 
surface did not show any shift in capacitance values. However, a large change could 
be detected beyond the semicircular region of a Cole-Cole plot, indicating binding 
events happening outside of the thick layers on electrode surface. This situation also 
occurred in another study which reported the development of the impedemetric 
biosensor using the Affimers to detect C-reactive protein (CRP) (Johnson et al., 
2012). The researchers found that the binding of the Affimers to CRP almost 
unaffected capacitance but the changes were dominated by charge-transfer 
resistance (Rct). The shifts of phase angle (Sharma et al., 2016, Raina et al., 2015) 
and the changes of absolute values of impedance (Dapra et al., 2013, Park et al., 
2018) have also been used to monitor sensor performance. However, both 
techniques were not able to distinguish the response of specific interaction from non-
specific binding (Section 5.3.3.1). Comparing the results from all four analyses, the 
percentage change in Rct is the most appropriate option for monitoring the binding 
of the Affimers and FGFR3 for the biosensor platform in this work. 
The concentrations of Affimers and NeutrAvidin were also studied to improve 
the performance of the sensors when exposing to the analyte. At the optimal 
concentrations of both Affimers and NeutrAvidin, the effects of steric hindrance from 
both molecules could be minimised and the specific binding of the Affimer to its target 
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analyte could be detected. However, non-specific binding was a major problem. A 
wide range of blocking agents from small molecules such as pyromellitic dianhydride 
(MW = 218) to a large protein such as bovine serum albumin (BSA, MW = 66,500). 
The results from the sensor performance showed that mPEG-biotin and BSA seemed 
to be the best blocking agents for Affimer-based sensors using the NeutrAvidin-biotin 
based sensor construction method. Even though both mPEG-biotin and BSA could 
be used to minimise non-specific binding problem of FGFR3 to the sensors with the 
range of detection in picomolar, non-specific interactions of other non-related protein 
analytes to the modified surface are still problematic. For mPEG-biotin, even though 
polyethylene glycol (PEG) has been proven for its resistance to the adsorption of 
proteins to solid surfaces (Liu et al., 2013, Ostuni et al., 2001, Furuya et al., 2006), it 
was proposed that PEG can interact with proteins via physical adsorption to the 
hydrophobic regions on the protein (Rawat et al., 2010). There was  evidence 
showing that PEG can bind to proteins such as BSA and human immunoglobulin G 
(Rawat et al., 2010, Ogi et al., 2009), and also promote the binding of bacteria to the 
modified surface (Riquelme et al., 2016). This may be an explanation for non-specific 
binding when using mPEG-biotin to block the surface.  In the case of BSA, even 
though it has been widely used as a blocking agent in many immunoassays such as 
ELISA and western blotting, non-specific binding may occur because of the 
hydrophobic parts of BSA. With this property, albumin is able to bind fatty acids and 
steroid hormones (Spector et al., 1969, Weisiger et al., 2008) and is used as a protein 
carrier in serum. As an abundant soluble protein in plasma, albumin can also interact 
with other molecules including drugs, toxins, metal ions, amino acids (tryptophan and 
cysteine), and proteins (Weisiger et al., 2008, Borgstrom and Erlanson, 1978, Nygren 
et al., 1990, Schnitzer et al., 1992). This makes it possible for BSA to form 
hydrophobic interactions with some proteins, leading to non-specific binding detected 
by sensitive sensors. In a previous study by (Riquelme et al., 2016), bovine serum 
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albumin (BSA) and chicken serum albumin (CSA) were investigated for their ability 
of removing non-specific binding of bacteria to gold surface. The researchers found 
that BSA or CSA alone were not effective when used to block the surface from 
bacteria. However, BSA or CSA in combination with Tween 20 could significantly 
reduce non-specific binding from bacteria to the surface (Riquelme et al., 2016). 
Tween 20 is a surfactant that is normally added to the buffer used for the ELISA and 
western blotting in order to remove any unwanted components. This leads to the idea 
that if Tween 20 at low concentrations is introduced into the wash buffer used during 
biosensor measurement, non-specific binding formed by weak interactions between 
proteins and modified surface might be removed. However, because Affimers as 
bioreceptors are proteins, it is necessary to ensure that in the presence of a 
surfactant like Tween 20, the structure of the Affimers is still intact and can function 
properly. 
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Chapter 6  
General discussion 
 
6.1  General discussion 
 During the past decades, an increasing number of biosensor reports have 
emerged. This indicates a popular trend of biosensors becoming an analytical tool 
for point-of-care diagnosis and environmental monitoring. However, few biosensors 
have become commercialised because most of them cannot the meet standard 
requirements for commercial production. To achieve this aim, optimising fundamental 
factors for sensor fabrication is the first step in the process. 
 The overall objective of this project was to develop and optimise the method 
to fabricate impedimetric biosensors employing Affimers, a type of synthetic non-
antibody binding protein scaffolds, as a biorecognition element to detect a target 
analyte of interest. The tasks were divided into three parts, starting from Affimer 
selection from a phage display library, followed by Affimer characterisation using 
different approaches to characterise selected Affimers, and ending with the use of 
Affimers for biosensor construction. In this chapter, key and interesting technical 
observations, considerations and recommendations will be pointed out together with 
future work. 
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6.2   The challenge of Affimer selection against small 
molecules 
 Affimers are synthetic non-antibody binding proteins recently developed 
(Tiede et al., 2014, Tiede et al., 2017). As with many synthetic binding proteins, the 
selection of Affimers against a specific target can be conducted by biopanning a 
phage display library. In this thesis, dichlorodiphenyltrichloroethane (DDT), a small 
molecule insecticide, was selected as target for Affimer selection. Even though the 
originally established method from BSTG selected a number of Affimer clones from 
the Affimer population, none of the selected Affimers showed binding to the original 
form of DDT. During three biopanning cycles, biotinylated DDT was employed to pull 
out the phage displaying Affimers. Biotinylated DDT contains biotin, a short spacer 
and the DDT moiety. The data in Chapter 4 (Section 4.2) showed that most likely the 
selected Affimers recognised the biotin-spacer plus DDT construct used for selection 
but not DDT alone.  
 The selection of Affimers specific for small molecules is challenging. This is 
because the size of the target is much smaller as compared to bacteria and large 
biomolecules such as proteins. Proteins normally present multiple epitopes which 
facilitate the binding of Affimers to them. However, this is not the case for small 
molecules. Recently, an established protocol for selecting Affimers against small 
molecules was reported (Tiede et al., 2017). Counter selection was used to extract 
Affimers against 2,4,6-trinitrotoluene (TNT), a small organic compound. A TNT 
analogue, 2,4,6-trinitrobenzene sulfonic acid (TNBS) was conjugated with ovalbumin 
and IgG, resulting in TNBS-ovalbumin and TNBS-IgG conjugates. Two different 
conjugates were successfully used to perform the counter selection and Affimers 
showing specificities to TNT were obtained. This leads to the idea of protocol 
modification for selecting Affimers specific to DDT. The task will be more challenging 
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than the case of TNT because of the hydrophobic nature of DDT and extra steps to 
conjugate DDT to carrier proteins may be needed. However, conjugation of a DDT-
protein carrier has been published elsewhere (Abad et al., 1997, Hong et al., 2002). 
It was also noticeable that when performing ELISA to check the specificity of selected 
Affimers to TNT, the detectable range fell in the µM range (Tiede et al., 2017). 
However, DDT is a hydrophobic molecule, making it poorly soluble in water (nM 
range). It is recommended that any assays to determine the binding of Affimers and 
DDT need to be carefully optimised. 
 
6.3   Production and characterisation of Affimers for 
FGFR3 detection 
 The second analyte to be detected in this thesis was fibroblast growth factor 
receptor 3 (FGFR3). FGFR3 is a tyrosine kinase membrane protein in the FGFR 
family and is involved in many biological processes including cell proliferation, 
survival, migration and differentiation (Wesche et al., 2011). As overexpression and 
mutation of this protein are commonly found in bladder cancer cells, FGFR3 seems 
to be a promising biomarker for bladder cancer surveillance (Tomlinson et al., 2007). 
This means monitoring the risk of bladder cancer development could become 
possible with FGFR3 detection. Several Affimers against FGFR3 protein were 
selected from a phage display library via biopanning and subcloned into a pET11a 
expression vector for protein production in E.coli. Although producing Affimers using 
the bacterial system is well-known and convenient to operate compared to antibody 
production, because of the unique properties of each Affimer, some factors needed 
to be adjusted in order to obtain Affimers of high quality and yield. 
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 The structure of Affimers has been claimed for its high thermal stability (Tiede 
et al., 2014). The melting temperature (Tm) can be up to 101 oC. However, this is not 
routine. In this work, even though GFP and FGFR3-21 Affimers provided high yields 
when the originally established expression protocol by BSTG (Raina et al., 2015, 
Tiede et al., 2014, Tiede et al., 2017) was applied, the expression yields for FGFR3-
8 and FGFR3-14 Affimers were low and insufficient. By skipping the  
50 oC heating step in the original protocol, the yields for FGFR3-8 and FGFR3-14 
Affimers were significantly improved (Section 3.5.3). This indicates the unique 
properties of each Affimer, governed by 18 random amino acid sequences split over 
two variable peptide regions; this represents a significant proportion, around 20%, of 
the whole Affimer molecule. 
 In this thesis, a single cysteine residue was introduced at the C-terminus of 
an Affimer (Section 3.3). The Affimers do not contain Cys in the scaffold or loops and 
the additional cysteine can be used as a specific site for conjugation. This 
modification site allows users to control the orientation of Affimers when applying 
them in different biorecognition assays. In our work, as NeutrAvidin-biotin interaction 
was employed as a bridge and a maleimide reaction with biotin-maleimide was used 
to modify Affimers via the Cys-SH (Section 4.3.1). The successful conjugation of 
Affimers and biotin-maleimide was confirmed using ELISA and LC-MS (Figure 4.6, 
4.7 and 4.8). This linkage permitted us to orient Affimers in the upright orientation in 
ELISA (Section 4.3.2), surface plasmon resonance (SPR) (Section 4.3.3), 
immunoprecitipation (pull-down) assay (Section 4.3.4). As a result, all three 
characterisation methods showed specific binding of some selected Affimers to 
FGFR3 proteins with no response by GFP Affimer as a negative control bioreceptor.  
  A common problem for Affimer users is aggregation (Raina et al., 2015, 
Mahatnirunkul, 2017). This event is often encountered when performing dialysis or 
during storage. In the original BSTG protocol, 20 - 40% (v/v) glycerol is generally 
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added into storage buffer in order to keep Affimers in their original conformation 
during storage. However, this is not optimum for impedimetric biosensor platforms 
since glycerol can interfere with sensor fabrication. The aggregation results from 
dimerisation of two Affimer molecules via disulfide linkage formation. In our cases, 
we found that diluting Affimer concentration to under 1 mg/ml could minimise 
aggregation and the problem disappeared when Affimers were biotinylated.  
 In addition to specific biorecognition properties like antibodies, Affimers are 
monoclonal and have a single, unmodified polypeptide. This means they can be 
expressed in prokaryotic systems such as E.coli. The problem of batch-to-batch 
variations is minimised and the cost of production reduced. With these advantages, 
a wide range of applications based on Affimers have emerged (Tiede et al., 2017, 
Kyle et al., 2015, Rawlings et al., 2015). In the area of biosensors, Affimers have 
been employed for the detection of C-reactive protein (Johnson et al., 2012), anti-
myc tag antibody (Raina et al., 2015), human interleukin-8 (Sharma et al., 2016), and 
methylene blue (Koutsoumpeli et al., 2017). In this thesis, we have developed the 
first Affimer-based impedimetric sensors to detect FGFR3 protein. 
 
6.4   Optimising fundamental parameters affecting 
impedimetric biosensor performance 
 To achieve the high sensitive and specific detection of any target of interest, 
several fundamental factors affecting sensor performance are basically taken into 
account when designing a method of sensor fabrication. In this thesis, some of the 
important parameters were considered and discussed in more detail as follows.  
 The choice of electrodes is one of the most important factors governing the 
achievement of the measurement. In this project, commercial gold screen-printed 
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electrode chips were employed for the whole experiments. The benefit of using this 
type of electrode is one chip contains two working electrodes, a reference electrode 
and a counter electrode. Therefore, the distances of internal electrodes can be fixed. 
However, the electrode surface is rough on the nano/microscales (Ahmed, 2015). 
This leads to the problem with sensor reproducibility. To minimise variation, using 
electrodes made from the same batch is recommended. 
 Regarding the surface roughness of the gold screen-printed electrodes, 
polytyramine, a non-conductive polymer, was utilised as a supporting layer for sensor 
fabrication. Polytyramine is known for its high stability, self-limiting insulating 
property, porosity and the presence of amine functional groups for modification 
(Ahmed et al., 2013, Losic et al., 2005). In the protocols published previously from 
the Millner group (Goode et al., 2016, Ahmed, 2015, Ahmed et al., 2013, Rushworth 
et al., 2014), tyramine was prepared in methanol with NaOH. However, it was 
observed that NaOH is not 100% soluble in MeOH and some NaOH left precipitated 
in solution. This leads to inconsistency of the solution concentration prepared at 
different times and causes problems with sensor reproducibility. Moreover, it was 
reported that tyramine is prone to precipitate rapidly during the polymerisation stage 
(Ahmed, 2015). In this study, tyramine was dissolved in Milli-Q water with NaOH. 
Tyramine dissolved completely in water and no precipitation was seen. When coating 
polytyramine on top of working electrodes, the surface was more resistive and 
capacitive than the surface deposited with polytyramine prepared in methanol (Figure 
5.7), indicating a thicker supporting layer. Interestingly, sensor performance was 
more reproducible with the modified protocol. 
 Optimising concentration of bioreceptors (Affimers) was essential in order to 
achieve the maximum level of analyte binding. Owing to the roughness of the 
Dropsens electrode surface, coverage of the surface when immobilising bioreceptors 
was probably not homogeneous (Ahmed, 2015). Too high concentration of 
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bioreceptors can cause excessive packing density on the surface, leading to steric 
hindrance affecting the accessibility of Affimer binding sites to the analyte. This is 
supported by (Holford et al., 2013) and (Ahmed et al., 2013) who found that too 
concentrated bioreceptors led to lower impedance response when detecting the 
targets compared to bioreceptors at their optimal concentrations. The reason for this 
event is that at concentrations beyond the optimal point, further non-specific 
adsorption of bioreceptors to the primary, well-organised layer occurs, resulting in 
more disordered and thicker films (Holford et al., 2013). In the case of insufficient 
bioreceptors loading, it affects the signal generation during the measurements, but 
also non-specific binding from unwanted components to unblocked surface, often 
electrodes, can occur (Ahmed, 2015). Optimal concentration of NeutrAvidin was also 
investigated in this project. As a linker connecting between polymer-coated surface 
and bioreceptors (Affimers), the packing density of NeutrAvidin can also determine 
the optimal coating density of bioreceptors to the surface. Excess or insufficient 
NeutrAvidin could lead to suboptimal Affimer loading (Ahmed et al., 2013, Ahmed, 
2015). 
 It should be noted here that the roughness of electrode surface is not the only 
source of sensor irreproducibility, but also each step of sensor assembly can be a 
source of variations. In this thesis, layer-by-layer sensor construction was done by 
manually pipetting. However, automated sensor fabrication could help minimise any 
errors caused by manual sensor assemblies. (Caygill et al., 2012) and (Holford et al., 
2013) reported that an automated BioDot platform could significantly improve sensor 
reproducibility compared to sensors fabricated manually.  
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6.5   Effect of blocking agents on sensor response 
 It has been hypothesised that unoccupied transducer surface could be a 
source of non-specific binding. Blocking agents were applied to remove non-specific 
binding effects. In this thesis, although several blocking agents were tested for their 
antifouling abilities to protein analytes, two of them, mPEG-biotin and bovine serum 
albumin (BSA), seemed to be the best options for blocking unwanted interactions.  
 In the case of mPEG-biotin, its blocking ability worked well when the sensors 
were exposed to FGFR3 protein, but non-specific binding still remained when the 
sensors were tested with other non-FGFR3 proteins (Section 5.3.3.4). Polyethylene 
glycol (PEG) is widely used to passivate surfaces in biomedical uses (Liu et al., 2013, 
Ostuni et al., 2001, Furuya et al., 2006). However, the enhancement by PEG of 
protein and bacteria adsorption has also been reported (Rawat et al., 2010, Ogi et 
al., 2009, Riquelme et al., 2016). The interaction between PEG and proteins could 
be from physical adsorption between hydrophobic regions on proteins and PEG 
(Rawat et al., 2010). 
 BSA has been widely used as an effective blocking agent in many 
immunoassays. In this work, BSA was confirmed for its blocking properties to FGFR3 
protein when used in the Affimer impedimetric sensor platform (Section 5.3.4.3). 
However, BSA failed to remove non-specific binding from non-FGFR3 protein 
analytes. Although BSA is hydrophilic, it has hydrophobic patches that can form 
hydrophobic interactions with other biomolecules. There are previous studies 
showing that BSA can interact with many analytes such as fatty acids, hormones, 
drugs, toxins, metal ions, amino acids and proteins (Weisiger et al., 2008, Borgstrom 
and Erlanson, 1978, Nygren et al., 1990, Schnitzer et al., 1992, Spector et al., 1969) 
and its natural biological role is to carry these molecules in the circulation. However, 
a previous study reported that BSA in combination with Tween 20 could apparently 
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resist non-specific binding from this strain of bacteria (Riquelme et al., 2016). Tween 
20 is commonly added into wash buffers used in ELISA in order to minimise non-
specific binding. This leads to the idea that introducing Tween 20 to wash buffer 
during sensor construction and measurements may help minimise non-specific 
binding from non-related analytes whereas specific binding from FGFR3 protein 
would still be retained. 
 
6.6   Limitations in the field and possible opportunity 
of the sensors 
 Bladder cancer is one of the most frequently diagnosed cancers and cause 
of deaths worldwide. With an increasing number of patients every year, methods of 
cancer detection at early stages and regular follow-up of cancer recurrence after 
transurethral resection are highly advantageous. Nowadays, several approaches are 
employed (Budman et al., 2008, Proctor et al., 2010). Although cystoscopy and urine 
cytology are used as standard methods for monitoring bladder tumours, they show 
some disadvantages such as invasiveness, cost ineffectiveness and patient anxiety 
for cystoscopy, and insensitivity for cytology. Biomarker-based assays (as described 
in Section 1.6.2) are also commercially available, but poor specificity is still a problem, 
leading to false positives. Accordingly, there is still room for biosensor development. 
 Up until now, only one published work has been related to the use of 
biosensor to detect FGFR3 (Shin et al., 2013). The researchers developed a DNA 
sensing platform using the shift of resonance wavelength to detect mutational status 
of FGFR3 gene as a marker for bladder cancer. As no biosensors detecting FGFR3 
protein have been reported yet, the work in this thesis is the first electrochemical 
biosensor that enables detection of FGFR3 protein. Even though more optimisations 
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to remove non-specific binding to the sensors and the real biological sample tests 
are still under investigation, the data until now present the idea of developing a more 
convenient, cheap, and label-free alternative to IHC and ELISA for the detection of 
FGFR3 protein as a promising maker for bladder tumour monitoring.  
 
6.7   Future work 
 In this thesis, non-specific binding from non-FGFR3 proteins is a major 
concern that makes the developed sensors impractical in use. Attempts of optimising 
blocking conditions to eliminate non-specific interactions of proteins and non-related 
components to the sensor surface are still in progress. In the ‘real world’ applications, 
pure samples like serial dilutions of a specific protein do not truly exist. In fact, the 
biological samples collected from patients contain a plenty of biomolecules which can 
potentially cause noise background when the sensors perform the measurements. 
Therefore, it is imperative for sensors to discriminate the specific interaction between 
the bioreceptor and the target from any non-specific interactions to the surface. Other 
than blocking agents used to minimise non-specific binding effect, the choice of 
electrodes is one of the most important factors relating to reproducibility of the sensor 
performance. Electrodes with flatter gold surface may be a better alternative to the 
Dropsens screen-printed gold electrodes used in this study. Carbon electrodes are 
also commercially available and could be considered as an alternative for sensor 
fabrication. Biotin-avidin interaction was used in this work, but non-specific binding 
was problematic as presented in Chapter 5. Different bioconjugate chemistries 
should be considered for biosensor surface functionalisation (Section 1.4.2.3). As an 
Affimer possesses a thiol functional group, it can directly interact with a gold surface. 
This thiol-gold interaction was successfully used for the impedance biosensor to 
detect Her4 (Zhurauski et al., 2018). Heterobifunctional linkers such as sulfo-SMCC 
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were also used to link bioreceptors with a free thiol group to the functionalised 
surface, leading to correct orientation of bioreceptors when detecting their target 
analytes (Goode et al., 2016). EDC/NHS conjugation was employed to construct 
Affimer-based biosensors to detect various target analytes (Johnson et al., 2012, 
Raina et al., 2015, Sharma et al., 2016). With a collection of bioconjugation 
techniques, fabricating biosensors with repeatable output can be achievable.  
 Another weak point of this work is that even though there was the evidence 
showing the high expression level of FGFR3 in urine collected from bladder cancer 
patients (Blanca et al., 2016), no pathological level of FGFR3 in urine has been 
reported yet. We recommend here that ELISA be a standard method to determine 
the detectable level of FGFR3 in urine samples from normal people and bladder 
cancer patients and this range of detection should be used as a reference for 
biosensors to detect FGFR3 as a biomarker for bladder cancer monitoring.  
Until the present, biosensing research has shifted towards label-free systems 
since they can offer cost effectiveness, simplicity and fewer reagents used. From a 
commercial perspective, precision and reproducibility are necessities for every 
sensor fabricated. Fundamental parameters need to be carefully optimised as every 
step of sensor assemblies leads to the success of sensor performance. It is also a 
requirement that the cost of sensor production should not be too high. Simplicity in 
use is also important when looking from a commercial view. Designing multitasking 
sensors by miniaturising input, measurement, signal generation and interpretation 
steps in one device could make the sensors easy to use in real situations. More 
importantly, those who work in this field should bear in mind that each target analyte 
has its unique properties. Therefore, a sensing platform designed for one target may 
not be suitable for others. On the other hand, it can be stated that every target 
requires its own optimisation. An optimised platform for a specific analyte like the 
work conducted in this thesis can only provide the way of assisting experimental 
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design for other targets. We hope that the Affimer-based impedimetric biosensor 
platform presented here may not only be an effective tool for bladder cancer 
surveillance, but also an initial platform to design methods of detecting other protein 
biomarkers of diseases. 
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